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Influenza A virus (IAV) is a major pathogen affecting many host species. The 
natural host is aquatic birds, in which the virus only causes mild or asymptomatic 
infections. The virus is able to adapt to domestic birds and mammals in which it can 
evolve to cause serious disease and high mortality rates, causing major losses in food 
production and putting severe strain on economies. IAV occasionally causes 
pandemics in humans, in which millions of people can die worldwide from a single 
outbreak. There is currently a lack of a universal vaccine and the antiviral drug options 
are far from ideal. Therefore, it is important to fully understand how avian IAV can 
cross the species barrier into domestic mammals and cause disease. This study set out 
to improve this understanding by investigating a group of avian IAV genes that are 
considered to be non-functional in mammalian hosts, thus understanding the 
mechanisms behind this could reveal precious information regarding the mechanisms 
behind host adaptation. 
The IAV genome is composed of eight segments of RNA. The segment 8 (NS) 
has evolved into two distinct lineages – the ‘A-’ and ‘B-alleles’. The B-allele NS genes 
are only rarely found in mammals and have been declared avian-restricted. However, 
when A- and B-allele NS genes were introduced into human H1N1 and H3N2 viruses, 
there was surprisingly little difference in virus replication in multiple mammalian cell 
types. Furthermore, the viruses replicated well and caused disease in mice, and the 
representative B-allele virus actually caused more severe disease than the A-allele 
counterpart. When computational analysis of available IAV sequences was performed, 
it was revealed that B-allele NS genes enter the mammalian population at a similar 
rate to A-allele genes. Thus, the data described in this study suggest that B-allele NS 
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segments are in fact able to complement virus replication in mammalian hosts and also 
contribute to severe disease. Thus, the dogma of the B-allele genes being avian 
restricted is misleading, and they should be considered when risk assessing the 






Influenza A virus (IAV) circulates in waterfowl, causing mostly asymptomatic 
infections. IAV can undergo host adaptation and evolve to cause significant disease 
and mortality in domestic poultry and mammals, applying an enormous socio-
economic burden on society. Sporadically, IAV causes global pandemics in man due 
to its zoonotic nature, and this can result in millions of deaths worldwide during a 
single outbreak. Host adaptation of IAV is an incompletely understood phenomenon, 
but is known to involve both host and viral determinants. It is essential to improve the 
understanding of the factors governing host range and pathogenicity of avian IAV, 
especially given the absence of a universal influenza vaccine and a limited weaponry 
of effective antiviral compounds. This study set out to improve the understanding of 
host adaptation of avian IAV, focussing on segment 8 (NS segment) of the virus 
genome. 
The NS segment of non-chiropteran IAV circulates as two phylogenetically 
distinct clades – the ‘A-’ and ‘B-alleles’. The A-allele is found in avian and 
mammalian viruses, but the B-allele is considered to be almost exclusively avian. This 
might result from one or both of the major NS gene products (NS1 and NEP) being 
non-functional in mammalian host cells, or from an inability of segment 8 RNA to 
package into mammalian-adapted strains. To investigate this, the NS segments from a 
panel of avian A- and B-allele strains were introduced into human H1N1 and H3N2 
viruses by reverse genetics. A- and B-allele reassortant viruses replicated equally well 
in a variety of mammalian cell types in vitro. Surprisingly, the consensus B-allele 
segment 8 out-competed an A-allele counterpart when reassortant H1N1 viruses were 
co-infected, with the parental WT segment 8 being most fit in this system. A- and B-
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allele NS1 proteins were equally efficient at blocking the mammalian IFN response 
both in the context of viral infection and in transfection-based reporter assays. 
Consensus A- and B-allele H1N1 viruses also caused disease in mice and replicated to 
high virus titre in the lung. Interestingly, the B-allele virus induced more weight-loss 
than the A-allele, although the parental WT virus was most pathogenic in vivo. 
To re-address the hypothesis that B-allele NS genes really are avian-restricted, 
the relative rates of independent Aves to Mammalia incursion events of A- and B-allele 
lineage IAV strains was estimated and compared using phylogenetic analyses of all 
publically available segment 8 sequences. 32 A-allele introduction events were 
estimated compared to 6 B-allele incursions, however the total number of avian A-
allele sequences outnumbered B-allele sequences by over 3.5 to 1, and the relative 
rates of introduction were not significantly different across the two lineages suggesting 
no bias against avian B-allele NS segments entering mammalian hosts in nature. 
Therefore, this study provides evidence that avian B-allele NS genes are not 
attenuating in mammalian hosts and are able to cause severe disease. Thus, this lineage 
of IAV genes, previously assumed to be avian-restricted, should be considered when 
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 Chapter 1: Introduction to influenza A virus 
 
1.1 General introduction to influenza A virus 
Influenza A virus (IAV) belongs to the family Orthomyxoviridae and has a 
genome composed of eight molecules of negative sense, single-stranded RNA 
(McGeogh et al., 1976) (Fig 1.1). The natural host of IAV are wild aquatic birds of the 
orders Anseriformes and Charadriiformes which are reservoirs for all subtypes of IAV, 
although the virus can undergo host adaptation to infect a variety of avian and 
mammalian species (reviewed by (Webster et al., 1992)). The virus is subtyped by the 
antigenicity of its surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). 
To date, there have been 16 HA subtypes and 9 NA subtypes described in avian 
viruses. Each strain of IAV contains one subtype each of HA and NA. All subtypes of 
both HA and NA have been isolated from wild aquatic birds, in the majority of possible 
combinations. Two chiropteran-specific subtypes of HA (H17 and H18) and NA (N10 
and N11) have been described in bat isolates (Tong et al., 2012, Tong et al., 2013), 
which have not been seen in any other species.  
Two forms of avian influenza viruses are described historically according to 
the severity of disease caused in the galliform host. IAV circulates in wild 
Anseriformes and Charadriiformes as an asymptomatic or low virulence form 
commonly referred to as ‘low pathogenic avian influenza’ (LPAI). LPAI replicates in 
cells lining the gut epithelium of waterfowl, is spread by the faecal-oral route, and 
remains infectious for a matter of weeks in cool lake water therefore promoting 
efficient spread within the natural host (Webster et al., 1978). LPAI can infect 





Fig 1.1. Influenza A virus genome. Shown is a schematic of the eight segments of 
the RNA genome and current known gene products. Coding regions are represented as 
rectangles with shading employed to denote alternative frames. The virus employs 
various protein coding strategies to express more than one protein per segment in 
certain cases. Splicing of mRNA is denoted by lines connecting two coding regions 
and ribosomal frame-shifting is shown by the right-angled arrow. Diagram represents 





consists of highly virulent strains that cause mortality rates of up to 100% within flocks 
within 2-3 days. This form is referred to as ‘highly pathogenic avian influenza’ 
(HPAI). HPAI infections in nature have, so far, only been reported with H5 and H7 
subtypes, although not all H5 and H7 subtypes cause HPAI. Serious disease caused by 
HPAI is associated with systemic spread in the host and an exaggerated pro-
inflammatory response, leading to severe pathology and often mortality (To et al., 
2001, Cheung et al., 2002, de Jong et al., 2006, Cornelissen et al., 2013, Kuchipudi et 
al., 2014). HPAI has become endemic in poultry in certain regions, particularly in 
South East Asia, with devastating impact on the agriculture and food security sectors 
(Chen et al., 2006b).  
Avian IAV can cross the host species barrier and evolve to cause severe disease 
and significant mortality in domestic mammals, including man. Human influenza virus 
predominantly targets the epithelial cells of the respiratory tract, and is transmitted 
directly or indirectly in airborne droplets with or without fomite contact (reviewed in 
(Killingley and Nguyen-Van-Tam, 2013)). IAV currently circulates in man as 
‘seasonal influenza’ with subtypes of H1N1 and H3N2 (and previously H2N2, as 
discussed below). The term seasonal influenza is used as the antigenicity of the HA 
and NA changes over time, a process called antigenic drift, which allows the virus to 
escape established population immunity and cause annual epidemics, typically over 
the winter months. The World Health Organisation (WHO) estimate that 3-5 million 
people suffer severe illness and 250 000 - 500 000 people die every year from these 
seasonal epidemics (World Health Organisation, 2014). 
Only H1, H2 and H3 subtype viruses have been confirmed to persist in humans 




these viruses tend to be isolated bird-to-human transmission events following direct 
contact with domestic birds (Schrauwen and Fouchier, 2014). It is through contact with 
domestic birds that HPAI can infect man and cause serious disease with high mortality 
rates. The first cases of HPAI H5N1 infections of humans occurred in 1997 in Hong 
Kong, from which 6 of 18 people infected died (reviewed in (Chan, 2002)). H5N1 
HPAI re-emerged in China in 2003 and spread across the Middle-East to North-East 
Africa, and has caused over 400 deaths in humans since (World Health Organisation, 
2016b). Beginning in March 2013, severe LPAI H7N9 infections of humans have been 
reported from contact with poultry in China (Gao et al., 2013). 133 human infections 
and 43 deaths were reported during the spring of 2013 (World Health Organisation, 
2013) and the virus is still continuing to cause disease and fatalities in China (World 
Health Organisation, 2016a). Therefore, avian IAV continues to pose a significant 
threat to human health. Fortunately, avian viruses generally transmit poorly between 
humans, although there is evidence of limited human-to-human transmission (Wang 
et al., 2008a). There is a global fear that a highly pathogenic virus will infect humans, 
evolve to be able to spread rapidly, and cause another pandemic. 
1.1.1 Influenza A virus pandemics 
There have been five confirmed IAV pandemics in man since the 20th century, 
each of which are described below. All prevalence and mortality statistics reported 
below were taken from the World Health Organisation (WHO) pandemic influenza 
website (World Health Organisation, 2016c). 
1.1.1.1 1918 H1N1 pandemic 
The first IAV pandemic of the 20th Century was caused by an H1N1 virus that 




pdm1918 H1N1 is estimated to have caused approximately 50 million deaths 
worldwide and therefore represents one of the most deadly human pathogens in 
history. The virus caused particularly high mortality (estimated ~2.5%) in young adults 
(20-40 years old), the majority of whom probably perished from secondary bacterial 
pneumonia (Taubenberger and Morens, 2006, Morens et al., 2008). The origins of the 
pdm1918 H1N1 virus are still the subject of debate in the field. It has been proposed 
that a fully avian virus, or an avian virus with a human H1 subtype, adapted to humans 
(Taubenberger et al., 2005, Worobey et al., 2014c). Others have suggested that it arose 
from the genetic reassortment of viruses circulating in humans and swine (Smith et al., 
2009). The impact of this pandemic was not only huge because of the number of 
associated fatalities, but also because all subsequent human pandemic strains are 
derived from pdm1918 H1N1, and descendants still continue to be endemic in humans 
and swine (Taubenberger and Morens, 2006). 
1.1.1.2 1957 H2N2 pandemic 
The 1957 H2N2 pandemic virus (pdm1957 H2N2), often referred to as ‘Asian 
flu’, incurred a much lower mortality rate than the pdm1918 H1N1 pandemic and 
caused approximately 1-4 million deaths worldwide. The pdm1957 H2N2 emerged 
following genetic reassortment of an avian H2N2 virus with a circulating human H1N1 
virus – with the former donating HA, NA and polymerase basic protein 1 (PB1) 
segments (Scholtissek et al., 1978). H2N2 continued to circulate in humans for just 
over a decade, until the emergence of the 1968 H3N2 pandemic.  
1.1.1.3 1968 H3N2 pandemic 
The 1968 H3N2 pandemic (pdm1968 H3N2) virus, also known as ‘Hong Kong 




H2N2 strain, resulting in an H3N2 virus harbouring avian-derived PB1 and HA 
segments (Scholtissek et al., 1978). The virus caused approximately 1-4 million deaths 
worldwide and has persisted in the human host as H3N2 seasonal influenza to date, 
having replaced the H2N2 subtype.  
1.1.1.4 1977 H1N1 pandemic 
The 1977 H1N1 strain (pdm1977 H1N1), also called ‘Russian Flu’, marked the 
re-introduction of an H1N1 virus circulating in man. The Russian Flu viruses were 
reported to be genetically very similar to H1N1 viruses circulating in the 1950s prior 
to the H2N2 Asian Flu outbreak, apparently missing years of evolution that would be 
expected from persistence in the human host (Nakajima et al., 1978). This has led to 
the suggestion of an accidental or deliberate release of the virus from a laboratory or 
live vaccine trial (Rozo and Gronvall, 2015). Given the close relation to H1N1 
circulating in the 1950s, the pdm1977 H1N1 virus primarily caused mortality in young 
adults under the age of 25, as they had not been exposed to pre-circulating H1N1 and 
had not acquired immunological memory. 
1.1.1.5 2009 H1N1 pandemic 
In 2009 a swine-derived H1N1 virus (pdm2009 H1N1) emerged in humans and 
spread worldwide, originating in Mexico. Pdm2009 H1N1 spread efficiently between 
humans but mostly only caused mild infections, accounting for approximately 100 000 
to 400 000 deaths within the first year of the outbreak. The virus was the result of 
reassortment between three lineages of swine influenza (Garten et al., 2009). The HA, 
nucleoprotein (NP) and nonstructural (NS) segments were derived from the ‘classical 
swine’ lineage, an H1N1 descendant of the pdm1918 H1N1 strain circulating in pigs 




derived from ‘Eurasian swine flu’, an avian virus that adapted to and has subsequently 
circulated in pigs in Europe and Asia since the late 1970s (Scholtissek et al., 1983). 
Finally, the polymerase segments PB2 (polymerase basic protein 2), PB1 and PA 
(polymerase acidic protein) were derived from ‘triple reassortant swine flu’, a lineage 
of swine flu that itself is a reassortment of avian, human and swine origin viruses (Zhou 
et al., 1999, Garten et al., 2009). Pdm2009 H1N1 is still circulating currently in man, 
having replaced the 1977 Russian Flu origin H1N1 strain. 
1.2 IAV genome  
The IAV genome is approximately 13.5 kb in size. Each segment encodes for 
at least one protein that is essential for virus replication. Table 1.1 summarises the 
main roles of all characterised IAV gene products. IAV utilises various protein coding 
strategies to expand the coding capacity of its small genome, which are outlined below 
in 1.2.2 Virus gene products and protein coding strategies and represented 
diagrammatically in Fig 1.1. 
1.2.1 Genomic viral RNA and ribonucleoproteins 
Genomic viral RNA (vRNA) is normally encapsidated by multiple copies of 
the nucleoprotein (NP). One copy of each subunit of the trimeric viral polymerase 
(PB2, PB1 and PA) is also bound to the promoter region of vRNA forming the viral 
ribonucleoprotein (vRNP), the minimal unit of transcription and replication (Huang et 
al., 1990). NP binds to the phosphate backbone of vRNA with high affinity in a 
sequence-independent manner (Baudin et al., 1994). NP homo-oligomerises and binds 




























1 PB2 2341 PB2 Faithful transcription 759 Part of heterotrimeric polymerase. Binds host mRNA 5’ cap for ‘cap snatching’ to 
prime viral mRNA transcription (Blaas et al., 1982) 
PB2-S1 Spliced mRNA 508 Inhibitor of RIG-I signalling (Yamayoshi et al., 2016). 
2 PB1 2341 PB1 Faithful transcription 757 Part of heterotrimeric polymerase. Catalyses elongation of nascent RNA (Braam 
et al., 1983). 
PB1-N40 Alternative AUG site 718 Currently unknown 
PB1-F2 Alternative AUG site 87 Inhibits cellular MAVS to reduce IFN induction (Varga et al., 2012) 
3 PA 2233 PA Faithful transcription 716 Part of heterotrimeric polymerase. Endonuclease activity for ‘cap snatching’ of 
host mRNA 5’ cap to prime transcription of IAV transcripts (Dias et al., 2009). 
PA-X Ribosomal frame-
shift 
152 Endonuclease activity contributes to host cell shut-off (Jagger et al., 2012). 
PA-N155 Alternative AUG site 562 Currently unknown 
PA-N182 Alternative AUG site 535 Currently unknown 
4 HA 1775 HA Faithful transcription 565 Receptor binding, virus entry and virion budding. 
5 NP 1565 NP Faithful transcription 498 Encapsidation of vRNA and required for polymerase activity. 
6 NA 1413 NA Faithful transcription 454 Cleaves sialic acid receptors on surface of host cell to allow release of progeny 
virus and cleaves sialylated glycans in mucus to facilitate virus attachment to host 
cells. 
7 M 1027 M1 Faithful transcription 252 Major structural protein of virion and involved in virus assembly and budding. 
M2 Spliced mRNA 97 Proton channel involved in acidification of virion during virus entry and required 
for membrane scission during virion budding. 
M42 Spliced mRNA 99 Modified version of M2 (Wise et al., 2012) 
M3 ? ? Protein expression not detected to date. 
8 NS 890 NS1 Faithful transcription 230 IFN antagonism (Hale et al., 2008b) 
NEP Spliced mRNA 121 Required for nuclear export of vRNPs (O'Neill et al., 1998). 
NS3 Spliced mRNA 187 Currently unknown. 
NSP ? ? Protein expression not detected to date. 
tNS1 Alternative AUG site 150 or 
152 






approximately 24 nucleotides to encapsidate the RNA (Ortega et al., 2000, Ye et al., 
2006). Encapsidation reduces opportunity for the host cell to recognise non-self RNA 
and trigger an antiviral immune response which would be detrimental for virus 
replication. Each genomic segment contains conserved sequences at their termini (13 
nucleotides at the 5’ end, and 12 nucleotides at the 3’ end) that have partial 
complementarity (Robertson, 1979). The polymerase sits on the panhandle structure 
in the RNA formed by this complementarity, holding the ends together (Hsu et al., 
1987, Baudin et al., 1994, Klumpp et al., 1997). It is thought that PB1 forms the ‘core’ 
of the polymerase hetero-trimer and the overall structure is globular with multiple 
interactions between all subunits (reviewed in (Stubbs and te Velthuis, 2014)). vRNPs 
take the form of a helical filament, with the panhandle structure at one end opposite a 
helical loop structure at the other (Compans et al., 1972, Moeller et al., 2012, Arranz 
et al., 2012).  
1.2.2 Virus gene products and protein coding strategies 
Each segment of vRNA contains one major open reading frame (ORF) from 
which a protein product is translated following faithful transcription of mRNA. To 
date, it has been reported that IAV employs mRNA splicing, ribosomal frame-shifting, 
and alternative translation initiation mechanisms to expand its coding capacity.  
1.2.2.1 Faithful mRNA transcription from vRNA 
PB2, PB1 and PA are translated following transcription of unspliced mRNA 
from segments 1, 2 and 3 respectively. Segments 4 and 6 encode for the spike 
glycoproteins HA and NA respectively. Segment 5 encodes for NP, while unspliced 
mRNA transcribed from segments 7 and 8 are translated into matrix protein 1 (M1) 





1.2.2.2 Splicing of viral mRNA 
Unspliced PB2 mRNA is translated into the 759 amino acid PB2 protein. The 
PB2 mRNA can be spliced to express the recently described 508 amino acid PB2-S1 
product, a gene product conserved in pre-2009 human strains of IAV (Yamayoshi et 
al., 2016). PB2-S1 shares the N-terminal 495 amino acids with PB2, but the C-terminal 
13 amino acids are from the +1 reading frame. It has been suggested that PB2-S1 may 
inhibit RIG-I to dampen the IFN response during infection (Yamayoshi et al., 2016).  
There are three spliced mRNA species from segment 7 described to date 
(mRNAs 2-4) which all share the same splice acceptor site, but utilise different 5’ 
donor sites  (Lamb and Choppin, 1981, Alonso-Caplen et al., 1992, Shih et al., 1998). 
mRNA 2 is translated into the M2 proton channel (M2) which shares its 9 N-terminal 
amino acids with M1 but the C-terminal 88 amino acids are translated from the +1 
frame (Lamb and Choppin, 1981). mRNA 4 leads to M42 expression, a variant form 
of the M2 proton channel which shares its C-terminus with M2 but a distinct N-
terminus translated from the second AUG in the mRNA and from the +1 frame (Wise 
et al., 2012). mRNA 4 is also predicted to lead to translation of an internally deleted 
version of M1 called M4, but this protein has not been detected to date (Shih et al., 
1998, Wise et al., 2012). mRNA 3, which harbours an ORF with the potential to 
express a 9 amino acid product, has also been described. While protein expression has 
not been detected from this mRNA, there is evidence to suggest it regulates segment 
7 gene expression (Shih et al., 1995).  
Similarly, segment 8 mRNA is known to be spliced. The nuclear export protein 
(NEP), a 121 amino acid polypeptide essential for vRNP export from the nucleus 





in all strains of IAV (Lamb and Lai, 1980). NEP shares its N-terminal 10 amino acids 
with NS1, but the C-terminal 111 amino acids are translated from the +1 reading frame. 
Another spliced mRNA of segment 8 leads to translation of nonstructural protein 3 
(NS3) in a minority of strains that have acquired a mutation to introduce a splice 
acceptor site into the NS1 mRNA (Selman et al., 2012). NS3 represents an internally 
deleted version of NS1 that lacks residues 126-168, with a currently uncharacterised 
role in IAV replication (Selman et al., 2012). 
1.2.2.3 Ribosomal frame-shifting 
PA-X is a protein that shares the 191 amino acid endonuclease N-terminus of 
PA but has a strain-specific C-terminus of 41 or 61 amino acids translated from the +1 
reading frame of PA mRNA (Jagger et al., 2012). PA-X is expressed following a 
ribosomal frameshift event during translation of segment 3 mRNA (Firth et al., 2012). 
The PA-X protein contributes to host cell shut-off by destroying cellular RNA 
polymerase II (pol II) transcripts (Jagger et al., 2012, Khaperskyy et al., 2016). It is 
the only IAV protein currently described that is translated following a ribosomal 
frame-shifting event. 
1.2.2.4 Alternative translation initiation events 
PB1 mRNA has several start codons downstream of the conventional AUG for 
PB1 expression, which can be utilised in an alternative translation initiation process 
(Wise et al., 2011). PB1-F2 is expressed from the fourth start codon in PB1 mRNA in 
the +1 reading frame with respect to PB1. PB1-F2 has been reported to induce cell 
death and also inhibit interferon (IFN) production in the host cell (Chen et al., 2001, 
Varga et al., 2011). PB1-N40 is an N-terminally truncated version of PB1 translated 





a currently unknown function (Wise et al., 2009). PA-N155 and PA-N182 are 
expressed from the highly conserved in-frame AUG codons in segment 3 mRNA at 
codon positions 155 and 182, respectively, and therefore are N-terminally truncated 
(154 amino acids and 181 amino acids respectively) forms of PA that lack the 
endonuclease domain with currently unknown functions (Muramoto et al., 2013). 
Recently, alternative in-frame start codons in NS1 mRNA have been shown to be used 
which leads to translation of N-terminally truncated versions of NS1 (tNS1) (Kuo et 
al., 2016). The second and third in-frame codon of NS1 mRNA lie at codons 79 and 
81 which can both be used to yield a truncated version of NS1, of approximately 17 
kDa, that contributes to IFN antagonism (Kuo et al., 2016). It has also been suggested 
that segment 8 vRNA contains an ORF in the opposite sense to mRNA that may be 
utilised, but no protein product has been detected to date (Zhirnov et al., 2007, Clifford 
et al., 2009). 
1.3 Influenza virions 
Influenza virions are pleomorphic and can adopt either a spherical or 
filamentous morphology (Mosley and Wyckoff, 1946). Lab-adapted strains tend to be 
predominantly spherical with a typical diameter of 100 nm, while clinical isolates tend 
to be filamentous and can be up to 20 µm in length with a 100 nm diameter (Mosley 
and Wyckoff, 1946, Harris et al., 2006). A schematic of a spherical influenza virion is 
shown in Fig 1.2. The structural support of the virion is provided by oligomerised M1 
that forms a ‘shell’ underlying the host-derived phospholipid bilayer envelope. 
Embedded in the lipid envelope are the rod-shaped ‘spike’ glycoproteins HA and NA 
that protrude outwards (Laver and Valentine, 1969), as well as the homotetrameric 






Fig 1.2. Spherical influenza A virion. Shown is a cartoon of a spherical influenza A 
virion. Oligomers of the M1 protein provide a structural ‘shell’ to the virion, which lie 
beneath the host-derived lipid bilayer envelope. Surface glycoproteins HA and NA 
protrude outwards, embedded in the envelope by a transmembrane region located in 
the stem. The M2 proton channel is also embedded in the envelope. The ssRNA 
genome is encapsidated by multiple copies of NP. The heterotrimeric polymerase sits 
on the panhandle structure formed by complementation of the conserved sequences 
found at the termini of vRNA, forming the vRNP. One vRNP unit per segment of the 
genome is packaged per virion. Cartoon drawn by, and included with permission from, 






trimer, and NA a tetramer, in the lipid envelope. The number of HA molecules on the 
virus surface is thought to be present approximately four times more than NA; thus it 
is the dominant surface antigen of IAV (Webster et al., 1968). The vRNPs are 
packaged into the space within the M1 support layer, along with a few copies of NS1 
and NEP and other cellular factors that are incorporated during virus assembly and 
budding (Richardson and Akkina, 1991, Hutchinson et al., 2014). M1 forms 
interactions with both the lipid envelope and the vRNPs, the latter through interaction 
with NP (Ruigrok et al., 2000, Noton et al., 2007, Noton et al., 2009). Scanning 
transmission electron microscopy has allowed the 3D reconstruction of the structure 
of vRNPs in virions, and a ‘7+1’ arrangement has been proposed in which 7 segments 
encircle a central segment within the virion (Noda et al., 2012).  
1.3.1 Hemagglutinin structure and cellular processing 
As HA is involved in multiple aspects of IAV biology that are referred to 
throughout this chapter, a short introduction on its structure and cellular processing is 
outlined here. HA is co-translationally inserted into the host cell endoplasmic 
reticulum (ER) as a homotrimer of precursor polypeptides termed HA0. The trimer is 
transported to the cell surface via the trans-Golgi network where it is incorporated into 
the plasma membrane prior to virus budding (reviewed in (Skehel and Wiley, 2000)). 
HA0 contains a C-terminal transmembrane domain, a protease cleavage site, and a 
fusion peptide that mediates virus entry (Skehel and Wiley, 2000). HA undergoes 
proteolytic cleavage by cellular trypsin-like or furin-like proteases into its activated 
conformation: a prerequisite for virus entry into newly infected cells (Klenk et al., 
1975). The sequence of the protease cleavage site determines its susceptibility to 





reaching the plasma membrane or extracellularly (Klenk and Garten, 1994). Post-
cleavage, the two resulting peptides (HA1 and HA2) are held together by a disulfide 
bridge. HA1 comprises the N-terminal region and HA2 the C-terminal region 
containing the transmembrane domain, which is inserted into the lipid envelope of the 
virion, and also the fusion peptide (Skehel and Wiley, 2000). The ectodomain is 
composed of a ‘stem’, a triple stranded coiled-coil of α-helices formed by both the 
HA1 and HA2 peptides, and a globular ‘head’ of anti-parallel β-sheets which contains 
the receptor-binding site and the major epitopes for antibody binding formed by the 
HA1 peptide (Skehel and Wiley, 2000).  Each monomer of the HA trimer has a receptor 
binding site located in a depression on the top of the HA trimer, distal to the 
transmembrane C-terminal stem (Weis et al., 1988).   
HA is N-glycosylated in both the stem and head regions, which is important 
for function. The glycosylation of the head region is variable between HA subtypes 
and contributes to immune evasion by blocking antibody access to epitopes (Skehel et 
al., 1984), but in the stem region oligosaccharides are more conserved and are 
important for HA stability and membrane fusion (Ohuchi et al., 1997).  
1.4 Virus life cycle 
A defining aspect of IAV biology is that all RNA synthesis occurs in the 
nucleus, which is uncommon for RNA viruses. One immediate advantage of this is the 
utilisation of the host splicing machinery to expand the coding capacity of the virus. 
Additionally, this may help reduce the likelihood of activating cytoplasmic sensors of 
viral RNA and triggering an immune response. Nuclear replication also grants easier 





which is important for replication as described in this section. A schematic of the 
influenza replication cycle is shown in Fig 1.3. 
1.4.1 Virus entry 
IAV infection begins with the attachment of virion(s) to the surface of a host 
cell. The HA protein binds to N-acetylneuraminic (sialic) acids commonly found at 
the termini of various glycol-conjugates on the surface of host cells (Johnson et al., 
1964). Spherical virions bound on the surface of cells are internalised by clathrin-
mediated endocytosis, triggered by activation of cellular receptor tyrosine kinases 
(Eierhoff et al., 2010), while filamentous virions enter via micropinocytosis (Rossman 
et al., 2012). To enter the cell cytoplasm, the virus must fuse its own membrane with 
that of the endosome. Membrane fusion is carried out by cleaved HA. In the N-
terminus of the HA2 peptide, adjacent to the protease cleavage site, lies a hydrophobic 
stretch of 20-25 amino acids known as the fusion peptide. Following acidification of 
late endosomes, cleaved HA undergoes a pH-dependent conformational change 
allowing the insertion of the fusion peptide into the endosome membrane, thus HA is 
inserted into both viral and endosomal membrane at this point (Jardetzky and Lamb, 
2004). Multiple HA trimers undergo this conformational change. This is then followed 
by further substantial protein re-folding, bringing the fusion peptide (in the endosomal 
membrane) close to the C-terminal transmembrane domain of HA (in the viral 
envelope), thus bringing the two membranes into close proximity. The energy released 
following this conformational change provides the energy for the two membranes to 
fuse (Jardetzky and Lamb, 2004). H+ ions also pass through the M2 proton channel to 







Fig. 1.3. Schematic of virus life cycle. Shown is a diagram of the IAV replication 
cycle. The virus enters the host cell following attachment of HA to sialic acids on the 
cell surface and subsequent endocytosis. Acidification of endosomes triggers 
membrane fusion driven by HA and entry of vRNPs. vRNPs enter the nucleus where 
transcription and replication takes place. Newly synthesised copies of the virus 
genome assemble with translated viral proteins to form progeny vRNPs, which 
undergo nuclear export and trafficking to the cell surface. Virus assembly and budding 
occurs and infectious virus particles are released to infect new cells. Figure is taken 






and vRNPs (Bui et al., 1996). Free vRNPs are then able to enter the cytoplasm of the 
cell, completing virus entry.  
1.4.2 Nuclear import of vRNPs and transcription and replication 
machinery 
The nucleus is surrounded by a double membrane known as the nuclear 
envelope. Supramolecular protein assemblies termed nuclear pore complexes (NPCs), 
mediate molecular exchange between the nucleus and the cytoplasm through the 
nuclear envelope. Ions and molecules with a radius of 2.6 nm or below can passively 
diffuse through the NPC, but anything larger must be actively transported using signal-
dependent mechanisms and specific receptors (Eibauer et al., 2015). Soluble transport 
proteins, such as importins which belong to the karyopherin family of proteins, can 
bind directly to cargo and mediate shuttling into the nucleus, (Stewart, 2007). 
Importins bind cargo containing a nuclear localisation signal (NLS) in the cytoplasm, 
transport it through the NPC by interacting with nucleoporins, and dissociate from 
their cargo in the nucleus. The import pathway can be referred to as classical or non-
classical. In classical nuclear import, the NLS contains basic amino acids arranged in 
either a single cluster or a bipartite motif separated by a short linker. The NLS interacts 
with an importin α isoform, of which six have been described in man (α1, α3, α4, α5, 
α6, α7) which in turn interacts with importin β1 before entering the nucleus. 
Alternatively, a non-classical pathway can be employed using a different NLS and 
transport protein. There have been several non-classical pathways described, for 






vRNPs are too large to diffuse through the NPC, so active transport is required 
for nuclear import. The pH-induced dissociation of M1 from vRNPs exposes NLSs on 
NP which drive vRNP nuclear import (O'Neill et al., 1995). There have been three 
NLSs described in NP, but an N-terminal ‘unconventional’ NLS, NLS1 (1-
MASQGTKRSYxxM-13), is thought to be the major driver of vRNP nuclear import 
(Bullido et al., 2000, Cros et al., 2005, Hutchinson and Fodor, 2012) . The subtype of 
importin-α utilised by IAV vRNPs has been shown to be strain-specific (Gabriel et al., 
2011). Once in the nucleus, the viral polymerase can carry out a primary round of 
transcription and the viral mRNAs are subsequently exported to the cytoplasm for 
translation.  
Viral polymerase components that are translated in the cytoplasm require 
nuclear import to aid further transcription and replication of the genome. As these 
translated polymerase components do not exist as RNPs, different nuclear import 
mechanisms are employed. Two regions of PB2 are required for nuclear import. 
Residues 449–495 and a C-terminal bipartite NLS (738-KRx12KRIR-755) are required 
for classical nuclear import using importin α5 (Tarendeau et al., 2007). PB1 and PA 
must interact and form heterodimers in the cytoplasm prior to nuclear import, which 
is via a non-classical pathway utilising ran binding protein 5 (Fodor and Smith, 2004, 
Deng et al., 2006b). It is thought that a bipartite NLS (187-RKRRx16KRKQR-211) in 
PB1 mediates the interaction with ran binding protein 5 (Hutchinson et al., 2009, 
Hutchinson and Fodor, 2012). As mentioned above, NP utilises the classical import 
pathway to enter the nucleus. Now, all components required for transcription and 






1.4.3 Transcription and replication of the IAV genome 
All transcription and replication of the viral genome is conducted by the 
trimeric polymerase. The panhandle structure formed by complementarity of the 5’ 
and 3’ ends of the encapsidated vRNA serves as the promoter for this (Luytjes et al., 
1989). Each of the eight vRNPs of the IAV genome serve as a separate transcription 
unit. Transcription is primed by a ‘cap-snatching’ mechanism, which involves the 
binding to and cleavage of RNA fragments (10-13 nucleotides in length) containing a 
5’ 7-methylguanosine cap (m7GpppXm) from host precursor mRNAs (pre-mRNAs) to 
provide a primer for viral transcription (Plotch et al., 1981). The IAV polymerase 
interacts with actively transcribing RNA polymerase II, and this may allow easier 
access to a pool of host capped pre-mRNAs (Engelhardt et al., 2005). The binding of 
the polymerase to host pre-mRNA 5’ caps is mediated by the PB2 subunit (Blaas et 
al., 1982). The PA subunit of the polymerase harbours endonuclease activity in its N-
terminal 209 residues, and this conducts the cleavage of the cap (Hara et al., 2006, 
Yuan et al., 2009, Dias et al., 2009). PB1 harbours the polymerase function, catalysing 
RNA elongation reading the vRNA as a template in the 3’ to 5’ direction (Braam et 
al., 1983). Transcription is terminated at a 5-7 nucleotide long poly(uridine) (poly(U)) 
stretch located 15-17 nucleotides from the 5’ end of the vRNA template (Robertson et 
al., 1981). It is thought that the 5’ end of vRNA is associated with the polymerase 
throughout transcription while the template is ‘threaded’ through the PB1 active site 
in the 3’ to 5’ direction, and when the polymerase reaches the poly(U) stretch it cannot 
move any further due to steric hindrance causing the active site to pause over the 
poly(U) tract (Moeller et al., 2012). The poly(U) stretch serves as a template for 





polymerase (Poon et al., 1999). Therefore, the nascent viral mRNA resembles a mature 
host mRNA with a 5’ 7-methylguanosine cap and a 3’ poly(A) tail.  The viral mRNA 
can then assemble into messenger ribonucleoproteins (mRNPs) and utilise the host cell 
nuclear export and translation machinery for protein expression, with or without 
splicing depending on the segment.   
In contrast to transcription, genome replication utilises a full, positive-sense, 
copy of vRNA as an intermediate template termed complementary RNA (cRNA). 
Therefore, there are two stages of genome replication: i) synthesis of cRNA using 
vRNA as a template and ii) synthesis of vRNA using cRNA as a template. Both cRNA 
and vRNA contain a 5’ triphosphate moiety, suggesting genome replication is primer-
independent (Hay et al., 1982). The precise mechanism of initiation of cRNA and 
vRNA synthesis is the subject of debate, but involves different strategies for both 
(Deng et al., 2006a, Zhang et al., 2010). Nascent RNA synthesised during replication 
is encapsidated by free NP and polymerase subunits in the nucleus to form progeny 
vRNPs, and these will subsequently undergo nuclear export prior to virus assembly 
and egress. One copy of cRNA can provide a template for multiple rounds of vRNA 
synthesis, and cell-fractionation studies have shown that cRNA remains in the nucleus 
throughout infection (Shapiro et al., 1987, Tchatalbachev et al., 2001).  
It is currently not fully understood how the viral polymerase distinguishes 
between transcription and replication functions, since the same promoter is used in 
both instances. Some studies have implied a role of accumulating viral proteins 
following translation, such as NEP, while others have suggested a role for small RNAs 
(22-27 nucleotides in length) corresponding to the 5’ end of vRNA which appear 





proposes that newly synthesised trans-acting polymerases associate with free 5’ ends 
of vRNA and synthesise cRNA, whilst the 3’ end is still associated with the original 
polymerase of the vRNP (Moeller et al., 2012, Fodor, 2013). However, there is 
conflicting data in the literature regarding this mechanism which needs further study 
(Fodor, 2013). 
1.4.4 Viral mRNA processing 
After transcription of viral mRNAs is complete, they are thought to resemble 
host mature mRNAs during the processes of splicing, nuclear export and translation 
and are therefore processed in a similar fashion (Amorim et al., 2007, Read and Digard, 
2010, Bier et al., 2011, York and Fodor, 2013). All splicing of viral mRNAs that 
contain an intron is performed by the host splicing machinery, although viral proteins, 
such as NS1, may regulate this process (Robb and Fodor, 2012).  
Mature cellular mRNAs interact with a host of proteins during nuclear export, 
including the cap binding complex (CBC), poly(A) binding proteins, and the 
transcription/export complex (TREX). The major nuclear export factor for cellular 
mRNA through the NPC is the nuclear export factor 1 (NXF1) pathway. It is thought 
that the 5’ end of nascent viral mRNA is released from the transcribing polymerase, 
allowing the binding of the CBC which initiates mRNP assembly (Bier et al., 2011). 
The observation that the viral polymerase interacts with actively transcribing cellular 
RNA pol II suggests that newly synthesised viral mRNAs will be in close proximity 
to host proteins involved in mRNA assembly into mRNPs (Engelhardt et al., 2005). 
Indeed, inhibition of cellular RNA pol II leads to retention of viral transcripts in the 
nucleus, suggesting that nuclear export is reliant on host transcription (Amorim et al., 





factor which is part of the TREX, and also NXF1, suggesting they utilise similar 
pathways to host mRNA nuclear export (Wang et al., 2008b, Hao et al., 2008, Read 
and Digard, 2010, Bier et al., 2011). However, there is also evidence that specific viral 
mRNAs may utilise alternative nuclear export pathways other than NFX1 (Read and 
Digard, 2010, Larsen et al., 2014). Eukaryotic initiation factor 4E (eIF4E) was also 
found to bind to viral mRNAs, providing evidence that viral mRNAs are recruited to 
ribosomes and translated as cellular mRNAs would be (Bier et al., 2011). 
1.4.5 Nuclear export and trafficking of vRNPs 
At later stages of infection, progeny vRNPs must undergo nuclear export and 
trafficking to the plasma membrane for virion assembly and virus budding in order to 
infect new host cells. IAV vRNPs utilise the nuclear transport factor chromosome 
region maintenance (CRM1), also called exportin 1, to actively transport vRNPs across 
the NPC into the cytoplasm- as demonstrated by nuclear retention of vRNPs following 
addition of a specific CRM1 inhibitor leptomycin B (Elton et al., 2001, Watanabe et 
al., 2001). CRM1 binds to leucine-rich nuclear export signals (NES) on cargo, and also 
to Ran-GTP (guanosine triphosphate-binding nuclear protein Ran), and traverses the 
NPC by interacting with nucleoporins. Once in the cytoplasm, Ran-GAP (Ran-GTPase 
activating protein) catalyses the conversion of Ran-GTP to Ran-GDP (Ran-guanosine 
diphosphate), and results in dissociation of CRM1 from its cargo.  
After progeny vRNPs are made in the nucleus, they are trafficked to the nuclear 
periphery where they tether to chromatin, which may improve access to the CRM1-
mediated nuclear export pathway (Chase et al., 2011). Both M1 and NEP have been 
shown to be essential for vRNP export (Martin and Helenius, 1991, O'Neill et al., 





31-MITQFESLKL-40) and it is thought that NES 2 forms the predominant interaction 
with CRM1, while NES1 interacts with cellular chromodomain-helicase-DNA-
binding protein 3 (CHD3) to aid recruitment to chromatin to increase exposure to 
CRM1 (O'Neill et al., 1998, Neumann et al., 2000, Huang et al., 2013, Hu et al., 
2015b). NEP has not been associated with binding to vRNPs alone, but M1 and NEP 
are known to interact via the NLS on M1 and a site including tryptophan-78 of NEP 
(Yasuda et al., 1993, Akarsu et al., 2003). Therefore, a proposed model implicates the 
M1 protein in forming a ‘bridge’ to connect vRNPs to the NEP, and CRM1-mediated 
nuclear export is facilitated by NEP-CRM1 interactions.  
Once in the cytoplasm, vRNPs need to reach the plasma membrane prior to 
virus assembly and budding. vRNPs associate at the microtubule organisation centre 
(MTOC) at the outside of the nucleus following nuclear export, which requires an 
interaction with cellular Y-box-binding protein 1 (YB-1) (Amorim et al., 2011, 
Kawaguchi et al., 2012). It is thought that vRNPs ‘piggy-back’ on Rab11 GTPase-
positive recycling vesicles that are trafficked to the apical membrane on tubulin 
networks (Momose et al., 2011, Amorim et al., 2011, Eisfeld et al., 2011). Rab11 
interacts with vRNPs via the PB2 subunit of the polymerase (Amorim et al., 2011), 
and there is thought to be a form of dissociation mechanism at the apical membrane, 
as Rab11 has not been detected in virions to date (Hutchinson et al., 2014, Eisfeld et 
al., 2015).  
1.4.6 Virus assembly and budding 
All eight genomic RNA segments must package into a budding particle for it 
to be infectious. Available data has revealed that a segment-specific packaging 





(Hutchinson et al., 2010)). Electron tomography and scanning transmission electron 
microscopy data revealed that the majority of virions contain eight segments (Noda et 
al., 2006, Noda et al., 2012). Additionally, fluorescent in situ hybridisation studies on 
RNA inside captured IAV virions also suggested that each of the eight segments are 
present in one copy per virion in the majority of particles (Chou et al., 2012).  
Each segment of the IAV genome contains conserved RNA ‘packaging 
signals’ in the terminal coding and non-coding regions (Duhaut and McCauley, 1996, 
Fujii et al., 2003, Gog et al., 2007). IAV displays a lack of synonymous variation 
within these regions, and synonymous mutations of these conserved codons can reduce 
packaging efficiency (Fujii et al., 2003, Gog et al., 2007, Hutchinson et al., 2008). 
These terminal sequences are also sufficient to allow packaging of non-IAV RNA into 
budding virions in place of a genuine IAV segment (Liang et al., 2005). Therefore it 
is thought that these RNA signals mediate segment-specific packaging to ensure one 
copy of each segment is incorporated into a budding virion. The precise mechanism of 
how the virus utilises these signals (RNA-RNA or RNA-protein interactions) to 
mediate selective packaging is still debated, although there is accumulating evidence 
to suggest RNA-RNA interactions are important (reviewed in (Gerber et al., 2014).  
The assembly and packaging of the vRNPs into the virion is thought to be 
driven by interactions between the integral membrane proteins HA, NA and M2, with 
M1, which in turn interacts with vRNPs. IAV utilises lipid rafts for sites of budding – 
regions of the plasma membrane that are rich in cholesterol and sphingolipids 
(Scheiffele et al., 1999). HA and NA molecules naturally congregate at lipid rafts and 
insert into the membrane (Leser and Lamb, 2005), while M2 accumulates in areas of 





mutation of the cytoplasmic tails of HA or NA reduce lipid raft association, cause 
abnormal virion morphology, and inhibit virus assembly (Zhang et al., 2000, Takeda 
et al., 2003), and mutation to the M2 cytoplasmic tail interferes with the M1-M2 
interaction and inhibits efficient virus assembly (Chen et al., 2008). Therefore it is 
thought that the cytoplasmic tails of HA, NA and M2 all interact with M1 (which will 
in turn be interacting with NP of vRNPs) and this interaction is important for virus 
assembly at points of budding.    
Insertion of HA and NA into the plasma membrane initiates membrane 
curvature and budding. Additionally, it has been shown that cellular F-type proton-
translocating ATPase (F1Fo-ATPase) is required for efficient budding and is recruited 
by NEP (Gorai et al., 2012), suggesting that host factors are also likely to be important 
in the process. M1 is recruited to sites of budding by interactions with the cytoplasmic 
tails of HA, NA and M2. M1 monomers will polymerise following these interactions, 
possibly through an induced conformational change, and begin to form the structural 
‘shell’ of the virion underneath the host-derived lipid bilayer, with which it forms 
electrostatic interactions (Ruigrok et al., 2001). vRNPs arrange in the ‘7+1’ 
arrangement perpendicular to the budding tip (Noda et al., 2006), and are packaged 
into the budding virion through interactions with the M1 oligomers. Once the 
membrane has curved sufficiently, M2 performs membrane scission by insertion of an 
amphipathic helix in its cytoplasmic tail into the membrane, inducing positive 
membrane curvature at the neck of the budding virion (Rossman et al., 2010). The fact 
that M2 localises to the membrane adjacent to lipid rafts will concentrate M2 
molecules at the neck of the budding virion to aid scission (Rossman et al., 2010). 





to prevent re-attachment of progeny virions to the cell that has already been infected, 
allowing release of virions to infect new cells (Palese et al., 1974).  
1.5 Influenza A virus evolution 
1.5.1 Antigenic drift 
Antigenic drift describes the gradual mutation of the epitope regions of viral 
surface proteins with time, resulting in structurally distinct antigenic regions that can 
‘escape’ existing host acquired adaptive immune responses (neutralising antibodies). 
Drift arises from a high error rate of the viral RNA polymerase that lacks a proof-
reading mechanism. It is estimated that the virus polymerase makes one error every 
time the full genome is replicated (Drake, 1993). Indeed, it is thought that for every 
round of virus replication in an infected cell, a ‘quasi-species’ of virus is released, the 
majority with a mutation(s) in the genome with respect to the original infecting virus 
(Lauring and Andino, 2010). Most mutations will be deleterious to the virus, 
compromising replicative ability, and these mutant viruses will not propagate well. 
Some mutations will be advantageous for replicative fitness and these mutations can 
become dominant in the virus population over multiple rounds of replication.  
Antigenic drift explains the seasonal nature of H1N1 and H3N2 outbreaks in 
man. Population humoral immunity to circulating viruses will become ineffective as 
antigenic drift causes divergence in the epitopes of the virus – most notably the 
receptor binding ‘head’ of HA. This phenomenon provides a serious challenge in 





1.5.2 Antigenic shift  
Antigenic shift describes the swapping of genetic material between two or 
more viruses by reassortment leading to the emergence of a new subtype of virus in a 
population. Reassortment is the ‘swapping’ of genome segments between two or more 
genetically distinct viruses that co-infect the same host cell at the same time. If the 
resulting combination of segments produces a viable virus that can successfully 
replicate, a ‘reassortant’ virus emerges. This provides an opportunity for the virus to 
mutate extremely rapidly and to a dramatic extent. This also provides an opportunity 
for genetic material to cross the host species-barrier by reassorting into a virus 
background that is adapted to a different host species. In addition, Anseriform and 
Charadriiform birds can carry IAV by seasonal migration over a range of distances 
that can span across continents, allowing long range transmission and also genetic 
reassortment between strains that would be otherwise geographically separated (Olsen 
et al., 2006). 
Sequence and surveillance data suggest genetic reassortment occurs between 
viruses that are adapted to different host species, allowing the emergence of new 
subtypes within a particular host (reviewed in (Steel and Lowen, 2014)). Reassortment 
events between avian and mammalian IAV strains were pivotal in the induction of four 
of the five reported human influenza pandemics during the last century (see 1.1.1 
Influenza A virus pandemics). Similarly, reassortment within wild and domestic birds 
was important for the evolution of HPAI H5N1 viruses that are endemic in South East 
Asia in wild and domestic birds (Steel and Lowen, 2014, Schrauwen and Fouchier, 





1.6 Control of influenza A virus 
The rapid evolution of the virus presents a major challenge in developing 
efficient vaccines and antivirals due to the selection of resistant strains. Currently, 
there is a lack of an effective universal vaccine, and only a limited supply of fully 
effective antiviral compounds.  
1.6.1 Vaccination 
The aim of vaccination is to elicit an adaptive immune response in the host, by 
the administration of antigen, that will be activated upon subsequent infection of the 
pathogen and prevent severe infection. The main antigen of IAV for activation of the 
adaptive immune response lies in the membrane-distal receptor-binding ‘head’ of the 
HA surface glycoprotein, although NA also contains significant epitopes. The epitopes 
in the HA globular head are too distinct between (and even within) different subtypes 
for a vaccine to be designed targeting all strains of the virus (Wiley and Skehel, 1987). 
Instead, either a trivalent inactivated vaccine (TIV) is used which includes antigens for 
relevant circulating human H1 and H3 strains, and also a relevant circulating influenza 
B virus strain, or a trivalent live attenuated virus vaccine (TLAV) is used (reviewed in 
(Pica and Palese, 2013)). More recently, TIVs are becoming phased out and replaced 
by a quadrivalent inactivated vaccine (QIV) which includes an additional influenza B 
lineage strain (Beran et al., 2013).  Inactivation of viruses in TIVs is achieved by 
treatment of purified virus with non-ionic detergents, while live-attenuated viruses are 
cold-adapted and can only replicate well in the cooler temperatures of the nasal 
epithelium (Pica and Palese, 2013). TIVs or QIVs are usually administered 





offered to children, elderly, immunocompromised or individuals with current 
respiratory complications such as asthma.  
Antigenic drift of IAV requires new vaccines to be made each year. The World 
Health Organisation are responsible for selecting which virus strains are included in 
annual vaccines and this process involves consulting surveillance data to choose 
appropriate candidates. Reassortment is the current method of choice for generating 
vaccines by co-infecting eggs with a high-growth virus (e.g. the lab-adapted A/Puerto 
Rico/8/1934 (H1N1); PR8) and a strain containing the surface glycoproteins of 
interest, and selecting the highest growing reassortant virus containing the HA and NA 
of interest (Fulvini et al., 2011). The high-growth background of PR8 permits high HA 
titre in egg-grown stocks, the equivalent of which would not be achievable with wild-
type clinical strains. This process of vaccine production can take months, which 
highlights the importance of developing and stockpiling effective antiviral compounds 
in the case of a new outbreak. 
Vaccines directed against broadly conserved regions (universal vaccines), 
which in theory would be much more difficult for viruses to escape from by antigenic 
drift, are the focus of much research. Examples include targeting the ectodomain of 
the M2 proton channel, the conserved stem region and protease cleavage site of HA, 
conserved sites near the enzymatic active site or cytoplasmic tail of NA, and also 
inducing a T-cell response to conserved viral epitopes in NP and M1 (reviewed in (Pica 
and Palese, 2013)). This area of research presents a very promising avenue of potential 






In the absence of effective universal vaccines, antiviral drugs provide much 
needed prophylaxis of IAV during major outbreaks. Currently, there are two classes 
of FDA-approved antiviral drugs for IAV treatment: i) Neuraminidase inhibitors 
oseltamivir (Tamiflu™), zanamivir (Relenza™) and the more recently approved 
peramivir (Rapivab™) and laninamavir (Inavir™) and ii) adamantanes (adamantine 
and rimantadine) that inhibit the M2 proton channel. Adamantanes were traditionally 
the drug of choice, but preference has switched to NA inhibitors as adamantane-
resistant IAV strains have become widespread. 
Adamantanes were the first antiviral drugs to be approved for the treatment of 
IAV infection. The adamantanes used as antivirals against IAV are amantadine (1-
aminoadamantane hydrochloride) and rimantadine (α-methyl-1-adamantane 
methylamine hydrochloride). Amantadine and rimantadine inhibit the M2 proton 
channel of IAV, probably by occluding the pore and therefore preventing virus 
uncoating (Cady et al., 2010). Resistance to adamantanes has been reported to occur 
very rapidly in subjects treated for IAV infection, and mutations in the hydrophobic 
transmembrane domain of M2 (residues 26 – 38), appear to confer this resistance (Hay 
et al., 1986, Belshe et al., 1988). Although adamantane resistance is not ubiquitous 
across all IAV subtypes, it is thought that global incidence of resistance is increasing 
in human IAV, as well as HPAI H5N1 strains in Asia (Dong et al., 2015). In 2009, the 
Centers for Disease Control and Prevention (CDC) reported that all circulating human 
H3N2 and pdm2009 H1N1 viruses sampled in the United States of America were 
resistant to amantadine (Centers for Disease Control and Prevention, 2009). 





Tamiflu™ and Relenza™ are currently the only NA inhibitors approved in the 
majority of countries worldwide. Rapivab™ is approved in Japan, Korea, China and 
USA, while Inavir™ is only approved in Japan. NA inhibitors were designed using 
structure-based drug discovery, utilising crystal structures of the NA enzyme with 
sialic acid analogues bound to the active site (von Itzstein et al., 1993). These 
neuraminidase inhibitors block the active site of all subtypes of NA with high affinity, 
an inhibition which prevents the release of virions from infected cells (Palese et al., 
1974). Tamiflu™ is the most heavily used NA inhibitor worldwide, but resistance has 
developed, predominantly in human H1N1 seasonal strains but also in a minority of 
cases of pdm2009 H1N1 and HPAI strains (Hurt et al., 2009b). H1N1 seasonal IAV 
has evolved resistance to Tamiflu™ via a H275Y amino acid substitution in NA, which 
still permits replication and transmission of the virus as efficiently as wild-type but the 
IC50 value of Tamiflu™ is heavily increased (Kawai et al., 2009). The efficacy of 
Rapivab™ to the H275Y Tamiflu™-resistant NA is also reduced, but Relenza™ 
efficacy is not affected (Hurt et al., 2009a). NA inhibitors are stockpiled in case of 
future serious IAV outbreaks to provide a level of control until an effective vaccine is 
developed.  
There is currently ongoing research to develop novel antiviral compounds that 
target conserved viral or host factors that could safely inhibit virus replication in the 
host (reviewed in (Yen, 2016)). One promising drug is Favipiravir (T-705; 6-fluoro-3-
hydroxy-2-pyrazinecarboxamide) which is currently under clinical evaluation for use 
as an anti-IAV compound. T-705 is a prodrug that has been shown to inhibit the RNA 
polymerase of a broad spectrum of IAV strains, and other RNA viruses, with high 





705 is phosphoribosylated by cellular enzymes and is incorporated into nascent RNA 
molecules made by the viral polymerase, preventing efficient elongation (Furuta et al., 
2013). 
1.7 Host adaptation  
Host adaptation is an important facet of IAV biology. Generally speaking, it is 
quite rare for a virus to successfully adapt to a new species. Usually, specific genetic 
traits of a virus are required to facilitate efficient replication in a new host and to cause 
disease. These traits can be acquired through reassortment and/or adaptive mutations. 
Host factors are also key in setting host range of IAV strains. The contribution of both 
host and viral factors in setting host range and pathogenicity of IAVs is incompletely 
understood and is an area of intense research. Host adaptation can result in a virus 
becoming introduced into a population that may not have existing adaptive immunity. 
If the virus is able to cause disease and transmit well between individuals in the new 
host species, then serious outbreaks can result (the pdm1918 H1N1 strain being an 
example). Of particular concern is the ability of HPAI to cross the species barrier into 
man and adapt to transmit well. Therefore, it is imperative that the determinants of 
host range and pathogenicity are fully elucidated to improve risk assessment of IAV 
strains that may have potential to cause serious outbreaks in domestic mammals or 
man.  
Given the aims of the study described in this thesis, the adaptation of avian 
influenza viruses to mammalian hosts will be the main focus of discussion in this 
section unless otherwise stated. Below, some of the best characterised viral 





1.7.1 Viral determinants of host switching and virulence 
Several IAV genes have been implicated in setting mammalian host range and 
pathogenicity (reviewed in (Cauldwell et al., 2014, Schrauwen and Fouchier, 2014)). 
The most important viral determinant is widely accepted as being the HA gene, as 
receptor-binding and virus entry is strongly dependent on both the HA subtype and 
host species, while the protease cleavage site of the precursor HA0 polypeptide is a 
determinant of virulence and tissue tropism (Webster and Rott, 1987).  
1.7.1.1 Hemagglutinin 
The receptor of IAV, sialic acid, is commonly found at the terminus of glycans 
and glycosphingolipids on the surface of host cells (reviewed in  (Varki et al., 2009)). 
The second carbon atom of sialic acid forms a glycosidic bond (alpha linkage) with 
the underlying sugar. The most common alpha linkage is with either the third or the 
sixth carbon atom of galactose to form α-2-3- or α-2-6- linkages, respectively. These 
two variations have different conformations that are often specifically recognised by 
different HA subtypes. Avian IAV HAs predominantly bind preferentially to the α-2-
3- linkage, whereas human IAV HAs preferentially bind to α-2-6- linkages (Connor et 
al., 1994).  The location and abundance of the α-2-3- and α-2-6- linkages on the surface 
of host cells differ from species to species, influencing the species- and tissue-tropism 
of IAVs (Matrosovich et al., 2004). α2,6-linked sialic acids are predominantly found 
on ciliated epithelium cells of the upper respiratory tract in humans, while α2,3-linked 
receptors that are broadly present on the epithelial cells of the avian gut but are only 
found predominantly in the lower respiratory tract of man (Matrosovich et al., 2004).  
This species-specific distribution of receptor subtypes poses a barrier for avian viruses 





acquired allowing a switch of specificity to α2,6-linked receptors. Indeed, mutations 
to the receptor binding domain of HA have been linked to a switch in receptor 
specificity following the adaptation of avian viruses to humans (Matrosovich et al., 
2000). A single point mutation, Q226L, conferred increased binding of avian H2 and 
H3 subtypes for α2,6-linked receptors, and E190D and D225G mutations were linked 
to the H1 switch to α2,6-linked receptors (Matrosovich et al., 2000). Interestingly, dual 
specificity in pdm2009 H1N1 viruses has been reported and is associated with a 
D222G adaptive mutation (Chutinimitkul et al., 2010).  
The cleavage sequence of HA0 determines which cellular proteases are able to 
cleave HA into its active form. Most HAs contain a single arginine residue in the 
cleavage sequence (monobasic cleavage site) and are cleaved by trypsin-like proteases, 
which are predominantly secreted into the respiratory epithelia of birds and mammals, 
and gut epithelium of avian species (Klenk and Garten, 1994). HPAI H5 and H7 
viruses possess a multi-basic cleavage site (MBCS) that can be cleaved by furin-like 
proteases that are expressed ubiquitously and can act intracellularly, and this is 
correlated with systemic infection and high virulence in birds and mammals (Webster 
and Rott, 1987, Stieneke-Grӧßer et al., 1992, Hatta et al., 2001). Removal of the MBCS 
from an H5N1 HPAI virus restricted infection to the respiratory tract of ferrets and 
reduced virulence, but insertion of an MBCS into an H3N2 human virus did not permit 
systemic infection and high virulence (Schrauwen et al., 2011, Schrauwen et al., 2012). 
Thus, the MBCS is likely required for high virulence in gallinaceous poultry, but not 
sufficient, and there is likely an interplay of multiple host and viral factors.  
The pH stability of cleaved HA is also a determinant of host range. Premature 





inactivates the virus, as HA can no longer perform membrane fusion (Stegmann et al., 
1987). It was reported that IAV of different HA subtypes differed in their sensitivity 
to acidic pH - HPAI of H5 and H7 subtypes seemed most sensitive to acidic pH in 
comparison to human and LPAI HA subtypes (Scholtissek, 1985). The human nasal 
cavity can display acidic pH as low as 5.2 (Washington et al., 2000), thus HPAI 
subtypes are likely required to acquire adaptive mutations to improve pH stability in 
order to avoid premature fusogenic activation of HA in the nasal cavity.  
1.7.1.2 Neuraminidase  
Adaptive mutations in both the enzymatic region of NA and the ‘stalk’ have 
been described following a change in host tropism (Wagner et al., 2002).  A compatible 
combination of HA and NA genes is required for a virus to replicate efficiently – as 
both effectively perform the opposite role to each other during the virus life cycle. The 
compatibility is dependent on the trade-off of receptor-binding affinity of HA versus 
the NA enzymatic activity and stalk length (Wagner et al., 2002). The evolution of a 
‘short stalk’ by a 19 amino acid deletion has been reported following host adaptation 
of avian influenza from waterfowl into domestic poultry, which is linked to increased 
virulence in poultry and mammals despite a reduction in receptor cleavage of host cells 
(Matrosovich et al., 2000, Matsuoka et al., 2009). Conversely, there is evidence to 
suggest that a short stalk inhibits efficient mammal-to-mammal transmission of HPAI 
(Blumenkrantz et al., 2013). This is correlated with inefficient virus release from 
infected cells and also an inability of the virus to penetrate host mucus layers in the 
epithelia which are rich in sialylated glycans which bind and inhibit receptor binding 
by HA (Blumenkrantz et al., 2013). Taken together, the evidence shows that the NA 






Avian IAV polymerases usually require adaptive mutations for efficient 
transcription and replication activity in mammalian host cells, and to cause high 
pathogenicity (Taft et al., 2015). The best characterised signature of host range lies at 
position 627 of the PB2 subunit of the polymerase. Most avian viruses contain 
glutamate at position 627 (E627), while many mammalian-adapted viruses have 
acquired a lysine (K627) (Subbarao et al., 1993, Chen et al., 2006a). E627 in PB2 
usually confers poor polymerase activity in mammalian cells in RNP reconstitution 
assays, but introducing the E627K adaptive mutation can improve polymerase activity 
(Naffakh et al., 2000, Massin et al., 2001, Moncorge et al., 2010, Foeglein et al., 2011). 
It is thought that cRNA synthesis is compromised for E627 polymerases in mammalian 
cells, and therefore genome replication is inhibited (Mänz et al., 2012). Furthermore, 
mutating the PB2 of an H3N2 and an H5N1 virus isolated from man to lose the 
mammalian-adaptation signature (K627E) reduced transmission between guinea pigs 
(Steel et al., 2009). High virulence of HPAI H5N1 and H7N9 in man has also been 
correlated with the E627K signature (Hatta et al., 2001, Zhang et al., 2014a). Recently, 
it was determined that the E627K adaptive mutation is required for complementarity 
of the polymerase with human acidic nuclear phosphoprotein 32 family member A 
(ANP32A) (Long et al., 2016). ANP32A is a host factor involved in transcriptional 
regulation and mRNA export that is diverse between avian and human species, and 
appears to be essential to support avian IAV polymerase function in human cells (Long 
et al., 2016). E627K is not essential for all infections of mammalian hosts, however. 
This is exemplified by the pdm2009 H1N1 virus which harbours the avian E627 





and Q591R (Mehle and Doudna, 2009, Yamada et al., 2010), and D701N, (Li et al., 
2005, Steel et al., 2009), can compensate. 
1.7.1.4 NS segment and host range 
The products of the NS segment are important for setting host range and 
pathogenicity, which forms the foundation of this project. Adaptive mutations have 
been noted in the major products of segment 8, NS1 and NEP (Forbes et al., 2012, 
Mänz et al., 2012). The roles of the NS genes during infection, and their influence on 
host adaptation and pathogenicity, are discussed more extensively below in 1.9 The 
NS segment of IAV.  
1.8 The innate immune response and influenza virus infection 
In this section, the innate immune response to IAV is discussed, with a 
particular focus on the mammalian type I IFN response.  
1.8.1 The interferons 
Interferons (IFN) are cytokines that have potent antiviral activities, and 
contribute to the innate immune response to viral infection. Following detection of a 
viral pathogen, cells secrete interferons which act through a cognate receptor to 
upregulate a host of interferon sensitive genes (ISGs) that include antiviral restriction 
factors. It is thought that a fully functional IFN response is sufficient to limit virus 
replication and prevent disease in the host; although most viruses have evolved 
mechanisms to circumvent the IFN response (reviewed in (Randall and Goodbourn, 
2008)). The IFNs exist as three families, each with distinct structural homologies and 
a family-specific receptor through which antiviral mechanisms are mediated: type I, 





I and type III IFNs are used in direct response to viral infection and involve similar 
sensing and signalling pathways, leading to the upregulation of a similar array of ISGs 
(Kotenko et al., 2003, Sheppard et al., 2003, Crotta et al., 2013, Wack et al., 2015). 
Type II IFN (IFN-γ) is secreted by activated T cells and natural killer cells, and has an 
immunomodulatory role (Platanias, 2005). Type III IFN includes IFN-λ1, IFN-λ2, 
IFN-λ3 (also known as interleukin-29, interleukin-28A, interleukin-28B, ; IL-29, IL-
28A and IL-28B, respectively), and IFN-λ4, and is predominantly produced by 
infected airway epithelial cells (Kotenko et al., 2003, Sheppard et al., 2003, Crotta et 
al., 2013, Wack et al., 2015). There are many type I IFNs, and in humans these include 
IFN-α (IFN-α itself has at least 14 different subtypes), IFN-β, IFN-ε, IFN-κ, and IFN-
ω. The best characterised type I IFNs are IFN-α and IFN-β, while the roles of IFN-ε, -
κ, and –ω are less well understood. From here onwards the term ‘type I IFN’ will refer 
to IFN-α and IFN-β only. IFN-β is secreted by most cell types, while IFN-α is 
predominantly secreted from leukocytes (Platanias, 2005).  
1.8.2 Sensing of IAV infection and IFN response 
The primary cells that produce IFN in response to IAV infection are infected 
airway epithelial cells, plasmacytoid dendritic cells and macrophages (reviewed in 
(Killip et al., 2015)). Infected cells can sense pathogen associated molecular patterns 
(PAMPs) using either the RIG-I-like receptor (RLR) cascade, Toll-like receptor (TLR) 
pathway, or the Nod-like receptor cascade. Influenza A virus infection is detected in 
most cell types by the RLR pathway, which contains the cytoplasmic DExD/H box 
RNA helicases retinoic acid-inducible gene 1 (RIG-I), melanoma differentiation-
associated protein 5 (MDA5) and laboratory of genetics and physiology 2 and a 





be predominantly sensed by cytoplasmic RIG-I, although MDA5 has also been 
reported to be important for efficient ISG upregulation in response to IAV (Benitez et 
al., 2015). Conversely, LGP2 overexpression has been reported to reduce IFN 
production caused by H3N2 infection (Malur et al., 2012). The RLR pathway senses 
IAV infection in most cell types, barring plasmacytoid dendritic cells, which use TLR 
family proteins TLR3 and TLR7 to detect IAV (Killip et al., 2015). Fig 1.4 shows a 
schematic for the pathways involved in IFN induction and signalling in response to 
IAV infection.   
RIG-I possesses two N-terminal caspase activation and recruitment domains 
(CARD), an RNA helicase domain, and a C-terminal  regulatory domain (CTD) that 
normally inhibits the exposure of the N-terminal CARD domains by holding the 
protein in a ‘closed’ conformation (Loo and Gale, 2011). It is thought that blunt-ended 
RNA duplexes with a 5’ triphosphate moiety are primarily responsible for RIG-I 
activation during influenza infection (Schlee et al., 2009), and the panhandle structure 
present in each segment of vRNA is sufficient to activate RIG-I (Liu et al., 2015a). 
The 5’ triphosphate RNA binds to the CTD and RNA helicase domains of RIG-I, 
inducing a conformational change to expose the N-terminal CARDs (Loo and Gale, 
2011). The CARDs require ubiquitination for full activity, which is mediated by 
cellular tripartite motif-containing protein 25 (TRIM25) (Gack et al., 2007), RING 
finger protein leading to RIG-I activation (RIPLET) (Oshiumi et al., 2009), or Mex-3 
RNA Binding Family Member C MEXC (Kuniyoshi et al., 2014). RIG-I signalling is 







Fig. 1.4. The interferon system. Shown are schematics of the pathways involved in 
type I interferon (IFN) induction following IAV infection (left hand side) and 
signalling (right hand side). Cytoplasmic RIG-I and MDA-5, and endosomal TLR3, 
all sense dsRNA associated with viral infection. Signalling cascades are induced 
(arrows show activation) and ultimately activate the transcription factors IRF-3 and 
NF-κB which upregulate the IFN-β promoter. Secreted IFN-β works in an autocrine 
and paracrine fashion to induce an antiviral state in host cells through activation of the 
type I IFN receptor and kinases Jak1 and Tyk2. Jak/STAT signalling results in the 
activation of the transcription factor complex ISGF3 which acts to upregulate the 
promoter of a plethora of ISGs. The induced ISGs act to restrict virus replication 
through a variety of mechanisms. Jak/STAT signalling also up-regulates type I IFN 
expression to amplify the response to infection. Figure was made by Prof. Rick Randall 






-inducible double stranded RNA dependent activator) to the C-terminal regulatory 
domain, which is required for a full IFN response to viral infection (Kok et al., 2011). 
The exposed and polyubiquitinated CARDs of RIG-I then interact with mitochondrial 
antiviral signalling protein (MAVS), which polymerises and activates I kappa B kinase 
(IKK) and TANK-binding kinase 1 (TBK1) (Loo and Gale, 2011). TBK1 and IKK 
phosphorylate the transcription factor interferon regulatory factor-3 (IRF-3) which 
subsequently localises to the nucleus. IKK phosphorylates inhibitor of κB (IκBα) 
which induces its degradation. IκB degradation frees the transcription factor nuclear 
factor kappa B (NF-κB) to also localise to the nucleus. These transcription factors 
subsequently upregulate the activity of the IFN-β promoter in conjunction with other 
transcription factors (such as the AP-1 heterodimer of ATF-2 and c-Jun) as part of the 
‘enhanceosome’ (Fig 1.4) (Loo and Gale, 2011).  
IFN-β is translated and secreted, and mediates responses in an autocrine and 
paracrine fashion via the IFN-α/β receptor (IFNAR) – leading to the upregulation of 
hundreds of interferon sensitive genes (ISGs) (Fig 1.4) (Randall and Goodbourn, 
2008). Neighbouring uninfected cells are therefore primed for virus infection, 
inhibiting virus spread. IFN-β binding to IFNAR activates janus kinase 1 (JAK1) and 
tyrosine kinase 2 (TYK2), and these phosphorylate signal transducer and activator of 
transcription 1 and 2 (STAT1 and STAT2) which form a heterodimer (Randall and 
Goodbourn, 2008). The phosphorylated STAT1/STAT2 heterodimer complexes with 
interferon regulatory factor 9 (IRF9), forming a complex called interferon stimulated 
gene factor 3 (ISGF3) in the cytoplasm. ISGF3 then undergoes nuclear import, where 
the complex acts to activate the promoters of many ISGs, by binding to IFN-stimulated 





in the promoters of type I IFNs to engage in a positive feedback loop to amplify the 
response to viral infection. The mechanism of action of select ISGs, known to be 
involved in the control of IAV, are overviewed below in 1.8.3 Interferon sensitive 
genes. 
The RIG-I pathway for sensing IAV infection has been well characterised for 
a number of years. Recently, there has also been evidence published proposing a role 
of a stimulator of interferon genes (STING)-mediated activation of IFN production 
following membrane fusion during IAV infection (Holm et al., 2016). STING-
mediated induction has been best described for DNA viruses. Cytoplasmic DNA is 
sensed by cyclic GMP-AMP (cGAMP) synthase (cGAS), which leads to 2’ 3’ cGAMP 
production. 2’ 3’ cGAMP binds to STING inducing a conformational change, which 
is then able to activate TBK1 (Ishikawa et al., 2009). As in the RIG-I pathway, TBK1 
activates IRF3 leading to IFN-β production. In the context of IAV infection, STING 
was shown to sense membrane fusion during IAV entry, independently of cGAS. 
Furthermore, a recombinant fusion peptide derived from HA was shown to interact 
with and inhibit STING to prevent IFN induction (Holm et al., 2016).  
It has been proposed that IFN production in response to IAV infection is 
stimulated by defective interfering particles (DIPs) containing defective viral genomes 
(DVGs). DVGs do not contain a fully functioning complement of vRNA segments, 
usually with an internal deletion or truncation in a larger genomic segment (PB2, PB1, 
PA) (Nayak, 1980). Although the mechanism of increased IFN induction has yet to be 
fully elucidated, studies have correlated an increased proportion of DVGs with 





2014). Therefore, IFN induction during IAV infection may be mediated by DI 
particles, rather than fully functional particles.  
1.8.3 Interferon sensitive genes 
Select ISGs are discussed below that have been well characterised in IAV 
infection and/or are relevant to experiments described in the results chapters of this 
thesis.  
1.8.3.1 Mx1 
Interferon-induced GTP-binding protein Mx1 (Mx1) is a mammalian 
guanosine triphosphatase (GTPase) that is induced by type I and type III IFN and 
confers protection against a variety of viruses including IAV (Staeheli et al., 1986). 
Protection against IAV is thought to be mediated by disrupting the interactions of the 
NP and PB2 proteins, resulting in an inhibition of polymerase activity (Verhelst et al., 
2012). The origin of NP appears to determine sensitivity to Mx1, with avian viruses 
appearing more sensitive to its antiviral mechanisms, and therefore Mx1 is considered 
an important barrier to avian influenza infection of mammals (Dittmann et al., 2008, 
Zimmermann et al., 2011, Verhelst et al., 2012).  
1.8.3.2 PKR 
The double-stranded RNA-dependent protein kinase PKR is an important 
mediator of antiviral response to infection (Gale and Katze, 1998). PKR is expressed 
ubiquitously, but is also upregulated by IFN signalling. PKR binds dsRNA and 
phosphorylates itself upon activation. PKR targets include the alpha subunit of 
eukaryotic initiation factor 2 (eIF2α) and I kappa B (IκB), the regulatory subunit of 





eukaryotic translation and requires bound GTP. Inactive eIF2α-GDP is released from 
the ribosome, and is normally ‘recycled’ by the eIF2β subunit, a guanine nucleotide 
exchange factor, to active eIF2α-GTP. Phosphorylation of eIF2α by PKR increases 
eIF2α affinity to eIF2β, rendering it unavailable for recycling and subsequent initiation 
events (de Haro et al., 1996). Thus, translation is inhibited and this reduces virus 
protein synthesis and therefore production of infectious virus (Gale and Katze, 1998). 
Phosphorylation of IκB activates NF-κB, which becomes free to enter the nucleus and 
upregulate type I IFN and ISG promoter activity (Kumar et al., 1994). The IAV 
interferon antagonist NS1 has evolved to bind and inhibit PKR (Min et al., 2007), and 
PKR knockout mice permit efficient replication of an IAV lacking NS1 that fails to 
replicate in WT mice (Bergmann et al., 2000). Therefore PKR is an important inhibitor 
of IAV.  
1.8.3.3 2’ 5’-oligoadenylate synthetase family  
The 2’ 5’-oligoandenylate (2-5A) synthetase (OAS) family consists of OAS1, 
OAS2, OAS3 and the 2’ 5’ oligoadenylate synthetase-like protein (OASL). OAS1, 
OAS2 and OAS3 all synthesise 2-5As from ATP, while OASL lacks this enzymatic 
activity. OAS proteins, like PKR, are activated by dsRNA during viral infection. The 
synthesis of 2-5As in response to viral infection activates ribonuclease L (RNase L). 
Activated RNase L destroys RNA species in the host cell, including viral mRNAs and 
cellular ribosomal RNAs, contributing to a reduction in viral protein synthesis and 
therefore replication (Drappier and Michiels, 2015). A recent study has implicated 
OAS3 as the major activator of the RNase L pathway in response to viral infection (Li 





OASL does not activate the RNase L pathway as it lacks the enzymatic activity 
to produce 2-5As. It has been proposed that OASL acts to increase the sensitivity of 
RIG-I to viral RNA species by mimicking polyubiquitin to facilitate RIG-I activation, 
and also by binding and recruiting dsRNA to RIG-I (Zhu et al., 2014).  
1.8.3.4 IFITM family 
The interferon induced transmembrane protein (IFITM) family are a family of 
proteins with two transmembrane domains linked by a highly conserved loop. In 
humans there are five IFITM genes (IFITM 1, 2, 3, 5 and 10), of which IFITM1, 2 and 
3 have been reported to possess antiviral activity against a wide range of viruses 
including IAV (reviewed in (Perreira et al., 2013). The IFITM proteins are thought to 
inhibit IAV at the entry step of virus infection (Brass et al., 2009, Feeley et al., 2011, 
Amini-Bavil-Olyaee et al., 2013). IFITM1 localises at the cell surface and early 
endosomes, while IFITM2 and 3 localise to late endosomes and lysosomes (Feeley et 
al., 2011, Mudhasani et al., 2013, Amini-Bavil-Olyaee et al., 2013). IFITM3 has been 
shown to be important in restricting morbidity and mortality in vivo against IAV 
(Everitt et al., 2012). Notably, IFITM1, 2 and 3 were highly induced in ducks infected 
with an H5N1 HPAI strain which did not cause significant pathogenicity, but were not 
up-regulated chickens which were highly susceptible to disease (Smith et al., 2015). It 
has therefore been suggested that the increased susceptibility of chickens to HPAI, 
relative to ducks, may be due to a poor upregulation of ISGs, including IFITM 1, 2 
and 3, which may be correlated with the galliform host lacking RIG-I (Magor et al., 
2013, Smith et al., 2015). Thus, the IFITM family of proteins represent host factors 
that are important for restriction of IAV and appear significant in defining the 





1.8.3.5 IFIT family 
The interferon-induced protein with tetratricopeptide repeats (IFIT) family 
members include IFIT1, IFIT2, IFIT3, and IFIT5. The IFIT family proteins are usually 
expressed at low levels under normal conditions, but are among the highest 
upregulated ISGs in response to IFN and viral infection (reviewed in (Fensterl and 
Sen, 2015)). IFIT1, 2 and 3 work in tandem to form a large multiprotein complex 
following stimulation with IFN, which sequesters 5’ triphosphate RNA via IFIT1-
RNA interactions; and this has antiviral effects against IAV (Pichlmair et al., 2011). 
Overexpression of either IFIT1, IFIT2 or IFIT3 alone did not exhibit antiviral activity, 
demonstrating the importance of the multiprotein complex assembly in the antiviral 
activity (Pichlmair et al., 2011). Additionally, it has been suggested that some IFIT 
family members may directly inhibit translation by interfering with the assembly of 
the translation initiation complex, reducing viral protein synthesis (Fensterl and Sen, 
2015). 
1.8.4 Viral IFN antagonists 
IAV has evolved mechanisms to counter and circumvent the IFN response, 
which would otherwise clear the virus (reviewed in (Randall and Goodbourn, 2008)). 
The NS1 protein is the major viral IFN antagonist and has evolved multiple 
mechanisms to inhibit the RLR pathway, reduce the expression of IFNs and ISGs, and 
block the action of multiple antiviral effectors. The roles and mechanisms of this 
protein are discussed in depth below. In addition to the NS1 protein, other viral 
proteins have been linked to inhibiting the IFN response, and are briefly outlined in 





1.8.4.1 The IAV polymerase and IFN antagonism 
As described earlier, the polymerase of IAV synthesises mRNA in a 
mechanism involving the ‘cap-snatching’ of 5’ 7-methylated caps from host pre-
mRNAs, destroying them. This is expected to contribute to host shut-off, and therefore 
would reduce the expression of proteins involved in RLR signalling, IFN induction 
and ISG expression. Furthermore, PB2, PB1 and PA of the influenza polymerase have 
all been shown to inhibit RIG-I signalling by binding to and inhibiting MAVS (Iwai 
et al., 2010, Graef et al., 2010).  
1.8.4.2 PB1-F2 
PB1-F2, expressed from an alternative start codon in the +1 ORF to PB1 from 
PB1 mRNA, also binds and inhibits MAVS to reduce IFN expression (Conenello et 
al., 2011, Varga et al., 2011, Varga et al., 2012). Following interaction with MAVS, 
PB1-F2 is thought to decrease mitochondrial membrane potential (Varga et al., 2012), 
which has been reported to be important for full MAVS-mediated IFN induction 
(Koshiba et al., 2011). 
1.8.4.3 PA-X 
PA-X selectively destroys host pol II derived mRNA transcripts in a process 
that requires host RNA endonuclease Xrn1 (Khaperskyy et al., 2016). It is thought that 
PA-X discriminates between host and viral mRNAs by mRNAs that use host 3’ 
processing machinery (Khaperskyy et al., 2016). This process results in a reduced 
immune response to infection in H1N1 and H5N1 viruses (Jagger et al., 2012, Gao et 
al., 2015b, Hayashi et al., 2015, Hu et al., 2015a) but conversely an increased response 






IAV hemagglutinin has been proposed to target the IFN-α/β receptor IFNAR 
for degradation by inducing its ubiquitination, and this has been shown to reduce the 
activation of the IFN-β promoter (Xia et al., 2015). As described earlier, HA also binds 
to STING to reduce STING-mediated induction of the IFN response (Holm et al., 
2016). 
1.8.5 Macrophages and IAV infection 
Macrophages are sentinel cells with key roles in mounting innate and adaptive 
immune responses to pathogens.  Alveolar macrophages (AM) are among the first 
immune cells that will come into contact with IAV during infection, residing in the 
lumen of the airways and alveoli. AMs contribute to viral clearance by phagocytosis 
of virions and infected cells, and are the main producers of type I IFN and pro-
inflammatory cytokines during IAV infection, and studies have shown the importance 
of macrophages in controlling influenza replication and disease (Tumpey et al., 2005, 
Kumagai et al., 2007, Kim et al., 2008, Tate et al., 2010). The release of pro-
inflammatory mediators, such as TNF-α and interleukin-1β, act to trigger 
inflammation in the area of infection leading to the recruitment of various innate 
immune cell populations that act to clear the virus and virus-infected cells. The pro-
inflammatory response, however, contributes to inflammation-induced lung damage. 
Pro-inflammatory mediators, particularly TNF-α, have been proposed to be 
responsible for the increased severity of lung pathology noted in human infection with 
HPAI H5N1 and the 2013 H7N9 viruses (Cheung et al., 2002, Lee et al., 2009b, To et 
al., 2016). Macrophages are also important in the induction of immunological memory 





in the control of IAV, but can also contribute to severe pathology during infection with 
HPAI and other strains.  
While airway epithelial cells are the primary target for IAV, macrophages can 
still be infected and undergo productive replication, although this appears to be in a 
strain- and macrophage-subtype specific fashion (reviewed in (Nicol and Dutia, 
2014)). The role of productive infection of macrophages in pathogenicity is not clear 
and remains to be elucidated (Nicol and Dutia, 2014). 
1.9 The NS segment of IAV 
The NS segment (segment 8) and its role in setting host range and 
pathogenicity of IAV in mammalian hosts forms the focus of this study. This section 
provides an introduction to the segment 8 genes of IAV. In particular, the phylogeny 
of the NS segment is discussed.  
1.9.1 NS segment gene products 
1.9.1.1 Nuclear export protein 
As described previously, NEP is translated from spliced segment 8 mRNA 
(Lamb and Lai, 1980). While the structure of the N-terminus of NEP (residues 1-53) 
has not been reported, a crystal structure of the C-terminus has revealed it forms a 
dimer of two helical hairpins composed of two antiparallel helices, forming an 
antiparallel four-helix bundle (Akarsu et al., 2003). The N-terminus harbours two 
hydrophobic nuclear export signals which mediate nuclear export of vRNPs as 
described earlier in 1.4.5 Nuclear export and trafficking of vRNPs. NEP is therefore 





NEP accumulation is typically ‘late’ in infection due to low abundance of NEP 
mRNA (only ~ 10% of all segment 8 mRNA), resulting from a ‘suboptimal’ 5’ splice 
donor site (Robb et al., 2010, Chua et al., 2013). It has been suggested that NEP 
regulates genome replication by triggering the switch of the viral polymerase complex 
from transcription to replication, following observations that NEP expression 
increases the levels of cRNA and vRNA in RNP reconstitution assays (Robb et al., 
2009). It has been proposed that the use of a suboptimal 5’ splice donor site is 
important as an early accumulation of NEP might cause a premature switch from 
transcription to replication and be detrimental to virus replication (Chua et al., 2013) 
NEP has been show to incur adaptive mutations when a virus crosses the 
species barrier (Mänz et al., 2012, Forbes et al., 2012). In particular, the M16I adaptive 
mutation is thought to compensate for the lack of activity of H5N1 avian polymerases 
with the PB2 E627 signature in human cells by allowing efficient cRNA synthesis 
(Mänz et al., 2012). This function is thought to be mediated by the C-terminal end of 
NEP, and it has been proposed that the M16I adaptive mutation allows a more efficient 
structural conformation to expose the C-terminus (Reuther et al., 2014b). 
NEP is known to undergo post-translational modification by phosphorylation 
and  conjugation with a small ubiquitin-like modifier (SUMO; SUMOylation), but the 
role of this in infection is not yet clear (Pal et al., 2011). S23, S24 and S25 of NEP can 
be phosphorylated (Hutchinson et al., 2012), but site-directed mutations of these serine 
residues to alanine (thus preventing phosphorylation) did not have any effect on virus 
replication in vitro or in vivo (Reuther et al., 2014a). Thus, it remains unclear whether 






1.9.1.2 Nonstructural protein 1 
i) General introduction 
NS1 is a multifunctional dimeric protein with a strain-specific size typically 
between 217-237 amino acids, but is commonly 230 amino acids in length (Suarez and 
Perdue, 1998). NS1 was traditionally thought to be a nonstructural protein, but recent 
mass-spectrometry analysis of purified virions has provided evidence that a small 
number of NS1 molecules are incorporated into virus particles (Hutchinson et al., 
2014). NS1 interacts with RNA and a variety of host-cell proteins in a host-and strain-
specific manner to primarily antagonise the innate immune response of the host, but 
also to optimise the host cell environment for virus replication (reviewed in (Hale et 
al., 2008b)). NS1 is a virulence factor essential for efficient viral replication and its 
main role is thought to be the antagonism of the host IFN response. An NS1-deletion 
mutant is heavily attenuated in tissue culture, but replication is significantly rescued 
in IFN-deficient VERO cells (García-Sastre et al., 1998), demonstrating the 
importance of IFN-antagonism by the NS1 protein.  
Efficient IFN antagonism by NS1 is likely an important facet of host adaptation 
of IAV. The consequences of an avian virus’ NS1 protein being unable to block the 
mammalian innate immune response could lead to rapid virus clearance and an 
inability to persist and adapt to the new host. Indeed, an analysis of NS1 protein 
sequences clearly showed host-dependent clustering, indicating a relationship between 
NS1 genotype and host range (Sevilla-Reyes et al., 2013). The NS1 protein of the 2013 
H7N9 subtype was shown to be competent in antagonising the IFN response in human 
cells without prior adaptation to the human host, unlike NS1 from other LPAI H7 





of avian NS1 proteins and found them all to be competent at blocking the IFN response 
in human cells, despite some WT avian viruses displaying attenuation in replication 
(Hayman et al., 2007). Also, pdm2009 H1N1 and seasonal H3N2 NS1 proteins have 
been shown to be poor at blocking the IFN response in human cells (Kuo et al., 2010, 
Hale et al., 2010b). However, efficient IFN antagonism may not be essential for host 
adaptation, but probably ‘helps’ a virus to persist long enough to acquire adaptive 
mutations in other regions of the genome (Hayman et al., 2007). 
ii) NS1 protein domain organisation  
Fig 1.5 shows schematic representations of the NS1 protein structure and 
domain organisation. Functional residues of NS1 are discussed and shown in Chapter 
2. The N-terminal 73 amino acids form an RNA-binding domain (RBD), a symmetrical 
homodimer composed of two monomers of three alpha-helices (Liu et al., 1997) (Fig 
1.5B). The RBD dimer binds single- and double-stranded RNA with low affinity 
(Hatada et al., 1992, Hatada and Fukuda, 1992) via electrostatic interaction with basic 
amino acids in helix 2 (R38 and K41) that are absolutely conserved across all IAVs 
(Wang et al., 1999). dsRNA-binding prevents the activation of the antiviral ISG OAS 
(Min and Krug, 2006). The RBD also binds polyadenylated mRNAs (Qiu and Krug, 
1994), viral genomic RNA (Hatada et al., 1997), vRNPs via interaction with NP (Robb 
et al., 2011), and binds specifically to a conserved motif in the 5’ end of all positive-
sense viral RNA as well as a motif in the 3’ untranslated region (UTR) of NS1 mRNA 
(Marc et al., 2013). The RBD contains nuclear localisation signals to allow nuclear 
import to perform its functions in the host cell (Greenspan et al., 1988), and NS1 has 
also been shown to be targeted to the nucleolus in a strain- and host-dependent manner 






Fig 1.5. NS1 structure and domain organisation. (A) A schematic of the domain 
organisation is shown for an NS1 monomer with the residue positions annotated. The 
RNA-binding domain (RBD, 1-73) and effector domain (ED, 85-206) are connected 
by a short linker (SL). Residues 206 to end (typically 217-237) form an unstructured 
tail (UT). ‘N’ and ‘C’ represent the N- and C-termini of the protein, respectively. (B) 
Shown is a dimer of two full-length NS1 proteins (green and wheat). The crystal 
structures of the RBD and ED have been characterised and are shown. The short linker 
and unstructured tail have not been observed in crystal structures and have been 
represented schematically in this diagram by the authors. EDs are shown in the 
proposed ‘helix open’ conformation. Cylinders represent α-helices and arrows 






The RBD is connected to a C-terminal effector domain (ED) by a short, flexible, linker 
(residues 74-85). Like the RBD, the ED (residues 85 to 206) of both human and avian 
NS1s forms a homodimer, each of which consists of seven β-sheets and three α-helices 
(Bornholdt and Prasad, 2006, Hale et al., 2008a) (Fig 1.5B). W187 is highly conserved 
and is important for ED dimerisation, which has been shown to be required for efficient 
RNA-binding by the RBD (Hale et al., 2008a). It has also been suggested that the NS1 
ED displays structural polymorphism to allow interaction with multiple different 
cellular binding partners dependent on conformation (Kerry et al., 2011a, Carrillo et 
al., 2014). The ED interacts with a plethora of host cell and viral proteins (these are 
detailed below) to influence the cellular environment to be optimal for viral 
replication. The ED also contains a nuclear export signal (residues 138-147) (Li et al., 
1998), and together with the NLSs in the RBD allow nucleocytoplasmic shuttling of 
the protein during infection to interact with multiple binding-partners in different sub-
cellular locations in the infected host cell.  
The C-terminus is formed of an unstructured tail (206 to end). The unstructured 
tail of NS1 sometimes contains a PDZ-binding motif (PBM) of the X-S/T-X-V type at 
residues 227-230 that differs between strains in a host-dependent manner. RSKV or 
RSEV sequences are found in the majority of human isolates, and an ESEV or an 
EPEV sequence is a signature for avian NS1s (Obenauer et al., 2006). Introducing the 
avian ESEV PBM into a lab-adapted H1N1 NS1 or an H5N1 NS1 increased virulence 
in mice and improved transmission efficiency (Jackson et al., 2008, Kim et al., 2014). 
Conversely, reverse genetics to re-instate the unstructured tail and to introduce a PBM 
into pdm2009 H1N1 NS1 (only 219 amino acids in length) did not improve virus 





2010c). Thus, the role of the PBM in NS1 in setting host range and pathogenicity is 
not fully understood. The unstructured tail is also thought to be involved in the 
inhibition of poly(A)-binding protein II (PABPII) (Chen et al., 1999), as described 
below. 
iii) IFN antagonism 
NS1 has evolved multiple mechanisms to block IFN induction and to inhibit 
intracellular antiviral effectors. The activation of the transcription factors IRF-3, NF-
κB, and AP-1 are inhibited by NS1 in a strain-dependent manner, reducing the activity 
of the IFN-β promoter (Talon et al., 2000, Wang et al., 2000, Ludwig et al., 2002). 
However, the precise mechanism of how NS1 inhibits these transcription factors is 
currently not fully understood (Krug, 2015). A direct interaction of NS1 with RIG-I, 
which inhibits downstream signalling and therefore IRF-3 and NF-κB activation, has 
been reported (Mibayashi et al., 2007). NS1 also binds the cellular E3 ligases TRIM25 
(Gack et al., 2009) and Riplet (Rajsbaum et al., 2012) in a species-specific manner to 
inhibit the ubiquitination and activation of RIG-I. Additionally, NS1 inhibits cellular 
PACT, also important in RIG-I activation (Tawaratsumida et al., 2014). However, NS1 
proteins from human seasonal H2N2 and H3N2, and some seasonal H1N1 strains, have 
been reported to be poor at blocking IRF-3 phosphorylation and IFN-β production 
despite an interaction with TRIM25 (Kuo et al., 2010). Thus, the mechanisms of IRF-
3 and NF-κB inhibition by NS1 are yet to be fully elucidated. 
NS1 also dampens host responses by inhibiting nucleocytoplasmic transport of 
mRNAs (Fortes et al., 1994, Qiu and Krug, 1994). The NS1 protein of certain strains 





(CPSF30) (Nemeroff et al., 1998) and PABPII (Chen et al., 1999) of the cellular 3’-
end pre-mRNA processing machinery. This leads to a reduction in cellular mRNA 
processing and nuclear export, and a subsequent decrease in IFN and ISG expression 
(Li et al., 2001, Noah et al., 2003). Viral mRNAs are thought to be unaffected by this 
since the 3’ poly(A) tails are obtained by re-iterative copying of the viral polymerase 
on poly-U tracts of the template (Poon et al., 1999), rather than by the cellular 3’ 
processing machinery. NS1 has also been reported to form inhibitory interactions with 
components of the mRNA nuclear export machinery (Satterly et al., 2007).  
As mentioned previously, NS1 is known to bind and inhibit PKR (Min et al., 
2007) and OAS (Min and Krug, 2006) to block these intracellular antiviral effectors.  
iv) NS1 and regulation of virus replication 
The NS1 protein binds to the AGCAAAAG motif in the 5’ UTR of viral 
mRNAs and enhances their translation (de la Luna et al., 1995, Marc et al., 2013). This 
is thought to be mediated by interactions with eukaryotic initiation factor 4G (EIF4G) 
(Aragόn et al., 2000) and poly(A)-binding protein I (PAB1) (Burgui et al., 2003), to 
form viral mRNA ‘translation initiation complexes’. NS1 also regulates viral 
polymerase activity, as a reduction in the production of viral vRNA, cRNA and mRNA 
has been observed in RNP reconstitution assays when NS1 is also expressed (Wang et 
al., 2010). It is currently unknown how NS1 regulates the polymerase.  
NS1 binds to and inhibits U6 spliceosomal RNA (sRNA) of the host 
spliceosome and this inhibits interactions with U2 and U4 sRNAs to regulate host cell 
splicing of pre-mRNA (Lu et al., 1994, Qiu et al., 1995). The effect on viral mRNA 





that NS1 inhibits the splicing of its own mRNA (Fortes et al., 1994, Garaigorta and 
Ortin, 2007), while others have reported NS1 does not influence segment 8 mRNA 
splicing (Lu et al., 1994, Robb et al., 2010). Likewise, while there is evidence to 
suggest segment 7 mRNA splicing is unaffected by NS1 (Salvatore et al., 2002), others 
have suggested that NS1 does regulate this (Lu et al., 1994, Robb and Fodor, 2012).  
Thus, it is not fully clear how NS1 regulates viral mRNA splicing. However, the 
inhibition of cellular pre-mRNA splicing is expected to contribute to host shut-off.  
v) NS1 and cell signalling 
The NS1 protein has been reported to regulate host-cell signalling via multiple 
mechanisms. It is known that NS1 binds to and prevents the regulatory p85β subunit 
of phosphoinositide 3-kinase (PI3K) preventing its auto-inhibitory function, which 
results in the activation of the catalytic p110 subunit of the kinase (Hale et al., 2006, 
Hale et al., 2010a). Mutating an essential amino acid required for the p85β interaction 
(Y89F) attenuated virus replication in tissue culture (Hale et al., 2006), and reduced 
virulence and pathogenicity in mice (Hrincius et al., 2012), suggesting the PI3K 
activation is important for virus replication. However, the mechanisms behind this pro-
viral response of PI3K activation are not fully understood (Ayllon et al., 2012). 
Furthermore, NS1 proteins from avian IAVs, and the pdm1918 H1N1 strain, are 
known to interact with an N-terminal Src homology 3 (SH3) domain in Crk (CT10 
(chicken tumour virus number 10) regulator of kinase) and CrkL (Crk-like) adapter 
proteins (Heikkinen et al., 2008), which regulate various cellular signalling pathways. 
The interaction of NS1 with Crk proteins inhibits the IAV-triggered activation of the 
Jun-N-terminal kinase (JNK) signalling pathway, and this is thought to be important 





et al., 2010). NS1 has also been implicated in altering the cell cycle by inhibiting RhoA 
(Ras homolog family member A) expression and activity to cause G0/G1 cell cycle 
arrest (Jiang et al., 2013). The G0/G1 phase has been suggested to be the most efficient 
stage for virus replication, possibly because cellular RNA polymerase II is most active 
and capped mRNAs are most abundant (He et al., 2010). 
vi) Post-translational modification of NS1 
NS1 is known to undergo strain-specific, post-translational modification. This 
includes phosphorylation and conjugation with SUMO and interferon-sensitive gene 
15 ubiquitin-like modifier (ISG15). T125 was identified as a phosphorylation site in 
human IAV NS1, which is phosphorylated by host cyclin-dependent kinases (CDK) 
and extracellular signal-regulated kinases (ERK) (Hale et al., 2009). Whilst a T125A 
mutation reduced viral fitness of A/Udorn/1972 (H3N2) (Udorn72), it has been 
suggested that this mutation alters the structure of NS1, abrogating a different function 
(Hale et al., 2009, Hsiang et al., 2012). Serines 42 and 48, and T197 have also been 
observed to be phosphorylated, but the roles of phosphorylation of these residues are 
currently not clear (Hsiang et al., 2012, Hutchinson et al., 2012). Phosphorylation of 
NS1 at T49 has been proposed to inhibit the ability of NS1 to perform IFN-antagonistic 
functions (Kathum et al., 2016). Thus, phosphorylation of NS1 may be important for 
virus replication. 
NS1 is also SUMOylated at three lysine residues (K70, K219 and K221), 
predominantly at K70 and K219 (Xu et al., 2011, Santos et al., 2013). Santos et al 
propose that an optimal level of SUMOylation is required for efficient IFN-





to block IFN induction (Santos et al., 2013). Additionally, NS1 is targeted for 
conjugation by the IFN-inducible ISG15, an ubiquitin-like protein, which conjugates 
to NS1 at K41, mediated by HECT and RLD domain containing E3 ubiquitin protein 
ligase 5 (Herc5 E3 ligase) (Zhao et al., 2010). ISG15 conjugation prevents NS1 nuclear 
import and IFN-antagonism to attenuate virus replication, but does not inhibit RNA-
binding by the NS1 protein despite conjugating to one of the RNA-binding residues 
(Zhao et al., 2010). It is not known whether NS1 sequesters cellular ISG15 from 
conjugation to other viral proteins, or whether the ISG15 conjugation prevents NS1 
carrying out its functions as efficiently (Zhao et al., 2010). Therefore, there are several 
reports suggesting the post-translational modification of NS1 may be important for 
IAV replication, but the mechanisms remain to be fully elucidated.   
1.9.1.3 Additional segment 8 gene products 
The NS3 protein is expressed in IAV strains in which the NS1 protein has 
incurred a D125G mutation (A374G in nucleotide sequence representing GAT->GGT 
in NS mRNA sequence) to introduce a second splice acceptor site into the mRNA. 
NS3 is an internally deleted version of NS1 protein that lacks residues 126-168 
(Selman et al., 2012). This mutation was initially noted following serial passage of a 
human H3N2 virus in mice and was found to increase virulence (Forbes et al., 2012). 
It has been speculated to be selected for following adaptation of avian viruses to 
mammalian hosts (Selman et al., 2012). However, the A-to-G substitution to form the 
NS3 splice acceptor site was only detected in 33 viruses out of over 18 000 isolates 
examined (Selman et al., 2012). Currently, the function of NS3 in virus replication is 





Negative sense protein (NSP; also referred to as NEG8) is a putative accessory 
gene product from an ORF in certain IAV strains, of strain-specific length, located on 
segment 8 vRNA (reading 5’ to 3’) and therefore in the opposite sense to mRNA 
(Zhirnov et al., 2007, Clifford et al., 2009). If actually utilised, this ORF would 
represent the first described ambisense property of the IAV genome. The putative gene 
product is predicted to be a transmembrane protein, although no protein product has 
been detected in a laboratory setting. Nevertheless, both sets of authors claim that the 
ORF has been positively selected for in human viruses (Zhirnov et al., 2007, Clifford 
et al., 2009). However, since an expression mechanism has yet to be validated (Clifford 
et al. suggest the possibility of translation initiation from segment 8 vRNA by an, as 
of yet undescribed, internal ribosome entry site and translation in a poly(A) tail-
independent manner) and no functional studies have been performed, it is difficult to 
speculate the importance of this putative gene product in IAV biology. 
Recently, it has been reported that alternative downstream AUG start codons 
can be utilised in NS1 mRNA to express an N-terminally truncated variant of the NS1 
protein (tNS1) (Kuo et al., 2016). The second and third in-frame AUG codons of NS1 
mRNA lie at position 79 and 81 respectively, with the latter being in a strong Kozak 
sequence and the former in a weak Kozak sequence. Both start codons were utilised 
by PR8 and Udorn72 to express a 17kDa product (Kuo et al., 2016). The tNS1 
contributed to inhibition of IRF3 activation and a reduction in IFN-β transcription in 
stimulated human cells for PR8, but not for Udorn72 (Kuo et al., 2016). Preventing 
the expression of tNS1 in PR8 by site-directed mutagenesis reduced virus replication 





1.10  The A- and B-alleles of the NS segment 
Traditionally, the NS segment of non-chiropteran IAV has been divided into 
two phylogenetically distinct ‘alleles’ (the ‘A- and B-alleles’) with strikingly low 
sequence similarity. The amino acid sequence identity of the NS1 protein is typically 
at least 93% within an allele but can be as low as 62% across the two lineages (Treanor 
et al., 1989, Ludwig et al., 1991, Suarez and Perdue, 1998, Hale et al., 2008b). Despite 
this variation in amino acid sequence identity, a crystal structure of a B-allele NS1 ED 
showed that the overall conformation is highly similar to that of an A-allele (Hale et 
al., 2008a). The A-allele lineage contains both avian and mammalian IAV sequences, 
while the B-allele lineage is predominantly avian (Ludwig et al., 1991). The vast 
majority of functional studies of the NS1 and NEP proteins of IAV to date have been 
conducted on A-allele genes.  
It has been widely accepted that B-allele NS segments are avian-restricted and 
attenuating in mammalian hosts. This hypothesis was formed over 25 years ago, and 
at the time of the study there were no reports of a B-allele virus being isolated from a 
mammalian host (Treanor et al., 1989). Treanor and colleagues generated segment 8 
reassortant viruses in the backbone of Udorn72 and assessed virus replication in 
squirrel monkeys. The B-allele reassortant viruses did not replicate as well in the 
nasopharynx in comparison to an avian A-allele counterpart, and were cleared more 
rapidly. However, virus titre in the trachea was not significantly different and the 
reassortant viruses replicated well in vitro. Nevertheless, the authors concluded that B-
allele NS segments are attenuating for IAV in mammalian hosts, a view that has been 





The first reported B-allele sequence isolated from a mammalian host was 
recorded following a major equine influenza outbreak in China in 1989. This equine 
virus outbreak, typified by A/equine/Jilin/1/1989 (H3N8), caused a high mortality rate 
(approximately 20%) and spread readily within horse populations (Guo et al., 1992). 
This provided the first piece of evidence that B-allele NS segments are not necessarily 
avian-restricted. Since then, additional B-allele viruses have been isolated from 
mammalian hosts. At the time of this study, there have been eight mammalian-derived 
B-allele sequences uploaded to GenBank, however there are tens of thousands of 
mammalian A-allele sequences available (discussed in detail in Chapter 5). 
Following the report by Treanor and colleagues, the Berg laboratory published 
a series of studies investigating the ability of A- and B-allele NS1 proteins to inhibit 
the IFN response in mammalian cells. Zohari et al reported that the NS1 protein from 
an A-allele H10 mink virus was more efficient at suppressing IFN-β gene expression 
in mink and human lung cells than a closely related H10 chicken B-allele virus NS1 
(Zohari et al., 2010b, Zohari et al., 2010a). Likewise, Munir and colleagues assessed 
A- and B- allele NS1 proteins of closely related H6N8 viruses isolated from mallards, 
and found that the A-allele NS1s were more competent than the B-alleles at preventing 
IFN-β, NF-κB and AP-1 promoter activation in stimulated human and mink lung cells 
(Munir et al., 2011b, Munir et al., 2011a, Munir et al., 2012). Thus, it was proposed 
that the mechanism underlying the apparent avian-restriction of B-allele viruses was 
an inability of avian B-allele NS1 proteins to counter the IFN response in the 
mammalian host. However, at no point were the differences seen in IFN reporter-based 






Contrary to the above reports, there is evidence to suggest that B-allele NS 
segments are not necessarily attenuating in mammalian hosts. Hayman and colleagues 
assessed a panel of avian NS1 proteins, including a B-allele representative 
(A/duck/Albany/76), using transfection-based reporter assays and found all were able 
to successfully inhibit IFN-β expression in human cells (Hayman et al., 2007). Others 
have described that a B-allele segment 8 increased the virulence and pathogenicity of 
an A-allele IAV parent in a mammalian host (Ma et al., 2010). The authors introduced 
the segment 8 from an H5N1 HPAI strain into the backbone of an A-allele H7N1 HPAI 
virus and found this improved replication in mammalian cells and improved the 
inhibition of IFN-β production (Ma et al., 2010, Wang et al., 2010). Additionally, the 
reassortant H7N1 caused mortality in mice, unlike the parental virus (Ma et al., 2010). 
Furthermore, A- and B-allele NS segment reassortant viruses on the background of 
PR8 induced similar degrees of pathology in mice (Kim et al., 2015a). Therefore, it is 
not clear why the B-allele NS segments are apparently restricted to avian hosts.  
1.11  Aims and approach 
The overall aim of this project was to improve the understanding of the 
mammalian adaptation of avian influenza viruses. If the mechanisms that cause the 
apparent avian-restriction of the B-allele lineage of NS genes could be fully elucidated, 
the understanding of viral and host determinants behind host adaptation would 
potentially be significantly enhanced. It is crucial that the scientific community 
improves understanding of the viral and host determinants that allow avian IAV to 
adapt to a new host and cause disease, particularly given the current absence of a 





as a warning of the potential devastation that can result from a highly pathogenic virus 
adapting to the human host.  
The basis of the project was the generation of segment 8 reassortant viruses 
harbouring segments 1-7 from a mammalian-adapted virus and the segment 8 from 
either the A- or the B-allele lineage. The viruses were generated by reverse genetics to 
be used as tools to assess replicative fitness in mammalian cells in vitro and in vivo, so 
that any differences could be attributed to the lineage of NS segment. Subsequently, 
functional analyses of segment 8 products and analysis of host cell responses to 
infection could reveal determinants of host adaptation linked to the genetic traits of 
IAV NS segments. 
Chapter 2 describes the generation of segment 8 reassortant viruses by reverse 
genetics and the characterisation their replicative fitness in mammalian host cells in 
vitro. In Chapter 3, the influence of segment 8 lineage on host cell responses, in 
particular the type I IFN response, is assessed. Analyses on the replicative fitness of 
NS reassortant viruses and host immune responses in vivo are reported in Chapter 4. 
In Chapter 5, an extensive phylogenetic analysis of available IAV segment 8 sequences 
is presented. Concluding remarks are presented in Chapter 6, and the materials and 






 Chapter 2: Replicative fitness of segment 8 




As discussed in more detail in Chapter 1, the overall aim of this study was to 
better elucidate mechanisms underpinning the proposed avian-restriction of IAV 
strains harbouring a B-allele NS segment. Understanding the mechanism of restriction 
would allow an improved understanding of the ability of avian IAVs to infect 
mammalian hosts, and in particular the contribution of the NS segment in Aves to 
Mammalia transmission.  
The aim of this section of the study was to assess replicative fitness of 
mammalian viruses that had been forcibly reassorted to contain an avian IAV segment 
8, from either the A- or B-allele lineage, in mammalian host systems in vitro. 
Differences in replicative fitness could therefore be attributed to the NS genes and this 
could provide a platform to understand the mechanisms behind the proposed avian-
restriction of B-allele NS segments. 
2.1.2 Hypothesis 
In this study, it was hypothesised that incorporation of an NS segment 
belonging to the B-allele clade of avian influenza strains would attenuate the 
replicative fitness of a mammalian-adapted IAV in mammalian cells in vitro, since B-
allele genes have been proposed to be unable to allow efficient IAV infection of 
mammalian hosts in previous reports (Treanor et al., 1989, Zohari et al., 2010a, Munir 





A-allele lineage. It was speculated that deficiencies of B-allele NS segments in 
mammalian host systems could arise from one or more of several mechanisms: i) an 
inadequate complementation with the viral polymerase could reduce replicative 
fitness, since NS1 and NEP have both been implicated in regulating viral polymerase 
activity in RNP reconstitution assays (Bullido et al., 2001, Robb et al., 2009, Wang et 
al., 2010). ii) Abnormal regulation of viral protein synthesis, since NS1 recruits eIF4G 
and PABPI to enhance viral mRNA translation (Burgui et al., 2003), inhibits the host 
cell spliceosome (Lu et al., 1994, Qiu et al., 1995) and may regulate segment 7 mRNA 
splicing (Robb and Fodor, 2012). iii) Inefficient control of the mammalian IFN 
response by B-allele NS1 proteins, as has been speculated in previous reports (Zohari 
et al., 2010a, Munir et al., 2011a, Munir et al., 2011b, Munir et al., 2012). iv) B-allele 
NS segments could be disadvantaged at the level of genetic reassortment into 
mammalian-adapted viruses compared to A-allele NS segments, due to differences in 
RNA packaging signals (Gog et al., 2007). v) An inability of B-allele NEP to perform 
nuclear export of vRNPs in mammalian cells would abolish virus propagation.  
2.1.3 Approach 
Initially, a panel of A- and B-allele segment 8 genes from North America (See 
Table 2.1 for NS genes) were incorporated into the mouse-adapted PR8 backbone, and 
used as tools to assess replicative fitness in mammalian cells in vitro. The NS segments 
were selected from a variety of LPAI strains isolated in North America between 1986 
and 2005, from multiple H and N subtype backgrounds (Table 2.1) by Prof. Jeffery 
Taubenberger (The National Institute of Allergy and Infectious Diseases, Maryland, 





Table 2.1. Virus strains. 
Virus 
Name 
Strain from which NS segment isolated Allele Accession 
number (NS) 
PR8 A/Puerto Rico/8/1934 (H1N1) A EF467817.1 
Cal7 A/California/7/2009 (H1N1) A Unpublished 
Udorn72 A/Udorn/72 (H3N2) A CY009640.1 
O175Aa A/green-winged teal/Ohio/175/1986 (H2N1) A CY018881.1 
O173A A/mallard/Ohio/173/1990 (H11N9) A CY021665.1 
O340A A/green-winged teal/Ohio/340/1987 (H11N9) A CY021873.1 
M1124A A/mallard/Maryland/1124/2005 (H11N9) A CY021473.1 
O265Ba A/Mallard/Ohio/265/1987 (H1N9) B CY017279.1 
O430B A/green-winged teal/Ohio/430/1987 (H1N1) B CY011044.1 
O264B A/mallard/Ohio/264/1986 (H3N8) B CY016399.1 
O339B A/pintail/Ohio/339/1987 (H3N8) B CY019201.1 
O668B A/mallard/Ohio/668/2002 (H4N6) B CY020793.1 
O671B A/mallard/Ohio/671/2002 (H4N6) B CY020801.1 
O35B A/northern shoveler/Ohio/35/1986 (H3N8) B CY020937.1 
O246B A/bufflehead/Ohio/246/1986 (H11N2) B CY017079.1 
Alb88Bb A/mallard/Alberta/88/1976 (H6N8) B M25373.1 
NY6750Ac A/mallard/New York/6750/1978 (H2N2) A M25376.1 
Sw412Ad A/mallard/Sweden/S90412/2005 (H6N8) A EU518721.1 
Sw418Be A/mallard/Sweden/S90418/2005 (H6N8) B EU518722 
NY107Bf A/New York/107/2003 (H7N8) B EU587374.2 
J89B A/equine/Jilin/1/1989 (H3N8) B M65020.1 
a Used as representative “consensus” A and B genes for specific experiments. 
b1-15 & 855-890 from A/blue-winged teal/ALB/221/1978(H7N2) (CY005035.1). g242a to 
remove BsmBI site. 
c1-16 and 855-890 from A/mallard/New York/6750/1978(H2N2) (M80945.1). 
d1-26 and 888-890 from A/duck/Italy/194659/2006(H3N2) (FJ432766.1). 
e1-26 and 882-890 from A/tufted duck/Mongolia/1409/2010(H1N1) (KC871435.1). a696c to 
remove BsmBI site. 





Rebecca Dunfee from Prof. Jeffery Taubenberger’s laboratory. The influence of the 
lineage of segment 8 on virus polymerase transcriptional activity, virus protein 
expression, and infectious virus production was studied in mammalian cells. 
2.1.3.1 A-and B-allele NS genes  
The amino acid sequences of the NS1 proteins from these LPAI viruses were 
at least 99% homologous within their respective clade, and typically shared only 71% 
sequence homology across the two groups (Fig 2.1), which is in keeping with previous 
publications (Ludwig et al., 1991, Suarez and Perdue, 1998). The NEP proteins were 
generally less divergent between the two clades, typically sharing 84% sequence 
identity (Fig 2.2). The literature was reviewed on NS1 and NEP proteins and residues 
which have been characterised as being important for protein function were noted. 
These were compared across the A- and B- allele NS1 and NEP proteins used in this 
report (Figs 2.1 and 2.2). Most key functional residues of NS1 and NEP were 
conserved in B-allele proteins. In NS1, R38 and K41 which are important for RNA 
binding and circumvention of the antiviral response (Wang et al., 1999, Min and Krug, 
2006)  as well as E96 and E97, which are involved in binding to and inhibiting TRIM25 
and therefore activation of RIG-I (Gack et al., 2009), were conserved in B-allele NS1s. 
However, the F103 residue - which has been shown, along with M106, to be essential 
for the binding and inhibition of cellular 30-kDa cleavage and polyadenylation 
specificity factor 30 (CPSF30), a protein involved in the 3’ processing of pre-mRNAs 
(Nemeroff et al., 1998, Li et al., 2001, Kochs et al., 2007, Das et al., 2008) - was highly 
conserved in A-allele NS1s but appeared to be invariably different (Y103) in B-allele 
NS1 proteins used in this study (Fig 2.1). This observation has been reported elsewhere 






Fig 2.1 NS1 protein alignment. NS1 protein sequences from selected IAV strains 
were aligned using clustal omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) using 
default parameters. Alignments were processed using Boxshade Server 
(http://www.ch.embnet.org/software/BOX_form.html). Features of functional interest 
are annotated in the alignment. 
a – 21RFADQELG28 and 21LLSMRDMC28 mostly conserved within A- and B- alleles, 
respectively (Munir et al., 2011b). 
b – 35-41 nuclear localisation signal (Greenspan et al., 1988, Melen et al., 2007, Han 
et al., 2010). 
c – R38 essential for RNA binding. K41 plays important role. (Wang et al., 1999). 





e – S48 and T49 are phosphorylation sites (Hutchinson et al., 2012). T49 
phosphorylation inhibits IFN-antagonism (Kathum et al., 2016). 
f – K70 SUMOylation site (Santos et al., 2013). 
g- Codons 79 and 81 can be used as an alternative start site for tNS1 expression in PR8 
and Udorn72 (Kuo et al., 2016). 
h – Y89 required for PI3K binding (Hale et al., 2006, Hale et al., 2010a). 
i – E96 and E97 dictate TRIM25 binding and inhibition (Gack et al., 2009). 
j – F103 and M106 important for efficient CPSF30 binding and inhibition (Twu et al., 
2007, Kochs et al., 2007, Das et al., 2008). 
k – 123-127 involved in PKR binding and inhibition (Min et al., 2007). 
l – D125G mutation (GAT > GTT) forms splice acceptor site leading to NS3 
expression (Selman et al., 2012). 
m – 138-147 nuclear export signal (Li et al., 1998). 
n – P164 and P167 involved in PI3K binding (Shin et al., 2007, Hale et al., 2010a).  
o – E186 involved in CPSF30 binding and inhibition (Nemeroff et al., 1998, Li et al., 
2001, Noah et al., 2003). 
p – W187 required for effector domain dimerisation (Kerry et al., 2011b). 
q – E196K mutation fails to inhibit IRF3 activation (Kuo et al., 2010). 
r - T197 phosphorylation site (Hutchinson et al., 2012). 
s - 211GPPLPPKQKRYMARRV226 A2 rabbit polyclonal antiserum epitope. 
t – 212PPLPPK CRKL217 motif binds CRKI/II and CRKL proteins to prevent strong 
activation of JNK-AFT2 pathway (Heikkinen et al., 2008, Hale et al., 2009). 
u – T215 phosphorylation site (Hale et al., 2009) 
v – 216-229 second nuclear localisation signal (Greenspan et al., 1988, Melen et al., 
2007, Han et al., 2010).  
w – K219 and K221 are SUMOylation sites (Xu et al., 2011, Santos et al., 2013).  
x – 223-230 involved in PABPII binding and inhibition (Chen et al., 1999, Li et al., 
2001). 
y – 227ESEV230 motif for PDZ-domain binding and virulence factor (Obenauer et al., 








Fig 2.2. NEP protein alignment. NEP protein sequences from selected IAV strains 
were aligned using clustal omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) using 
default parameters. Alignments were processed using Boxshade Server 
(http://www.ch.embnet.org/software/BOX_form.html). Features of functional interest 
are annotated on the alignment.  
a – S7L mutation seen in H5N1 human isolates which enhances avian H5N1 
polymerase activity (PB2 E627) in human cells (Mänz et al., 2012). 
b – 12-21 hydrophobic NES-1 that is important for nuclear export of vRNPS via 
interactions with CRM1 (O'Neill et al., 1998, Iwatsuki-Horimoto et al., 2004). 
c - M16I enhances avian H5N1 polymerase activity (PB2 E627) in human cells (Mänz 
et al., 2012). 
d – M16, M19 and L21 replacement with alanine abolishes NP nucleocytoplasmic 
transport (Neumann et al., 2000). 
e – S23, S24 and S25 highly conserved in NEP, and have been observed to be 
phosphorylated (Hutchinson et al., 2012).  





g – 31-40 hydrophobic NES-2 which is important in nuclear export of vRNPs via 
interaction with CRM1 (Huang et al., 2013). 
h - Y41C enhances avian H5N1 polymerase activity (PB2 E627) in human cells (Mänz 
et al., 2012). 
i – A48T enhances avian H5N1 polymerase activity (PB2 E627) in human cells (Mänz 
et al., 2012). 
j – E75G enhances avian H5N1 polymerase activity (PB2 E627) in human cells (Mänz 
et al., 2012). 
k – W78 involved in interaction with M1 to mediate nuclear export of vRNPs 






this study except in O668B, which has an isoleucine at this position. E186, which has 
also been reported to be an important residue for binding and inhibiting CPSF30 
(Nemeroff et al., 1998, Li et al., 2001, Noah et al., 2003) appeared conserved in both 
A- and B-allele NS1 proteins. Notably, there was an eight amino acid sequence, 
21RFADQELG28 and 21LLSMRDMC28, in the RNA-binding domain that was 
relatively well but divergently conserved in A- and B- allele NS1 proteins, 
respectively. This has also been reported elsewhere (Munir et al., 2011a, Munir et al., 
2012). However these sequences do not appear to be entirely conserved in all IAV 
NS1 strains and have not been characterised or attributed to a particular function of 
NS1 to date. 
W78 of NEP, which is thought to interact with viral M1 to facilitate nuclear 
export of vRNPs (Akarsu et al., 2003), was conserved in both avian A- and B-allele 
NEP proteins. Within the first nuclear export signal of NEP (residues 12-21), the B-
allele NEP proteins used here had a glutamic acid in place of a methionine/leucine at 
position 12 which was found in the A-allele NEP sequences (Fig 2.2). The significance 
of this in terms of NEP function is not currently known. 
The phylogeny of NS genes of influenza has been studied by other groups and 
has been reported in various publications. Figure 2.3 shows a phylogenetic tree of 
NS1-coding RNA sequences from a report by Sevilla-Reyes and colleagues (Sevilla-
Reyes et al., 2013) with the sub-groups that contain strains used in this report 
highlighted. The avian B-allele strains are clearly divergent from the A-allele 
sequences and form their own group. PR8 NS1 sequence falls into group A4.1 (H1N1), 
Udorn72 into A4.2 (H3N2), Cal7 into A3 (Classical swine), Sw412A falls into the 






Fig 2.3. Phylogenetic tree of NS1-coding RNA sequences. Shown is a phylogenetic 
tree of IAV NS1-coding RNA sequences grouped into subtypes. Red boxes highlight 
the sub-groups in which the NS1 sequences from strains used in this study belong: All 
B-alleles sequences are in the B group, PR8 belongs to A4.1 (H1N1), Udorn72 in A4.2 
(H3N2), Cal7 in A3 (Classical swine), Sw412A in A5.4 (Eurasian avian), and the 
North American A-allele sequences in A5.6 (American). Adapted from (Sevilla-Reyes 






the A5.6 (American) sub-group (Fig 2.3) (Sevilla-Reyes et al., 2013). Therefore a 
diverse range of NS segments were investigated in this study. 
2.2 Results 
2.2.1 Virus rescue of PR8-based segment 8 reassortants 
The first assessment of the ability of A- and B-allele LPAI NS segments to 
complement a mammalian-adapted virus was to attempt virus rescues.  293T cells were 
transfected with the PR8 reverse genetics plasmids (pDUAL) for segments 1-7 (de Wit 
et al., 2004), with segment 8 replaced with pHH21 plasmids for each of the avian IAV 
segment 8s of interest (Fig 2.4). A negative control sample was included that lacked a 
PB2 pDUAL plasmid, which was unable to generate infectious virus, and a fully wild-
type PR8 rescue was performed as a positive control. The supernatant was collected 
after 48 h, and this was termed the ‘passage zero’ (P0) stock.  
‘Passage one’ (P1) virus stocks were generated by infecting T25 flasks of 
MDCK cells with diluted P0 supernatants. 100 µl of P0 virus was diluted in 1 ml of 
VGM and used to infect MDCK cells (MOI < 0.01). Throughout the course of 
infection, cells were monitored using microscopy and successful infection was judged 
based on cell morphology in comparison to the mock-infected negative control sample 
(no PB2). At 48 h post-infection the supernatant of infected cells was clarified (3000 
rpm, 5 min) and stored. The P1 viruses were titrated by plaque assay and used for 
subsequent experiments. All viruses rescued readily. Mock-infected MDCK cells 
produced undetectable levels of virus (limit of detection 2.5 PFU/ml) (Fig 2.5). All 
viruses replicated to titres of 108 PFU/ml, with no statistically significant differences 






Fig 2.4. Schematic of reverse genetics system. 293T cells are co-transfected with 8 
pDUAL plasmids, each driving the production of mRNA and ‘vRNA-like’ RNA from 







Fig 2.5. Multi-cycle growth of PR8 NS segment reassortant viruses in MDCK 
cells. MDCK cell monolayers were infected at an MOI of 0.001 and virus in the 
supernatant was titrated by plaque assay after 48h. Data are the mean +/- SD (n = 5). 






indistinguishable between WT PR8 and all of the segment 8 reassortant viruses (data 
not shown).  RNA was extracted from virus in the supernatant and segment 8 RT-PCR 
was performed. DNA sequencing was used to confirm NS genes were correct and no 
mutations had occurred during virus growth (data not shown). Therefore, both avian 
A- and B-allele NS segments appeared to be compatible in a mammalian-adapted virus 
background in mammalian cells in vitro. These results suggest that B-allele NS 
segment products (NEP, NS1) are able to carry out functions important for virus 
replication efficiently in mammalian cells to allow infectious virus production, and 
that the avian segment 8s of both lineages are able to package into an otherwise 
mammalian-adapted virus. A panel of NS reassortant viruses was now available to 
systematically assess replicative fitness of A- and B-allele viruses in mammalian 
systems in vitro.   
2.2.2 Viral protein synthesis in infected MDCK cells 
There is evidence that both NEP and NS1 influence viral protein synthesis. 
NEP has been shown to reduce the levels of mRNA made by the viral polymerase in 
reconstitution assays (Bullido et al., 2001, Robb et al., 2009). NS1 is thought to recruit 
viral mRNAs, eIF4G and PABPI to form viral mRNA translation initiation complexes 
to enhance the translation of viral proteins (Burgui et al., 2003). Additionally, NS1 has 
been reported inhibit the host cell splicing machinery (Lu et al., 1994, Qiu et al., 1995), 
and this may influence the splicing of segment 7 pre-mRNAs (Robb and Fodor, 2012). 
Thus, given a clear role of segment 8 products in viral gene expression, the abundances 
of several viral proteins were quantified by western blotting during infection to see if 
the A- and B- allele lineage NS segment products were capable of supporting efficient 





cells were infected at high multiplicity and cell lysates were generated at 8 h post-
infection. Efficient infection was confirmed in all samples by immunofluorescence 
(IF) analysis of intracellular NP in a parallel infection (data not shown). SDS-PAGE 
and western blotting for various virus proteins was performed. Mock-infected samples 
contained undetectable levels of all viral proteins immunoblotted (Fig 2.6A). The 
levels of NP, M1, and M2 were similar, barring minor fluctuations, for all reassortant 
viruses. The ratio of M1:M2 was also quantified by densitometry, to assess any 
differences in splicing efficiency of segment 7 mRNA across the different virus 
infections. The ratios of M1:M2 were similar across all samples, with all ratios falling 
within two-fold of the WT PR8 sample (Fig 2.6B). Whilst the relative quantities of 
NS1 across the reassortant viruses could not be accurately determined due to potential 
different affinities of our available anti-NS1 antibodies, NS1 was detected in all virus-
infected samples. Anti-PR8-NS1 antiserum (V29) did not pick up B-allele NS1 
proteins, but anti-O265B-NS1 (A2, see Chapter 7: Materials and Methods for 
validation of antiserum, and see Fig 2.1 for epitope sequence on NS1 alignment) 
detected all avian NS1 proteins but not PR8 NS1. Avian NEPs were not detected by 
western blotting with the available antisera, but NEP expression was demonstrated 
using immunoprecipitation of 35S-labelled cell lysates with a rabbit polyclonal 
antiserum raised to PR8 NEP (Fig 2.6A). Again, a reliable comparison of NEP 
quantification was not viable due to potential epitope differences between different 
NEP proteins.  
These data show that avian A- and B- allele NS segment products are capable 







Fig 2.6 Protein synthesis by NS segment reassortant viruses in mammalian cell 
culture. (A) MDCK cells were infected at an MOI of 3 and cell lysates were prepared 
at 8 h p.i. To detect viral NP, NS1, M1 and M2 polypeptides as well as cellular tubulin, 
lysates were subjected to SDS-PAGE and immunoblotted with the appropriate 
antisera. To detect NEP protein, cells were infected at an MOI of 10 and metabolically 
labelled with 35S protein labeling mix between 6 h and 8 h p.i. Lysates were then 
immunoprecipitated with anti-NEP antiserum and precipitates analysed by SDS-
PAGE and autoradiography. Data are representative of more than one independent 
experiment. (B) The ratios of M1:M2 quantification determined by western blotting 
and densitometry following three independent MDCK cell infections as in (A). Data 





substantial differences in M1:M2 ratio, suggesting that splicing efficiency of segment 
7 mRNA is similar during infection with A- and B-allele reassortant viruses.   
2.2.3 Sub-cellular localisation of NS1 proteins in human cells 
It has been documented that the subcellular localisation of IAV NS1 is both 
host- and strain-specific (Melen et al., 2007, Volmer et al., 2010, Han et al., 2010). 
There is published evidence of differing sub-cellular localisations of A- and a B- allele 
NS1 proteins, derived from avian viruses, in transfection-based experiments using 
mammalian cells (Munir et al., 2011b). The authors suggested that the B-allele proteins 
displayed a delayed entry into the nucleus which may have detrimental consequences 
for virus replication. To ask whether there was a lineage-dependent difference in NS1 
sub-cellular localisation in mammalian cells for the strains used in this study, sub-
cellular localisation was assessed both in the context of virus infection by 
immunostaining and also using fluorescently-labelled NS1 proteins (NS1-GFP) in 
transfection-based studies (see Chapter 7: Materials and Methods for generation of 
NS1-GFP constructs). As discussed in Chapter 1, NS1 has been reported to interact 
with numerous cellular proteins both in the nucleus and in the cytoplasm to manipulate 
the cell for optimal conditions for virus replication. Therefore, differing sub-cellular 
localisation between A- and B-allele NS1 proteins may point to differences in function 
in mammalian cells between the two lineages, which could impact on virus replication.   
To assess NS1 subcellular localisation during infection, A549 cells were 
infected with PR8, O175A or O265B at an MOI of 5 and fixed at 8, 16 and 24 h post-
infection. The fixed cells were permeabilised and were stained for NS1 using rabbit 
polyclonal antisera (anti-RBD). Mock-infected samples were used to determine 





cells at all time-points post-infection with all viruses, although nuclear staining was 
also observed  to a lesser degree (Fig 2.7A, 16 h time-point not shown). The sub-
cellular localisation was similar between WT PR8, O175A and O265B NS1 proteins 
at all time-points. In no case was NS1 detected within the nucleolus (see arrowheads 
in ‘crop’ column of Fig 2.7A). Attempts to study NS1 sub-cellular localisation at 
earlier time-points during infection were not successful due to poor signal:noise of 
available antisera (data not shown). Therefore, NS1-GFP expressing plasmids were 
employed and sub-cellular localisation was assessed at early time-points post-
transfection. 
293T cells were transfected with pEGFPN1 (Clontech) with the NS1 ORF of 
either PR8, O175A or O265B upstream of the eGFP ORF which expressed the NS1 
protein C-terminally tagged with eGFP.  An empty pEGFPN1 plasmid was transfected 
as a control which expressed eGFP only, and a mock transfection was performed in 
which no plasmid was included in the transfection mix. Cells were fixed at 4, 5, 6, and 
8 h post-transfection, the DNA was stained with Hoechst dye, and GFP and Hoechst 
fluorescence was imaged using laser scanning confocal microscopy. The laser 
properties were kept the same across all samples at each time-point. Cells transfected 
with the empty pEGFPN1 vector displayed GFP fluorescence in both the nucleus and 
cytoplasm at all time-points (Figs 2.7B and 2.7C show the 4 h and 8 h samples 
respectively, 5 h and 6 h are not shown). Mock-transfections did not display detectable 
GFP fluorescence using the same laser properties. PR8 NS1-GFP displayed stronger 
fluorescence in the cytoplasm than the nucleus at all time-points, although nuclear 
fluorescence was also detected but to a lesser extent. At 4 h post-transfection, O175A 






Fig 2.7A. Sub-cellular localisation of NS1 during infection. A549 cells were 
infected with segment 8 reassortant viruses at an MOI of 5 and fixed at 24 h post-
infection. Cells were permeabilised and immunostained for viral NS1 (green, anti-
NS1-RBD) and DNA (Blue, Hoechst). White arrowheads show nucleoli. Images were 






Fig 2.7B. NS1-GFP sub-cellular localisation at 4 h post-transfection. 293T cells 
were transfected with either empty pEFPN1 plasmid or with pEGFPN1 with NS1 ORF 
of PR8, O175A or O265B upstream of GFP (green), or mock-transfected. DNA was 







Fig 2.7C. NS1-GFP sub-cellular localisation at 8 h post-transfection. 293T cells 
were transfected with either empty pEFPN1 plasmid or with pEGFPN1 with NS1 ORF 
of PR8, O175A or O265B upstream of GFP (green), or mock-transfected. DNA was 






(Fig 2.7B). With increasing lengths of time post-infection, both O175A and O265B 
NS1-GFP showed more dominant nuclear localisation and to similar extents between 
the two strains (Fig 2.7C). Indeed, in experiments described in Chapter 3 using the 
same NS1-GFP expression plasmids, O175A and O265B showed a strong tendency 
for nuclear localisation over cytoplasmic localisation at 24 and 48 h post-transfection, 
while PR8 NS1-GFP was mostly cytoplasmic (data not shown).     
Overall these data suggest that the lineage of NS1 did not obviously alter NS1 
sub-cellular localisation during infection of A549 cells or transfection of 293T cells, 
although there were differences between WT PR8 NS1 and the avian NS1s tested in 
transfection based studies, but not during infection. Additionally, the avian NS1 
proteins tested showed a different localisation pattern across the two systems used, 
however this is not particularly surprising as the cellular environments are different 
across infection and transfection studies. Finally, there was little evidence to suggest 
that the B-allele NS1 protein displayed a delay in nuclear localisation relative to A-
allele NS1, which has been suggested in a previous study using a transfection-based 
system (Munir et al., 2011b).  
2.2.4 The influence of A- and B- allele segment 8s on PR8 polymerase 
activity 
Both NS1 and NEP have been reported to influence influenza polymerase 
activity in IAV reconstitution assays, although there is conflicting evidence in the 
literature. Wang and colleagues reported that NS1 reduced the levels of all three viral 
RNA species (mRNA, cRNA and vRNA) (Wang et al., 2010), whilst little effect was 
noted in a separate study (Robb et al., 2009). Bullido and colleagues reported that NEP 





reporter (Bullido et al., 2001), while Robb and others reported that NEP increased the 
levels of both cRNA and vRNA, but reduced mRNA levels, of various IAV segments 
(Robb et al., 2009). 
 Therefore the influence of PR8 segment 8 and the avian A- and B- allele 
segment 8s on polymerase activity in a reconstitution assay was assessed. The 
reconstitution assay indirectly measures mRNA production from vRNA-like templates 
by the virus polymerase. pDUAL vectors for the components of the polymerase (PB2, 
PB1, PA, and NP - ‘3PNP complex’) are co-transfected, cellular RNA polymerase II 
will make mRNA for each component, and this will be translated to yield the 
polymerase complex. A reporter construct is co-transfected which contains a luciferase 
reporter gene in the reverse orientation, flanked by the UTRs of PR8 segment 8, under 
the control of an RNA polymerase I (pol I) promoter. Cellular pol I generates RNA 
that resembles vRNA to the polymerase complex, which will then be transcribed into 
mRNA by the polymerase and this is translated to produce luciferase (Lutz et al., 
2005). The luciferase activity is therefore proportional to the activity of the viral 
polymerase.  
293T cells were co-transfected with pDUAL plasmids for each component of 
the PR8 polymerase complex (3PNP) and the appropriate segment 8 plasmids 
(pDUAL PR8 segment 8, pHH21 plasmids for O175A and O265B segment 8 genes), 
along with the polI luciferase reporter plasmid. A no segment 8 control was included 
to assay the transcriptional activity of the PR8 polymerase in the absence of segment 
8 products. After 48 h, cells were lysed and luciferase activity assayed. Additionally, 
cell lysates were generated from parallel transfections for SDS-PAGE and western 





sample was also included, in which the viral polymerase cannot form and therefore 
any luciferase activity measured is not a result of viral transcription. This control gave 
relative luminescence units several orders of magnitude lower than samples with 
expected polymerase assay (data not shown).  
Polymerase activity was highest without the presence of segment 8 genes from 
any virus across two independent experiments (Fig 2.8A). The PR8 polymerase with 
WT segment 8 led to a mean luciferase activity of 69.5% compared to the 3PNP-only 
sample. Introduction of O175A or O265B segment 8 in place of WT PR8 NS led to 
average activities of 13.0% and 19.4%, respectively, in comparison to 3PNP-only, 
although there was no significant difference between O175A and O265B.  NS1 
expression was confirmed by western blotting in the PR8 and O175A samples using 
the V29 antiserum, and O265B NS1 expression was detected with A2 antiserum, while 
NS1 was undetected in the 3PNP-only sample with either antisera (Fig 2.8B). PB2 
expression was not detected in the no PB2 control, and was consistently detected at 
lower levels in O175A and O265B samples relative to PR8 and 3PNP-only across the 
two experiments (Fig 2.8B). NP was detected in all samples, although levels appeared 
reduced in O175A and O265B samples relative to the PR8 and 3PNP-only controls 
(Fig 2.8B). These data could perhaps suggest that an avian segment 8, from either the 
A- or B-allele, is not as efficient at complementing the PR8 polymerase. However, 
since there was less PB2 and NP expression in the O175A and O265B samples (Fig 
2.8B), the apparent reduction in virus transcription might result from lower levels of 
viral polymerase in the cell rather than an incompatibility of NS genes with the 






Fig 2.8. Influenza polymerase activity with segment 8 products. (A) 293T cells 
were co-transfected with pDUAL plasmids for the polymerase and NP genes of PR8 
and a segment 8 plasmid (pDUAL for PR8, pHH21 for O175A and O265B) alongside 
a polI firefly luciferase reporter for 48 h. Luciferase activity was measured at 48 h 
post-transfection as a readout for viral polymerase activity. Data are the mean +/- SEM 
(n =5). (B) Western blot of transfected cell lysates for viral PB2, NP and NS1. Cellular 
alpha-tubulin was blotted as a loading control. Shown are immunoblots from two 
independent experiments (‘Expt.1’ and ‘Expt. 2’). NS – non-significant, * p ≤ 0.05, ** 





whether the reduction in luciferase activity in O175A and O265B samples was caused 
by reduced expression of polymerase and NP proteins in the reconstitution assay or 
perhaps a dampening of the expression of luciferase mRNA due to NS1-driven shut-
off. The shut-off properties of various NS1 proteins are investigated in Chapter 3. 
2.2.5 Growth of PR8-based reassortant viruses in human cells 
Virus replication in other types of mammalian cells was also assessed to ensure 
that any potential fitness penalty of incorporating an avian B-allele segment 8 into a 
mammalian-adapted virus was not being ‘missed’ by looking solely in MDCK cells. 
Human lung A549 cells, human colorectal Caco-2 cells, and primary human CD14+ 
monocyte-derived macrophages were infected and peak virus titres were assessed. 
A549 cells were infected at an MOI of 0.001 and infectious virus was titrated at 48 h 
post-infection by plaque assay. All viruses replicated to titres above 106 PFU/ml in 
A549 cells (Fig 2.9A). There was no obvious attenuation for any of the segment 8 
reassortant viruses. Caco-2 cells were also infected at an MOI of 0.001 and virus titre 
was determined at 48 h post-infection. All viruses replicated to titres exceeding 108 
PFU/ml, and again there was no evidence of fitness penalty for A- or B-allele 
reassortant viruses (Fig 2.9B). CD14+ monocyte-derived macrophages were infected 
at an MOI of 3 for 24 h. As in other human cells, there was no evidence of attenuation 
for any virus assessed, with all viruses replicating to titres above 106 PFU/ml (Fig 
2.9C).Virus replication was verified by titrating a ‘post-wash’ sample at t = 0, in which 
cell supernatant was taken immediately after washing the cells three times with serum-
free media and therefore titrating residual input virus. The post-wash sample contained 
103 PFU/ml, approximately 3 log10 lower than end-point titre, indicating that virus 






Fig 2.9. A- and B-allele segment 8 reassortant viruses replicate efficiently in 
human cells. (A) Human lung A549 cells were infected at an MOI of 0.001 and virus 
in the supernatant titrated at 48 h p.i. by plaque assay. Data are the mean +/- SD of 3 
independent infections. (B) As in (A) but human Caco-2 cells were infected at an MOI 
of 0.001. The output of a single experiment is shown. (C) Primary human CD14+ 
monocyte-derived macrophages were infected at an MOI of 3 and virus in the 
supernatant was titrated at 24 h p.i. by plaque assay. Data are the mean +/- range of 2 





-infected samples contained undetectable levels of virus (limit of detection 2.5 
PFU/ml) and plaque phenotypes were indistinguishable between all viruses (data not 
shown).  
Therefore, all PR8-based segment 8 reassortant viruses tested replicated 
efficiently in a variety of both continuous and primary mammalian cells. These data 
provide further evidence that incorporation of an avian B-allele NS segment causes no 
obvious fitness penalty for an otherwise mammalian-adapted virus in mammalian cells 
in vitro. 
2.2.6 In vitro fitness of additional A- and B- allele segment 8 reassortant 
viruses.  
Since no significant attenuation of PR8-based segment 8 reassortant viruses 
bearing North American LPAI segment 8s from either the A- or the B- allele lineage 
was observed in a variety of mammalian cells, additional NS genes that have been 
discussed in previous reports were also assessed. NS genes from A/mallard/new 
york/6750/1978 (H2N2) (NY6750A) and A/mallard/Alberta/88/1976 (H6N8) 
(Alb88B) were selected, as these were the A- and B-allele representatives which were 
used in Treanor’s squirrel monkey infection report (Treanor et al., 1989). 
A/mallard/Sweden/S90412/2005 (H6N8) (Sw412A) and 
A/mallard/Sweden/S90418/2005 (H6N8) (Sw418B) were also chosen as these NS1 
proteins were assessed in studies by the Berg lab from which the authors proposed that 
B-allele NS1 proteins are deficient in preventing the induction of the mammalian 
innate immune response (Zohari et al., 2010a, Munir et al., 2011a, Munir et al., 2011b, 
Munir et al., 2012). A/New York/107/2003(H7N2) (NY107B) was included as this is 





A/equine/Jilin/1/1989 (H3N8) (J89B), an equine H3N8 B-allele virus which caused a 
major outbreak in horses in China that had a high mortality rate of up to 20% in some 
herds (Guo et al., 1992), was also selected.  
Corresponding DNA sequences for Alb88B, NY6750A, Sw412A, Sw418B 
and NY107B NS genes were synthesised and cloned into plasmids by BioMatik. In 
each case, the segment 8 termini sequences were not available on GenBank and so the 
sequence from the closest relative, determined by nucleotide BLAST analysis, was 
used (Table 2.1). Alb88B and Sw418B sequences were silently mutated to remove 
BsmbI sites, without altering NS1 or NEP protein sequences or disrupting conserved 
codons (Table 2.1). The NS genes were cloned into the pDUAL vector using BsmBI 
sites and were validated by sequencing (see Chapter 7: Materials and Methods for a 
description of the cloning procedure). The NS segment of J89B was cloned into 
pDUAL and kindly provided by Alice Coburn (Dr. Pablo Murcia’s laboratory, The 
Centre for Virus Research, The University of Glasgow).  
Viruses were rescued as described above in 2.2.1 Virus rescue of PR8-based 
segment 8 reassortants with the exception of Sw412A which did not rescue with 
multiple attempts. Replicative fitness of the reassortant viruses was assessed in MDCK 
cells by infecting at an MOI of 0.001 and titrating virus in the supernatant at 48 h post-
infection. Mock-infected samples contained no detectable virus (Fig 2.10). All other 
viruses replicated to high virus titres of 108 PFU/ml. Therefore the NS segments 
selected, barring Sw412A, also facilitated efficient virus replication of a mammalian 






Fig 2.10. Multicycle growth of additional PR8-based segment 8 reassortant 
viruses. MDCK cells were infected at MOI 0.001 and virus in the supernatant at 48 h 








2.2.7 Virus growth kinetics of PR8-based reassortants 
Virus growth kinetics of consensus PR8-based viruses was assessed in MDCK 
cells and A549 cells, to determine if there was an attenuation at earlier time-points 
during infection for the B-allele segment 8 reassortant viruses that may have been 
missed by looking at end-point titres. In both cases, cells were infected at low 
multiplicity (MOI = 0.001) and cell supernatant was collected at increasing time-points 
post-infection. In both experiments, mock-infected samples contained no detectable 
virus. In MDCK cells, the growth curves of PR8, O175A and O265B were very 
similar, with virus titres peaking at 108 PFU/ml at 24 h post-infection (Fig 2.11A). In 
A549 cell infection, WT PR8 and O265B replicated with very similar kinetics, peaking 
at 48 h post-infection with a titre of 107 PFU/ml (Fig 2.11B). O175A replicated with 
delayed growth kinetics in comparison, showing a reduction in virus titre of 
approximately one order of magnitude at 36 h and 48 h post-infection. These results 
show that a B-allele NS segment is capable of allowing efficient virus replication of a 
mammalian-adapted virus at early time-points in mammalian cells in vitro, and provide 
evidence of improved fitness in comparison to a counterpart A-allele NS segment. 
2.2.8 Growth of PR8-based reassortant viruses in embryonated chicken 
eggs 
To assess virus fitness in an avian host system, the allantoic cavities of 10-day 
old embryonated chicken eggs were inoculated with 1000 PFU of PR8, O175A or 






Fig 2.11. Virus growth kinetics. (A) MDCK cells and (B) A549 cells were infected 
at an MOI of 0.001 and virus in the supernatant was titrated by plaque assay at stated 
time-point. (A) Data are from a single experiment. (B) Data represents mean +/- SD 






plaque assay. Mock-infected eggs contained no detectable virus (Fig 2.12). All three 
viruses replicated to mean titres of 108 PFU/ml, and there was no statistically 
significant difference between the virus titres (unpaired t-test, n = 5) (Fig 2.12). These 
data suggest that the PR8-based segment 8 reassortant viruses are competent in an 
avian host system as well as a mammalian host system in vitro. 
2.2.9 Competition assays  
Since no obvious fitness penalties were observed for PR8-based segment 8 
reassortant viruses in terms of virus growth in vitro, the possibility of there being a 
more subtle ‘selection advantage’ for A-allele segment 8s into a mammalian-adapted 
viruses in mammalian cells was explored. A ‘competition assay’ was developed in 
order to estimate the proportion of virus progeny resulting from the co-infection of 
cells at low multiplicity with two different NS reassortant viruses which could reveal 
subtle changes in replication kinetics as the two viruses compete for uninfected cells 
(Fig 2.13A). A method of distinguishing between different segment 8 reassortant 
viruses was initially required. Therefore, an RT-PCR assay using primers specific for 
O175A and O265B segment 8 cDNA was developed. Specificity of these primer pairs 
on pHH21 plasmids for O175A and O265B cDNA was demonstrated by PCR, and 
strong signal:noise was only observed in homologous primer-template reactions (see 
Chapter 7: Materials and Methods for primer validation). Next, the RT-PCR specificity 
was tested following plaque-purification. MDCK cells were infected at MOI 0.001 for 
48 h with controls of either O175A- or O265B-only, or were co-infected with both 
(MOI 0.001 each), and virus in the supernatant was subjected to agarose plaque assay. 
Virus from isolated plaques was amplified in MDCK cells by plaque purification and 






Fig 2.12. Growth of PR8-based viruses in embryonated chicken eggs. The allantoic 
cavities of 10-day-old embryonated chicken eggs were inoculated with 1000 PFU of 
virus. Virus in the allantoic fluid at 48 h post-infection was titrated by plaque assay on 







Fig 2.13. Competition assay validation. (A) Schematic diagram of completion assay 
experimental set-up. Cells are co-infected with an equal PFU of each reassortant virus 
and the output progeny subjected to plaque assay under a semi-solid overlay. Once 
visible, isolated plaques are purified by taking up cellular debris and overlay in a pipet 
and ejecting material onto MDCK cells in culture. Virus is allowed to amplify before 
extracting RNA and lysing cells in an SDS buffer. Viruses forming isolated plaques 
are identified using RT-PCR for segment 8 vRNA and/or western blotting for specific 
NS1 proteins. (B) Establishment of a strain-specific RT-PCR assay for A- and B-allele 
viruses. Viral RNA was extracted following plaque purification of either O175A, 
O265B or (as examples) 2 unidentified viruses obtained from co-infection with both 
and analysed by RT-PCR with primers specific for the NS segment of either O175A 






‘No RT’ samples, in which the reverse transcriptase enzyme was removed from the 
RT-PCR, and no-template reactions (‘H2O’) gave no detectable PCR product (Fig 
2.13B). Strong signal was only detected in homologous primer-template reactions, as 
shown in the assay of the O175A- and O265B- only control infections and subsequent 
plaque purification (Fig 2.13B). The primer pairs were also tested on plaques that were 
purified following co-infection of MDCK cells with O175A and O265B – plaque 1 
only gave strong segment 8 RT-PCR product using O265B-specific primers, and 
plaque 2 with O175A-specific primers, thus the plaques were unambiguously scored 
as O265B and O175A respectively (Fig 2.13B). Therefore, this RT-PCR assay could 
be used reliably following plaque-purification of virus in the supernatant of co-infected 
cells to distinguish between O175A and O265B viruses, allowing an estimate of the 
proportion of each virus in the supernatant. To assay co-infections including WT PR8 
with either O175A or O265B, western blotting was employed using strain-specific 
anti-NS1 antiserum on cell lysates of MDCK cells following individual plaque 
purification. The V29 anti-NS1 antiserum only detected PR8 and O175A NS1 
proteins, while anti-O265B-NS1 antiserum (A2) only detected O265B and O175A 
NS1 proteins (see Fig 2.6A). Therefore, using a combination of RT-PCR and western-
blotting based assays, PR8, O175A and O265B viruses could be reliably distinguished 
following plaque purification.  
The initial question asked whether the consensus A-allele segment 8 had a 
selection advantage over the consensus B-allele segment 8 during a multi-cycle co-
infection in this system. This would ‘mimic’ a natural co-infection of a mammalian 
host where genetic reassortment could potentially take place in nature. MDCK cells 





proportion of infectious virus produced in the system was estimated by RT-PCR assay 
of 25 plaques following a 48 h infection. The output was then passaged at low MOI 
(0.001) twice further and 25 plaque purifications were assayed after each passage. In 
MDCK cells co-infected with both O175A and O265B, O265B appeared to 
consistently out-compete O175A, reaching a 72% proportion of all progeny virus after 
3 passages (Fig 2.14A). When WT PR8 was co-infected with either O175A or O265B, 
and 25 plaques assayed after 3 passages, PR8 comfortably out-competed both segment 
8 reassortant viruses, accounting for 96% of plaques in the O175A competition 
infection and 88% in the O265BB infection (Fig 2.14A). These data suggest that the 
WT PR8 segment 8 has a selection advantage over the avian segment 8s over multiple 
rounds of replication, but that the B-allele segment 8 was certainly no less fit in the 
PR8 backbone than the A-allele counterpart in this system, and possibly slightly fitter.  
In a previous report from the Digard lab, it was suggested that differences in 
the terminal RNA packaging signals in segment 8 might restrict the reassortment of B-
alleles into a mammalian-adapted viruses (Gog et al., 2007). The competition assay 
was employed to test this hypothesis. High-multiplicity co-infections of MDCK cells 
were performed, such that the majority of infected cells would contain both A- and B-
allele segment 8 vRNA. The proportion of A- and B-allele segment 8 vRNA in the 
progeny virions following a co-infection would therefore reflect the ability of each to 
be packaged into the PR8 backbone. MDCK cells were co-infected at an MOI of 3 for 
each virus for 16 h, and 25 plaques were purified from the infected cell supernatant 
and assayed using RT-PCR as described above. O265B out-competed O175A with a 







Fig 2.14. Segment 8 reassortant competition assays. (A) MDCK cells were co-
infected at an MOI of 0.001 (each) with the indicated mixtures of viruses and at 48 h 
p.i. the supernatant was analysed by plaque assay. 25 plaques were scored for the 
proportion of progeny and a further portion of the original supernatant passaged further 
at an MOI of 0.001. Data are from a single experiment. (B) MDCK cells were infected 
at an MOI of 3 per virus and the proportion of each virus in the supernatant was 
assessed after 16 h. Data are the mean +/- SEM for A v B (n = 3), and single 






To ensure that there was not a ‘bias’ of O265B vRNA in the infected MDCK 
cells, which could possibly compensate for any potential restriction of packaging into 
the PR8 background, the comparative levels of O175A vRNA and O265B vRNA in 
the co-infected cells was assessed using RT-qPCR. Following co-infection, total RNA 
was extracted from infected MDCK cells and cDNA of all vRNA was synthesised in 
an RT reaction using the Uni12’ primer. The comparative levels of O175A vRNA and 
O265B vRNA were then assessed using RT-qPCR with primers specific for both 
respective cDNA sequences (primer validation is described in Chapter 7: Materials 
and Methods).  RT-qPCR data showed that O265B segment 8 vRNA was present in 
infected cells at levels approximately 2.5-fold greater than O175A (data not shown). 
This is a similar ratio to the infectious virus in the supernatant, and suggests that the 
packaging efficiency of O265B vRNA into PR8 is comparable to O175A vRNA. 
When WT PR8 was competed against O175A or O265B in an identical co-infection 
setup, the proportion of PR8- and O265B-containing plaques was similar (52% to 48% 
respectively), while PR8 modestly out-competed O175A (69% to 31% respectively) 
(Fig 2.14B). Therefore, these data suggest that there is no obvious bias against an avian 
B-allele NS vRNP to be packaged into a mammalian-adapted virus background 
relative to an A-allele when both are present within a co-infected host cell. 
Overall, assessing the consensus viruses in this particular system revealed that 
WT PR8 segment 8 contained a selection advantage over the two consensus A- and B- 
allele avian segment 8s in mammalian cells in vitro. However, the data also indicated 
that the consensus B-allele vRNA, O265B, had a modest selection advantage over an 





2.2.10  Fitness of avian segment 8s in Udorn72 and Cal7 backgrounds 
PR8 is a useful and well-studied model for mammalian adapted viruses, 
although it has been heavily mouse-adapted following many passages (Taylor, 1941), 
during which it has diverged from clinically relevant strains. Therefore, the possibility 
of any potential fitness penalty of B-allele segment 8 viruses in mammalian hosts being 
‘masked’ by using a mouse-adapted strain was explored by generating reassortant 
viruses on additional virus backgrounds. Udorn72, a human H3N2 virus isolated in 
Russia in 1972 that has been well studied in influenza literature, was employed. Cal7, 
a prototypic 2009 H1N1 pandemic strain (reviewed in (Girard et al., 2010), and 
therefore a clinically relevant virus, was also used. 
The consensus North American LPAI A- and B-allele segment 8s (O175A and 
O265B, respectively) were chosen, as well as PR8 segment 8, to rescue on the 
background of these human viruses. The reverse genetics system for Udorn72, 
consisting of four pcDNA3.1 plasmids for the expression of the viral polymerase 
components (PB2, PB1, PA, NP) and eight pol I pHH21 plasmids for each of the eight 
segments of the genome (see Chapter 7: Materials and Methods for plasmid 
information) was kindly provided by Prof. Robert Lamb (Department of Molecular 
Biosciences, Northwestern University, Illinois, USA). The Cal7 reverse genetics 
system, an eight-plasmid system using bidirectional pHW2000 plasmids, was made by 
and kindly provided by Prof. John McCauley’s laboratory (The Francis Crick Institute, 
Mill Hill Laboratory, Mill Hill, London, UK). The Udorn72 viruses were rescued 
essentially as described in 2.2.1 Virus rescue of PR8-based segment 8 reassortants. 
The Cal7 viruses did not amplify well in tissue culture after rescue, and so viruses were 





To assess Udorn72-based viruses in vitro, multicycle infections of MDCK cells 
were performed. For an initial assessment, MDCK cells were infected at an MOI of 
0.001 and endpoint titres were assessed by titrating infectious virus in the supernatant 
at 48 h post-infection. Mock-infected cells produced no detectable virus (Fig 2.15A). 
All viruses replicated well in MDCK cells, achieving titres of 107 PFU/ml. Next, virus 
growth kinetics were assessed, and MDCK cells were infected at an MOI of 0.001. 
The supernatant of infected MDCK cells was collected at 4, 12, 24, 36, and 48 h post-
infection and virus was titrated by plaque assay. All viruses grew to titres of 107 
PFU/ml by 48 h post-infection with similar kinetics (Fig 2.15B). Whilst there were 
minor differences in virus titre noted at 24 h post-infection, peak titres were very 
similar, suggesting that the avian segment 8s were able to complement a mammalian-
adapted H3N2 virus in vitro.  
Egg-grown titres of Cal7-based viruses were similar – each virus replicated to 
mean titres of 105 PFU/ml (Fig 2.15C). No virus was detected in the mock-infected 
control (limit of detection 2.5 PFU/ml). To assess virus growth in vitro, MDCK-SIAT 
cells, a transfected cell line which stably express more human 2,6-sialyltransferase and 
therefore have higher levels of alpha -2,6- linked sialic acid-galactose moieties, were 
chosen (Matrosovich et al., 2003). This enhances Cal7 growth. MDCK-SIAT cells 
were infected at an MOI of 0.01, supernatant was collected at various time-points and 
infectious virus titrated by plaque assay on MDCK-SIAT cells. WT Cal7 and a 
Cal7/PR8 NS reassortant virus grew with similar growth kinetics during the multicycle 






Fig 2.15. Multicycle replication of Udorn72- and Cal7-based segment 8 
reassortant viruses. (A) MDCK cells were infected with Udorn72-based viruses at an 
MOI of 0.001 and virus in the supernatant was titrated at 48 h post-infection. Data are 
the mean +/- SD (n = 3). (B) MDCK cells were infected as in (A) and virus in the 
supernatant was titrated at indicated time-points. Data are the mean +/- range (n = 2). 
(C) The allantoic fluid of 10-day-old embryonated chicken eggs were inoculated with 
100 µl of Cal7-based P0 stocks. At 72 h post-infection, allantoic fluid was harvested 
and virus was titrate by plaque assay on MDCK-SIAT cells. Data are the mean +/- SD. 
(D) MDCK-SIAT cells were infected at an MOI of 0.01 with Cal7-based viruses and 
the supernatant titrated at indicated time-points. Data are the mean +/- range (n = 2). 
(E) As in (D) but 72 h post-infection only. Data are mean +/- range of five independent 
infections. There were no significant differences between the samples in an unpaired 





delayed growth kinetics, particularly at 24 h post-infection where virus titres were 
nearly 3 orders of magnitude lower than WT Cal7 and Cal7/PR8. However, a more 
thorough investigation into end-point (72 h) titres yielded no statistically significant 
difference in peak-titres across all viruses assessed across five independent infections 
(Fig 2.15E), suggesting that peak virus titres can be achieved with an avian A- or B-
allele virus in the background of a pandemic 2009 H1N1 virus, albeit with delayed 
kinetics. 
Overall, there was little evidence to suggest that a B-allele avian segment 8 is 
any more attenuated in a mammalian-adapted virus than an A-allele counterpart, in 
vitro in a mammalian host setting in H1N1 and H3N2 backgrounds. However, these 
data show that avian NS genes can attenuate growth kinetics of a recent human H1N1 






In this chapter, mammalian-adapted H1N1 and H3N2 segment 8 reassortant 
viruses were characterised in mammalian cells in vitro. These viruses harboured NS 
genes from a variety of A- and B-allele IAV strains isolated from a variety of hosts, 
with a diverse range of H and N subtypes, various locations and dates of isolation 
observed (Table 2.1).  The initial hypothesis was that reassortants with a B-allele NS 
segment would be attenuated in a mammalian-adapted virus in a mammalian host 
setting, based on several reports that the B-allele genes are avian-restricted (Treanor 
et al., 1989, Zohari et al., 2010a, Munir et al., 2011a, Munir et al., 2011b, Munir et al., 
2012). However, this hypothesis was not supported by the data described in this 
chapter which provided strong evidence that a B-allele NS segment can complement a 
mammalian-adapted IAV strain in the mammalian host in vitro efficiently.  
All viruses tested were able to produce expected levels of viral proteins during 
infection of MDCK cells, suggesting the B-allele NS1 and NEP proteins were not 
deficient in regulating viral protein synthesis (Figs 2.6A and 2.6B). NS1 sub-cellular 
localisation studies performed following infection or transfection of human cells 
revealed that consensus avian A- and B-allele NS1 proteins displayed similar 
localisation patterns at the time-points tested, although both showed a more nuclear 
localisation during transfection in comparison to WT PR8 NS1 (Figs 2.7A, 2.7B and 
2.7C). Although Munir and colleagues previously reported a delay in nuclear 
localisation of B-allele NS1 proteins using transfection-based experiments, and 
speculated that this may negatively impact virus replication (Munir et al., 2011b), NS1 
sub-cellular localisation is known to be strain- and host- specific (Melen et al., 2007, 





be concluded that there is a B-allele lineage-specific difference in NS1 sub-cellular 
localisation. Furthermore, the study by Munir and colleagues failed to demonstrate that 
the B-allele viruses were attenuated at the level of virus replication. 
The PR8-based reassortant viruses all replicated to high end-point titres during 
multicycle infections of MDCK cells (Fig 2.5), A549 cells (Fig 2.9A), Caco-2 cells 
(Fig 2.9B) and primary human CD14+ macrophages (Fig 2.9C). Similar replication 
kinetics during multicycle infections of MDCK and A549 cells (Figs 2.11A and 2.11B) 
were observed, although O175A failed to reach the peak titres achieved by WT PR8 
and O265B (Fig 2.11B). These data suggest that B-allele NS genes are in fact able to 
complement a mammalian-adapted virus in a variety of mammalian cells. It has been 
well established that both NS1 and NEP are required for efficient virus replication. 
Deletion of NS1 from PR8 leads to a serious attenuation of virus replication in vitro in 
MDCK cells (García-Sastre et al., 1998), and mutation of NEP to disrupt nuclear 
export function obliterates virus production (Neumann et al., 2000). Therefore, these 
data are a strong indicator that the NS1 and NEP proteins are performing essential 
functions adequately in mammalian cells. In Chapter 3, studies exploring the ability of 
NS1 to antagonise the IFN response and to perform host cell shut-off are described.  
When A- and B-allele viruses were co-infected in MDCK cells, the consensus 
B-allele virus out-competed the A-allele counterpart in both multi-cycle and single-
cycle competition assays (Figs 2.14A and 2.14B).  RT-qPCR of O175A and O265B 
vRNA in the infected cells suggested that there was no preferential vRNP packaging 
into the PR8 backbone for O175A over the vRNPs of O265B, which is an interesting 
result as it has been previously proposed that differences in RNA packaging signals of 





into mammalian-adapted viruses over B-allele vRNPs (Gog et al., 2007). However, it 
has been shown in a separate study that the terminal regions of segment 8 appear can 
undergo substantial sequence mutation without attenuating packaging (Fujii et al., 
2009), implying that there is a degree of plasticity in the segment 8 RNA packaging 
signals.  
The consensus avian B-allele NS segment also complemented a human H3N2 
virus efficiently in vitro (Figs 2.15A and 2.15B), further strengthening the argument 
that B-allele NS segments are not globally attenuating for mammalian viruses in the 
mammalian host. Whilst there was an observed attenuation of growth kinetics of a 
human p2009 H1N1 virus, this was no worse than the A-allele counterpart that was 
also assessed (Fig 2.15D), and peak viral titres were actually comparable to WT (Fig 
2.15E). Therefore, there is no evidence that an avian A-allele NS gene is more suited 
to a mammalian virus backbone than an avian B-allele counterpart.  
Treanor et al were amongst the first to suggest that avian B-allele genes 
attenuate IAV in the mammalian host (Treanor et al., 1989). They concluded that an 
H3N2 B-allele reassortant was attenuated in the squirrel monkey host, noting 
significantly reduced virus titres from nasopharyngeal swabs, and a reduced duration 
of shedding of infectious virus (Treanor et al., 1989). Furthermore, at the time of 
publication, there were no reports of B-allele IAV strains isolated from mammals, with 
an abundance of A-allele mammalian isolates, strengthening their conclusions. 
However, infectious virus titres in tracheal swabs were not significantly different, and 
in vitro the viruses  replicated equally well (Treanor et al., 1989). This suggested that 






Since the Treanor et al publication (Treanor et al., 1989), there have been  
conflicting publications regarding the apparent avian-restriction of B-allele NS genes. 
For example, Ma et al reported that introducing a B-allele NS segment from 
(A/Goose/Guangdong/1/96 (H5N1)) into an H7N1 HPAI virus (A/FPV/Rostock/34 
(H7N1)) improved growth kinetics in MDCK cells and also increased pathogenicity 
in mice relative to WT (Ma et al., 2010). These data raise doubt that all B-allele NS 
segments attenuate IAV in mammalian hosts. Additionally, since surveillance and 
sequencing efforts for IAV has improved vastly over time, there have been an 
increasing number of mammalian IAV isolates harbouring a B-allele NS segment 
appearing on public databases (a detailed assessment is described in Chapter 5), with 
the A/equine/Jilin/1/1989 (H3N8) prototype isolate being a particularly relevant 
example; a highly pathogenic virus that spread rapidly in horses and caused a high 
level of mortality (Guo et al., 1992). The latter example clearly shows that a B-allele 
virus is not only able to permit infection of a mammalian host, but can also cause 
serious disease. 
The data described in this section add further doubt to the dogma of B-allele 
NS genes being avian-restricted. Furthermore, there is even evidence that a B-allele 
NS segment may be more advantageous for the replicative fitness of a mammalian 
virus in the mammalian host in vitro. In the next chapter, the ability of B-allele NS1 
proteins to control the mammalian IFN response is examined. Additionally, host-cell 











 Chapter 3: Host cell responses to infection 




In the previous chapter, a variety of H1N1 and H3N2 segment 8 reassortant 
viruses were characterised in vitro and it was concluded that B-allele NS genes were 
able to facilitate efficient virus replication in mammalian host cells. These experiments 
were mostly concerned with assessing virus replication and propagation. In this 
section, the aim was to investigate host cell responses to infection with A- and B-allele 
NS reassortant viruses, asking whether; i) B-allele reassortant viruses could replicate 
in mammalian cells in which the antiviral state was active, and ii) if B-allele 
viruses/NS1 proteins could efficiently block the induction of the mammalian innate 
immune response. 
3.1.2 Hypothesis  
There have been reports published suggesting that B-allele NS1 proteins are 
deficient in controlling the mammalian innate immune response (Zohari et al., 2010a, 
Munir et al., 2011a, Munir et al., 2011b, Munir et al., 2012). These studies focused on 
NS1 proteins from virus strains that harboured an A- or a B-allele NS segment but 
were otherwise closely related. Reporter assays in human and mink lung cells 
suggested that the B-allele NS1 proteins were unable to efficiently block activation of 
IFN-β, NF-κB and AP-1 promoters. The authors speculated that this could contribute 
to an apparent avian-restriction of B-allele viruses, as mammalian hosts would induce 





studies failed to link their findings to an attenuation of virus replication in vitro or in 
vivo. 
Given that the data described in Chapter 2 strongly suggested that B-allele NS 
reassortant viruses were not attenuated in vitro, it was hypothesised that B-allele NS1 
proteins were able to antagonise the mammalian immune response efficiently. It has 
been shown that a PR8 mutant virus that does not express NS1 is heavily attenuated in 
MDCK cells, but can replicate to titres comparable to WT in IFN-deficient VERO 
cells (García-Sastre et al., 1998). This shows that effective IFN-antagonism from the 
NS1 protein is required for efficient virus replication in vitro, and since the B-allele 
reassortant viruses assessed in Chapter 2 all replicated well in vitro, it seemed possible 
that the IFN-response is well controlled during infection.  
3.1.3 Approach 
To assess the ability of NS reassortant viruses to circumvent the mammalian 
innate immune response, replication of PR8-based reassortant viruses in cells pre-
treated with IFN-β was compared across A- and B-allele viruses. Transfection-based 
reporter assays for IFN-β and ISRE promoter activity, as well as quantification of the 
levels of type I IFN secreted during infection of human lung epithelium cells, were 
also employed to measure the induction of the IFN-response and JAK/STAT-
signalling. Additionally, cytokine and chemokine profiling of infected human primary 
macrophages was investigated, as macrophages are important mediators of the host 
immune response and are important for clearance of IAV during infection. In 
collaboration, an intricate 10-plex mass-spectrometry technique was employed to 
perform quantitative temporal proteomics of infected human lung cells to compare 





B-allele NS1 proteins to induce host-cell shut-off was also assessed by metabolic 
labelling of infected cells and RNA polymerase II promoter reporter assays, as the 
consensus CPSF30-binding site differs in B-allele NS1 proteins (See Fig 2.1) and a 
deficiency in shut-off may lead to increased IFN- or ISG-expression. 
3.2 Results 
3.2.1 Ability of segment 8 reassortant viruses to replicate in established 
antiviral conditions. 
The first assessment of B-allele reassortant viruses to cope with the mammalian 
IFN response was to assess virus replication in human lung cells that had been 
stimulated with IFN-β. Cells were pre-treated for 24 h with differing concentrations of 
recombinant human IFN-β prior to a 48 h low multiplicity infection (MOI 0.01) with 
WT PR8 or the consensus PR8-based avian NS reassortant viruses (O175A and 
O265B). Virus titres were determined by plaque assay of infected cell supernatant, and 
titres were plotted normalised to ‘no-IFN’ control. Dose-inhibition curves 
demonstrated a clear dose-dependent antiviral effect of IFN-β pre-treatment (Fig 3.1A) 
High concentrations of IFN-β pre-treatment (300 U/ml and above) inhibited virus 
replication by several orders of magnitude relative to no-IFN samples for all viruses. 
All viruses were largely unaffected by concentrations of 6 U/ml and below. In terms 
of dose-inhibition, similar IC90 values were obtained for PR8, O175A and O265B 
(28.5 U/ml, 29.6 U/ml and 33.5 U/ml respectively). Cell lysates were generated at the 
end of the infection to assess the levels of an IFN-inducible protein (Mx1) to ensure 






Fig 3.1. Ability of viruses to replicate in the presence of an established antiviral 
conditions. A549 cells were pre-treated with varying concentrations of human 
recombinant IFN-β for 24 h prior to infection with the indicated PR8-based reassortant 
viruses at an MOI of 0.01. (A) Virus in the supernatant was titrated by plaque assay at 
48 h p.i.. Data are plotted as percentage of the no-IFN control for each virus. Data are 
mean +/- SD (n = 3). (B) Cell lysates were prepared at 48 h p.i., subjected to SDS-






these lysates confirmed that Mx1 was up-regulated with IFN-β treatment in a dose-
dependent manner (Fig 3.1B). Additionally, viral NP levels were reduced in samples 
pre-treated with higher concentrations of IFN-β (Fig 3.1B). 
Since the dose-inhibition curves were similar across the viruses tested, there 
was no evidence for a specific defect for a B-allele NS reassortant viruses in this 
system. The NS1 protein is implicated in inhibiting antiviral proteins that are induced 
by type I IFN such as PKR and OAS (which were discussed in more detail in Chapter 
1), therefore if a B-allele NS1 protein lacked the ability to inhibit certain mammalian 
antiviral effectors that an A-allele NS1 could, one would expect to see an increased 
sensitivity to IFN treatment for O265B and therefore a shift (to the left) in the dose-
inhibition curve presented in Fig 3.1A. Thus, the data from this experiment do not 
support the hypothesis that there is a specific deficiency of B-allele NS1 proteins in 
inhibiting the actions of IFN-inducible antiviral effectors in mammalian cells in vitro.  
3.2.2 Quantifying type I IFN production during infection 
Next, the levels of active type I IFN secreted during infection of human lung 
cells were quantified to ask if B-allele viruses are able to control the activation of the 
type I IFN response in the context of viral infection. To address this question, a reporter 
cell line (HEK-Blue™ IFN-α/β cells) was employed that expresses human secreted 
embryonic alkaline phosphatase (SEAP) under the control of the ISG54 promoter 
(Ahmed et al., 2013). This promoter is activated by an ISRE-dependent mechanism 
following JAK/STAT signalling which is induced by exogenous type I IFN.   
Initially, A549 cells were infected with varying multiplicities with WT PR8 or 





0.03 were tested and a PR8 NS1 RNA-binding mutant virus (residues R38 and K41 
mutated to alanine, ‘R38K41A’, made by Dr. Helen Wise previously in the Digard 
laboratory) which is known to be deficient in IFN-antagonism (Talon et al., 2000, 
Newby et al., 2007) was included as a positive control to test which multiplicity of 
infection was most appropriate to use for IFN quantification assays following 
infection. At the end of the 24 h infection, cells were fixed, permeabilised and 
immunostained for intracellular NP in all samples to assess the successful infection 
rate. Fig 3.2A shows the mock-infected sample, containing no detectable NP at the 
imaging parameters used, alongside WT PR8 at the three multiplicities tested which 
are included as representatives for all virus infections. At an MOI of 3, the majority of 
cells were infected. The infection rate accordingly dropped by approximately ten-fold 
for the MOI of 0.3 infection, and ten-fold further for the MOI of 0.03 infection. In 
order to inactivate virus in the supernatant prior to incubation with HEK-Blue cells, 
supernatants of all samples were treated with UV-irradiation. Fig 3.2B shows PR8 
virus titre in the supernatant pre- and post-UV treatment at the three multiplicities 
tested as determined by plaque assay. Prior to irradiation, there was 106 - 107 PFU/ml 
in the supernatant of the MOI 3 and 0.3 infections, and 104 PFU/ml in the supernatant 
of the MOI 0.03 infection, which was reduced to levels below the limit of detection 
(25 PFU/ml) by plaque assay following UV treatment. There was no detectable 
infectious virus in the mock-infected cells. To quantify the levels of type I IFN in the 
infected cell supernatants, the UV-treated supernatants were incubated with HEK-Blue 






Fig 3.2. Establishment of the HEK-Blue cell reporter assay to quantify type I IFN. 
A549 cells were infected at varying multiplicity for 24 h. (A) Immunostaining for 
intracellular NP was performed to verify successful infection rates. MOI used is 
indicated. PR8 infections are shown as a representative of all samples. (B) The 
supernatant was UV-treated to inactivate infectious virus particles in all samples. 
Shown are the virus titres pre- and post-UV treatment for PR8 infections at the three 
multiplicities tested. (C) Type I IFN in the supernatant was quantified using the HEK-
Blue cell reporter assay. Experiment was performed in triplicate for each sample and 
reproduced over two independent experiments. Shown are the data from a 
representative experiment. Solid line indicates ‘cells only’ background and represents 
the limit of detection which is approximately 6 U/ml according to the IFN-β standard. 






colourimetry following addition of substrate. Human recombinant IFN-β, also treated 
with UV under the same conditions of the infected cell supernatants, was also 
incubated on the HEK-Blue cells in varying concentrations to form a standard curve. 
A ‘cells only’, ‘media only’ and ‘substrate only’ were all included as negative controls, 
to determine the background level of the assay. The SEAP activity levels in the 
supernatant of HEK-Blue cells increased with increasing concentrations of exogenous 
IFN-β, indicating that the HEK-Blue cells were responding to exogenous type I IFN 
as expected (Fig 3.2C). The limit of detection of the assay, determined by the SEAP 
activity of the ‘cells only’ control and shown on the graph as a solid line, was 
equivalent to approximately 6 U/ml as determined by the IFN-β standard curve. As 
demonstrated above, 6 U/ml of IFN-β did not inhibit multicycle replication of PR8 and 
consensus NS reassortant viruses in A549 cells pre-treated with exogenous IFN-β (Fig 
3.1A). Mock-infected samples did not induce SEAP section above the levels of cell-
only or media-only controls. A549 cells infected with the PR8 NS1 mutant virus 
R38K41A resulted in large levels of IFN secretion at all multiplicities tested, inducing 
SEAP secretion equivalent to incubating the HEK-Blue cells with 100 U/mL of 
recombinant IFN-β – levels which inhibited virus replication by approximately 100-
fold in the dose-inhibition experiment described above (Fig 3.1A). Therefore, all three 
multiplicities tested were sufficient to induce a substantial IFN response in A549 cells. 
Infection of A549 cells with PR8, O175A or O265B did not induce type I IFN levels 
significantly above the limit of detection of the assay (unpaired t-test, n = 3). 
Therefore, PR8, O175A and O265B did not induce inhibitory levels of IFN, as 
determined by dose-inhibition curves described above (Fig 3.1A) during infection of 





 The number of viruses analysed was expanded to include the full panel of PR8-
based reassortants and the Udorn72-based reassortant viruses (see Table 2.1). In these 
experiments, an MOI of 3 was used in all infections. The results were similar to initial 
experiments, in that the only virus to induce notable type I IFN-secretion during 
infection of A549 cells was the PR8 R38K41A NS1 mutant virus (Figs 3.3A and 3.3B).   
Therefore, none of the A- or B- allele reassortant virus tested lacked the ability 
to suppress type I IFN secretion during infection of A549 cells. Conversely, an NS1 
mutant virus induced large responses, demonstrating the importance of the NS1 protein 
in suppressing type I IFN production in this system. These data suggest that B-allele 
NS1 proteins are in fact able to efficiently control the mammalian IFN immune 
response during infection, contrary to previous reports (Zohari et al., 2010a, Munir et 
al., 2011a, Munir et al., 2011b, Munir et al., 2012).  
3.2.3 NS1 suppression of IFN-β and ISRE promoters in poly(I:C)-
stimulated cells. 
Next, the ability of various A- and B-allele NS1 proteins to inhibit the IFN-β 
and ISRE promoters in transfection-based reporter assays was assessed.  A previous 
study has suggested that B-allele NS1 proteins are unable to efficiently block IFN-β 
production in mammalian cells, and also ISRE activation in transfection-based reporter 
assays (Munir et al., 2011b). Therefore, the representative NS1 proteins that were used 
in this study (Sw412A and Sw418B – see Table 2.1) were employed in transfection-
based reporter assays to study their suppression of IFN-β and ISRE promoter activity, 
alongside consensus LPAI North American NS1s (O175A and O265B) and other NS1 






Fig 3.3. Type I IFN during infection of A549 cells with PR8- and Udorn72-based 
reassortant viruses. Experimental design is described in Fig 3.2, except MOI of 3 was 
used in all infections. Solid line indicates ‘cells only’ background and represents the 
limit of detection which is approximately 6 U/ml according to the IFN-α 2a standard. 






The experimental design included transfecting 293T cells with reporter 
plasmids containing either the human IFN-β promoter or four tandem repeats of the 
IFN responsive (ISRE) core upstream of the Photinus pyralis (firefly) luciferase ORF 
(‘IFNβ::Luc’ and ‘ISRE::Luc’ respectively; kind gift of Prof. Richard Randall, The 
University of St Andrews (King and Goodbourn, 1994, King and Goodbourn, 1998, 
Didcock et al., 1999, Hagmaier et al., 2006)). These reporter plasmids were co-
transfected with NS1-GFP constructs (pEGFPN1) for 24 h. Subsequently, cells were 
transfected with polyinosinic:polycytidylic acid (poly(I:C)), a synthetic mimic of 
dsRNA produced during viral infection which therefore stimulates intracellular 
dsRNA sensors such as RIG-I (Yoneyama et al., 2004) (described in more detail in 
Chapter 1), and luciferase activity measured to assess the ability of the various NS1 
proteins to inhibit the induction of the cellular promoters in vitro. The luciferase 
activity following stimulation with poly(I:C) was therefore expected to be proportional 
to the induction of the promoter assessed. While the most appropriate measure of ISRE 
stimulation is to treat cells with type I IFN (King and Goodbourn, 1998), poly(I:C) 
treatment was employed here to  use an experimental design similar to the ISRE 
reporter assays used in the study by Munir and colleagues along with their 
representative NS1 proteins (Munir et al., 2011b), for a direct comparison.  
293T cells were seeded in 24-well plates, and were co-transfected with 50 
ng/well of reporter plasmid and 400 ng/well of effector for 24 h. All cells were 
transfected at similar levels as assessed by epi-fluorescent microscopy for GFP 
fluorescence (data not shown). 24 h post-transfection, cells were stimulated by 
transfection of 5 µg/well of poly(I:C) or mock-stimulated by transfecting a mixture 





was quantified. PR8-NP-GFP was employed as a negative control, as influenza NP is 
not known to influence induction of IFN-β or ISRE promoters. Background levels of 
the assay were determined by measuring luciferase activity in cells transfected with 
PR8-NS1-GFP only and by measuring the relative luminescence values when lysis 
buffer only was added to substrate. Both of these controls exhibited values several 
orders of magnitude lower than samples containing reporter plasmid (data not shown). 
Each effector tested had a stimulated and mock-stimulated sample, and fold-
stimulation values were calculated by dividing relative luminescence values obtained 
from stimulated cells over mock-stimulated cells. This would account for any potential 
influence on basal expression of luciferase between effectors used. 
When the IFN-β promoter reporter plasmid was co-transfected with NP-GFP 
and cells were stimulated with poly(I:C), there was a mean up-regulation of 9.7-fold 
luciferase activity in comparison to mock-stimulated cells, indicating strong activation 
of the promoter (Fig 3.4A). When the NS1-GFP proteins from PR8 or selected A- and 
B-allele viruses were co-transfected, the mean up-regulation lay between 1.5- and 2.5-
fold relative to unstimulated samples for all proteins tested, demonstrating an ability 
for all NS1s tested to inhibit the activity of the IFN-β promoter following stimulation, 
and to a similar extents (Fig 3.4A).    
The ISRE::Luc promoter reporter was tested in the same experimental setup. 
Co-transfection of NP-GFP resulted a mean up-regulation of luciferase activity by 3.8-
fold following stimulation with poly(I:C) with respect to mock-stimulated, indicating 
activation of the ISRE promoter element (Fig 3.4B). WT PR8-NS1 up-regulated 
luciferase activity by 7.3-fold relative to the unstimulated sample. The majority of the 






Fig 3.4. IFN and ISRE promoter activity in presence of NS1. 293T cells were co-
transfected with a luciferase reporter plasmid, containing (A) the IFN-β promoter or 
(B) tandem repeats of the ISRE core upstream of firefly luciferase, alongside various 
NS1-GFP expression plasmids. After 24 h, the cells were stimulated with poly(I:C). 
Luciferase activity was measured 24 h post-stimulation. NP-GFP was employed as a 
negative control effector. Data are plotted as mean fold-change relative to unstimulated 
sample. Data represents (A) the mean +/- range (n = 2) and (B) mean +/- SEM (n = 4) 
and is plotted as fold-change of induction compared to unstimulated cells. Dashed line 
in (B) represents the mean fold-induction of the negative control sample (NP-GFP). 
Statistically significant differences from respective NP-GFP negative control effector 






between 1.4- and 1.8-fold of the unstimulated values (Fig 3.4B). NY107B was an 
exception, as fold-stimulation values were effectively identical to the NP sample 
(mean up-regulation of 3.7-fold) indicating a failure to block activation of the ISRE 
promoter following poly(I:C) treatment (Fig 3.4B).  
These data suggest that B-allele NS1 proteins are able to directly inhibit the 
activation of the IFN-β promoter in stimulated cells, contrary to the conclusions of a 
previous report (Munir et al., 2011b). Furthermore, the majority of B-allele NS1 
proteins tested were able to supress ISRE promoter activation in stimulated cells, with 
the exception of NY107B. WT PR8 NS1 apparently increased ISRE promoter 
activation, and this finding is consistent with previous studies in which PR8 infection 
or transfection of a plasmid vector expressing PR8 NS1 protein either failed to block 
or increased the activity of an ISRE promoter in human cells following stimulation 
with type I IFN or poly(I:C) (Hayman et al., 2006, Hayman et al., 2007, Munir et al., 
2011b). These findings suggest that the ability of the NS1 protein to inhibit ISRE 
promoter activation is not dependent on the A- or B-allele lineage origin, but there is 
likely to be a strain-specificity in this ability. Indeed, avian B-allele NS1 proteins have 
been found to supress IFN-β promoter activity in human cells as efficiently as 
counterpart A-allele NS1 proteins in previous studies (Hayman et al., 2007, Ma et al., 
2010). 
3.2.4 Cytokine and chemokine secretion following infection of primary 
human macrophages with segment 8 reassortant viruses 
Macrophages are among the first immune cells to encounter IAV virions in the 
lung of the infected host, and studies have shown the importance of macrophages in 





Tate et al., 2010). Macrophages are thought to be the main producers of pro-
inflammatory cytokines and  type I IFN during IAV infection, and this is important for 
control of virus propagation (Kumagai et al., 2007). Therefore, the cytokine and 
chemokine secretion profiles of infected human macrophages were examined, to ask 
whether a B-allele virus might elicit an overly-strong response in macrophages that 
could contribute to an increased rate of clearance from an infected host.  
The production of cytokines and chemokines was assessed following the 
infection of primary Cluster of Differentiation 14-positive (CD14+) human 
macrophages with PR8, O175A or O265B. CD14+ monocytes were isolated from fresh 
blood donations and differentiated into macrophages by Dr. Alasdair Jubb, Dr. 
Malcolm Fisher (both of Prof. David Hume’s laboratory, The Roslin Institute, The 
University of Edinburgh) and Dr. Sara Clohisey (of Dr. Kenny Bailey’s laboratory, 
The Roslin Institute, The University of Edinburgh). Macrophages were infected at an 
MOI of 1, and after 24 h the supernatant was harvested and cells were fixed. 
Immunostaining of viral NP protein was performed on fixed and permeabilised cells. 
NP immunostaining was not observed in mock-infected cells, while successful 
infection of macrophages was seen in virus-infected samples, with the majority of cells 





Fig 3.5. Cytokine and chemokine profiling of infected human macrophages. 
Human CD14+ MDMs were infected at an MOI of 1 for 24 h. (A) Immunofluorescent 
staining of viral NP (green) in fixed cells was performed at 24 h post-infection to 
confirm successful infection. DAPI staining (blue) shows nuclei of cells. (B) The 
levels of various cytokines and chemokines in the supernatant was quantified using an 
immuno spot-blot array. The mean fold-change with respect to a mock-infected sample 
is represented as a heat map (n = 2). Cytokines and chemokines are ranked in 






chemokines, was used in an immunoblot array proteome profiler (see Table 3.1 for list 
of cytokines and chemokines assayed). The levels of cytokines and chemokines in the 
supernatant was taken to be proportional to the spot intensity following the near 
infrared detection protocol using the LiCor Odyssey platform. Samples quantified in 
duplicate using densitometry, calculated as mean fold-change with respect to the 
mock-infected sample, and plotted as a heat-map (Fig 3.5B). Table 3.1 summarises the 
roles of the cytokines quantified in this array, and provides the mean fold-change 
values from the mock-infected sample. It also defines the abbreviations used for each 
cytokine and chemokine described below. 
The cytokines and chemokines were ranked in descending order according to 
the fold-change values obtained in the PR8-infected sample. Visual inspection of the 
heat map revealed that, generally, the profiles of most cytokines and chemokines were 
similar across all samples. Certain proteins, such as MIF, TNF-α, CCL3 (a.k.a. MIP-
1α), and CCL5 (also called RANTES), all pro-inflammatory mediators, were highly 
up-regulated in all infected samples. Some were down-regulated in all samples, such 
as CXCL1 (a.k.a. GROα) and CCL1, but only by a maximum of 2-fold. The most 
striking difference between the profiles of PR8, O175A and O265B samples was the 
much larger expression of the pro-inflammatory mediators TNF-α, CCL3 and CCL5 
in PR8-infected macrophages in comparison to the NS reassortant viruses.  There was 
49.5-fold more TNF-α detected in PR8-infected samples in comparison to mock-
infected macrophages, while the mean up-regulation was only 6.5-fold in O175A-
infected macrophages, and 8.0-fold in the O265B-infected sample. CCL3 was up-

















Table 3.1 – Human CD14+ MDM cytokine/chemokine profiling. Secreted cytokines and chemokines were quantified following infection 
of human macrophages. The fold-change values represent the abundance of protein relative to the mock-infected sample. A brief description 
of the main role(s) of each cytokine and chemokine is provided.  
Cytokine/ 
chemokine 













- Regulates innate immunity and stimulates pro-inflammatory response.   55.0 57.3 78.3 (Calandra and 
Roger, 2003) 
TNF-α (Tumour 
Necrosis Factor α) 
- Pro-inflammatory roles. Mediator of fever and acute phase response. 
Antiviral properties by activating NF-κB pathway and inducing apoptosis. 
Correlated with lung tissue damage in HPAI infections.  
47.5 6.5 8.0 (To et al., 2016, Lee 
et al., 2009b, 
Cheung et al., 2002) 
CCL3 (chemokine 





Pro-inflammatory roles. Chemotactic for and activator of macrophages and 
CD8+ T-cells.  
 
36.5 7.5 11.5 (Trifilo et al., 2003) 
CCL5 (chemokine 




T Cell Expressed 
and Secreted) 
Chemotactic for several immune cell populations at inflammatory sites. 
Activator of NK cells. Important for anti-apoptotic signalling of alveolar 
macrophages during clearance of influenza-infected apoptotic cells.  
11.4 4.0 3.4 (Tyner et al., 2005) 
CXCL10 (C-X-C 
motif ligand 10) 
IFN-γ-induced 
protein 10,IP-10) 
Chemotactic for monocytes, macrophages, NK cells, T-cells, and dendritic 
cells. Secretion is stimulated by IFN-γ and also pro-inflammatory cytokines. 
Important for RSV clearance in mice.  
 































- Pro-inflammatory cytokine. Chemoattractant for CD4+ T-cells, monocytes, 
eosinophils and dendritic cells. Regulates CD4+ T-cell development.  
6.3 7.8 8.0 (Amiel et al., 1999) 
IL-6 (interleukin-6) - Pro-inflammatory cytokine secreted by T-cells and macrophages. 
Important mediator of fever and acute phase response. Essential for 
effective clearance of H1N1 IAV in mice.  
5.6 2.8 3.4 (Dienz et al., 2012) 
IL-1ra (interleukin-1 
receptor antagonist) 
- Anti-inflammatory cytokine. Antagonistic functions with the IL-1 receptor.  
Therefore inhibits of IL-1α and of IL-1β. Loss of IL-1ra leads to uncontrolled 
systemic inflammation and polyarthropathy. 
3.8 3.9 3.2 (Horai et al., 2000) 
Serpin E1 (serpin 





Serine protease inhibitor. Inhibits tissue plasminogen activator and 
urokinase. Inhibits plasminogen and therefore the breakdown of blood 
clots. Propose to be antiviral against IAV by inhibiting extracellular 
proteases required for HA cleavage.  
 
2.6 1.1 1.1 (Dittmann et al., 
2015) 
IL-5 (interleukin-5) - Essential for eosinophil maturation and recruitment to infected airway 
during IAV infection and recovery phase.   
2.4 1.0 0.9 (Gorski et al., 2013) 
IL-1β (interleukin-
1β) 
Catabolin Pro-inflammatory interleukin produced following activation of the 
nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin 
domain-containing 3 (NLRP3) inflammasome, which is activated by IAV M2 
protein. Contributes to lung tissue damage during IAV infection.   
2.1 3.2 2.9 (Ichinohe et al., 
2010, Kim et al., 
2015b) 
CXCL12 (C-X-C 
motif ligand 12) 
SDF-1  (stromal 
cell-derived factor 
1) 
Chemotactic for leukocytes and up-regulated in inflammatory response. 
Required for CD8+ T-cell recruitment during IAV infection.  



























IFN-γ (interferon-γ) - Type II IFN. Major macrophage activation roles. Chemoattractant of 
leukocytes, enhances NK cell activity, regulates B-cell functions. 
1.9 2.2 2.1 (Schroder et al., 
2004) 
CCL4 (chemokine 





Chemotactic for a variety of immune cells. Pro-inflammatory. 1.7 4.9 4.9 (Menten et al., 2002) 
IL-1α (interleukin-
1α) 
- Pro-inflammatory interleukin. Acts as an ‘alarmin’ to initiate the release of 
various pro-inflammatory cytokines and chemokines in acute inflammation.   
1.4 1.4 1.3 (Garlanda et al., 
2013) 
IL-2 (interleukin-2) - Important for growth, proliferation and differentiation of T-cells and required 
for T-cell immunological memory. Also promotes proliferation of B cells and 
NK cells.  
1.4 1.2 1.0 (Gaffen and Liu, 
2004) 
IL-4 (interleukin-4) - Induces differentiation of naïve helper T-cells into type 2 helper T cells. 
Multifunctional roles in regulating macrophages and lymphocytes.  




myeloid cells)  
 
- Soluble form of the TREM-1 receptor. Released by monocytes and 
modulates pro-inflammatory response. Thought to help prevent hyper-
responsiveness and therefore reduce inflammation-induced tissue 
damage.  






Anti-inflammatory cytokine. Helps protect epithelial cell layers. Regulates 
production of pro-inflammatory cytokines such as TNF-α.  
1.2 1.3 1.2 (Ouyang et al., 2011) 
IL-27 (interleukin-
27) 
- Anti-inflammatory cytokine. Suppressor of helper T cell responses and 
limits inflammation.  



































Chemotactic for monocytes, memory T-cells NK cells to sites of 
inflammation.  











CD154 (cluster of 
differentiation 
154) 
Expressed on surface of activated T-cells, B-cells, NK cells, and 
macrophages. Co-stimulatory protein required for activation of various 
immune cells via stimulation of CD40. Stimulates B cells to produce 
antibody. Induces release of pro-inflammatory cytokines from endothelial 
cells and fibroblasts to attract leukocytes to site of inflammation.  
1.1 1.4 1.3 (Korniluk et al., 
2014) 
CXCL11 (C-X-C 













CD54 (cluster of 
differentiation 54) 































- Pro-inflammatory cytokine. Stimulates type 17 helper T-cell response.  1.1 1.3 1.2 (Teng et al., 2015) 
CSF2 (colony 






Stimulates bone marrow stem cells to differentiate into granulocytes and 
monocytes. 
1.1 1.2 1.2 (Shi et al., 2006) 
IL-12 (interleukin-
12) 
p70 Pro-inflammatory cytokine. Stimulates differentiation of T-cells into IFN-γ 
producing class 1 helper T-cells.  
1.1 1.0 1.2 (Teng et al., 2015) 
IL-32α (interleukin-
32α) 
- Pro-inflammatory properties. Induces inflammatory cytokine secretion, e.g. 
TNF-α, IL-1β and IL-6 from macrophages.  
1.0 1.1 1.1 (Shoda et al., 2006) 
IL-13 (interleukin-
13) 
- Anti-inflammatory cytokine. Inhibits pro-inflammatory cytokine production 
in airway disease and allergic inflammation. 
1.0 1.5 1.5 (Wynn, 2003) 
IL-17 (interleukin-
17) 
- Pro-inflammatory cytokine produced by type 17 helper T-cells. Stimulates 
pro-inflammatory cytokine release and therefore recruits macrophages and 
neutrophils to sites of inflammation.  
0.8 0.9 0.9 (Jin and Dong, 2013) 
CSF3 (colony 





Stimulates bone marrow stem cells to differentiate into granulocytes. 
Stimulates growth, proliferation and differentiation of neutrophils. 






Type III IFN with antiviral properties. Similar mechanisms of action as type 
I IFNs but via different receptor. Up-regulation of ISGs in response to 
infection.  






























- Part of the complement system with multiple roles. Inflammatory peptide 
upregulating NF-κB and IL-1 in alveolar macrophages in lung injury.  
0.7 0.8 0.5 (Guo and Ward, 
2005) 
CCL1 (chemokine 
(C-C) motif ligand 1) 
I-309 Pro-inflammatory chemokine. Chemotactic for monocytes and T-cells. 0.5 0.7 0.9 (Miller and Krangel, 
1992) 
CXCL1 (C-X-C 
motif ligand 1) 








O265B. CCL5 was up-regulated 11.4-fold in PR8-infected macrophages, but only 4.0-
fold and 3.4-fold in O175A- and O265B-infected macrophages, respectively.  
Serpin E1, a plasminogen inhibitor, and IL-5, a chemotactic cytokine for 
eosinophils, were both detected at levels over 2-fold greater in the PR8-infected 
samples in comparison to both O175A and O265B. CCL4 (a.k.a. MIP-1β), a 
chemotactic for a variety of immune cells, was up-regulated 4.9-fold in O175A and 
O265B samples, but only 1.7-fold in PR8-infected macrophages. Otherwise, all other 
cytokines/chemokines were detected at levels within a 2-fold range across PR8-, 
O175A- and O265B-infected samples.    
Overall, PR8-infected macrophages appeared to produce and secrete a higher 
level of pro-inflammatory cytokines than O175A and O265B. The profiles of O175A 
and O265B were, in general, relatively similar. There was no evidence of an excessive, 
pro-inflammatory response in macrophages infected with the consensus B-allele 
reassortant virus. 
3.2.5 Quantitative temporal proteomics – host response of infected 
human lung cells 
In this experiment, a collaboration with Dr. Michael Weekes (Cambridge 
Institute for Medical Research, University of Cambridge, Cambridge, UK), Dr. Joao 
Paolo and Prof. Steven Gygi (University of Harvard, Massachusetts, USA) was formed 
to investigate changes to the overall host-cell proteome during infection using a 
multiplexed tandem mass tag (TMT)-based mass spectrometry technique (Weekes et 
al., 2014). Human lung A549 cells were infected at high MOI with PR8, O175A or 





analysis allowed the direct comparison of the relative abundance of thousands of 
peptides in infected cells across different time-points and different viruses. 
Human lung A549 cells were infected in 100 mm dishes with either PR8, 
O175A or O265B at an MOI of 5 for 8, 16 and 24 h (only O175A and O265B infections 
were performed at 24 h time-point, due to a processing limit of 10 samples overall for 
the TMT-based mass spectrometry system). Each dish contained two 13 mm glass 
coverslips that were retrieved at the end of infection for separate western blotting and 
immunofluorescence analyses. Successful infection was demonstrated by western 
blotting for viral NP and specific NS1 proteins in cells lysed in SDS lysis buffer (Fig 
3.6A). V29 detected PR8 and O175A NS1 expression, and A2 detected O175A and 
O265B expression, as expected (see Fig 2.6). Mock-infected cell lysates did not 
contain detectable NP or NS1. Immunostaining of intracellular viral NP in cells fixed 
at each time-point confirmed a mean infection rate of approximately 95% across all 
samples (Fig 3.6B shows the 8 h time-point as a representative). The remaining cells 
were lysed using a guanidine-HCl lysis buffer and lysates were processed for mass-
spectrometry in the Gygi lab as described in a previous report (Weekes et al., 2014). 
Dr. Michael Weekes processed the mass-spectrometry data and provided values for all 
quantified peptides as fold-change with respect to the average of the mock-infected 
samples.   
Overall, 6862 unique proteins were quantified from the infected A549 cell 
samples (see Table S3.1 included as an .xlsx file on CD). Among these, peptides from 
the major viral proteins were identified at high abundance in infected cells (data not 
shown). Fig 3.7A shows the fold-change values with respect to the average of the 






Fig 3.6. Validation of infection for quantitative temporal proteomics. (A) A549 
cells were infected at an MOI of 5 and cell lysates were generated at the indicated 
time-points. Western blotting for viral NP and strain-specific NS1 was performed on 
cell lysates. Blotting for A-allele NS1s (V29) and avian NS1s (A2) was performed on 
separate gels. Alpha-tubulin was used as a loading control. (B) Immunofluorescent 
staining of intracellular NP (green) in fixed cells was used to estimate successful 
infection rates at each time-point. Shown are 8 h post-infection samples. DAPI staining 







Fig 3.7. Quantitative temporal proteomics of infected A549 cells. A549 cells were 
infected at an MOI of 5, cell lysates generated at the indicated time-points and 
polypeptide composition determined by TMT-based quantitative mass spectrometry. 
(A) All host-cell peptides detected at 16 h p.i. represented as fold-change relative to 
mock-infected samples, and ranked in descending order of relative abundance in the 
PR8 sample. Dashed lines indicate the 2-fold relative abundance range relative to the 
mock-infected samples. (B) Values represented as a heat map of mean fold-change 
with respect to mock-infected samples. The zoomed portion shows a sub-cluster of 
heavily up-regulated antiviral proteins. (C) Quantitative temporal expression of 
specific antiviral restriction factors Mx1, OASL, IFIH1, IFIT1, IFIT2 and IFIT3 is 
plotted. Values are plotted normalised to maximum-detected fold-change per protein. 
Heat map in (B) was made by Dr. Michael Weekes (Cambridge Institute for Medical 






order of relative abundance in the WT PR8-infected sample. The majority of peptides 
fell between the -2 and +2 fold-induction range in a similar expression profile for all 
viruses. Only a minority of host proteins changed abundance by 2-fold or more during 
infection, and the majority of these were down-regulated – see Tables 3.2 and 3.3 for 
the ten proteins that displayed the largest increase or decrease, respectively, at 16 h 
post-infection in the PR8-infected sample. All proteins identified that were up- or 
down-regulated by 2-fold or more, relative to mock-infected samples, were analysed 
to identify potentially interesting patterns.  
All host-proteins were clustered (by Dr. Michael Weekes) according to fold-
change relative to the average of the mock-infected samples, which was plotted as a 
heat-map (Fig 3.7B). Of the proteins that were highly up-regulated, a cluster of 
antiviral proteins was noted in all viral-infected samples. This group included the 
antiviral host proteins Mx1, OASL, IFIH1 (also known as Melanoma Differentiation-
Associated protein 5 or MDA5), IFIT1, IFIT2, and IFIT3 (Figs 3.7B and 3.7C, and 
Table 3.2 which also defines abbreviations). Notably, these antiviral proteins were 
most highly up-regulated in PR8-infected samples at all time-points tested, with the 
quantity of these antiviral proteins invariably at least 2-fold greater than O175A and 
O265B at the 16 h time-point, while the abundance levels were more comparable 
between O175A and O265B infections. When Mx1 protein abundance in infected 
A549 cell lysates was quantified by western blot, it was noted that PR8 induced greater 
Mx1 expression than O175A and O265B relative to the mock-infected sample (see 








Table 3.2. Up-regulated cellular proteins during infection of A549 cells quantified by mass-spectrometry. Shown are the top ten cellular 
proteins that were most strongly up-regulated in the 16 h infection with WT PR8, ranked in descending order. Values represent fold-change 
over mock-infected sample. Fold-change values are shown for all time-points tested for all samples.   
Gene 
symbol 
Protein name PR8 O175A O265B 
8 h 16 h 8 h 16 h 24 h 8 h 16 h 24 h 
OASL 2'-5'-oligoadenylate synthase-like protein 18.15 32.28 4.66 4.25 5.65 5.61 8.19 6.15 
MX1 Interferon-induced GTP-binding protein Mx1 7.45 28.22 2.07 4.84 6.08 3.32 13.34 12.50 
IFIT2 Interferon-induced protein with tetratricopeptide 
repeats 2 
12.06 24.58 2.44 2.54 2.63 3.17 3.97 3.97 
IFIT1 Interferon-induced protein with tetratricopeptide 
repeats 1 
8.81 16.81 2.68 3.15 3.12 3.76 6.57 5.26 
IFIT3 Interferon-induced protein with tetratricopeptide 
repeats 3 
5.84 12.02 1.88 2.29 2.45 2.67 4.22 3.69 
PLG Plasminogen 4.59 9.31 4.64 9.35 8.38 3.52 6.38 8.10 
ISG15 Ubiquitin-like protein ISG15 3.27 9.27 1.54 2.38 9.85 1.71 3.44 3.61 
LRCH4 Leucine-rich repeat and calponin homology 
domain-containing protein 4 
4.74 9.26 4.97 7.57 9.77 3.43 5.38 6.99 
IFIH1 Interferon-induced helicase C domain-containing 
protein 1 
5.04 9.12 1.80 1.98 1.60 2.37 3.77 2.97 













Table 3.3. Down-regulated cellular proteins during infection of A549 cells quantified by mass-spectrometry. Shown are the top ten 
cellular proteins that were most strongly down-regulated in the 16 h infection with WT PR8, ranked in descending order. Values represent 




Protein name PR8 O175A O265B 
8 h 16 h 8 h 16 h 24 h 8 h 16 h 24 h 
RFWD3 E3 ubiquitin-protein ligase RFWD3 0.49 0.17 0.26 0.11 0.14 0.32 0.12 0.14 
AHR Aryl hydrocarbon receptor 0.44 0.24 0.48 0.22 0.14 0.49 0.12 0.12 
CRIM1 Cysteine-rich motor neuron 1 protein 0.34 0.24 0.40 0.22 0.16 0.52 0.23 0.20 
ID1 DNA-binding protein inhibitor ID-1 0.62 0.24 0.12 0.11 0.07 0.20 0.09 0.05 
FGFR4 Fibroblast growth factor receptor 4 0.53 0.24 0.14 0.18 0.00 0.24 0.15 0.14 
FGFR1 Isoform 21 of Fibroblast growth factor receptor 1 0.45 0.24 0.48 0.25 0.17 0.44 0.24 0.19 
TFAP4 Transcription factor AP-4 0.52 0.25 0.38 0.17 0.12 0.42 0.21 0.11 
C14orf119 Uncharacterized protein C14orf119 0.54 0.26 0.30 0.09 0.06 0.53 0.14 0.10 
MYO10 Unconventional myosin-X 0.55 0.27 0.70 0.31 0.26 0.68 0.34 0.25 






An analysis of down-regulated proteins was likewise performed. Table 3.3 
shows the ten most down-regulated proteins at 16 h post-infection relative to the mock-
infected samples in the WT PR8-infected sample, and also defines abbreviations. An 
initial inspection of these down-regulated proteins failed to highlight any striking 
patterns following a search in the literature in an attempt to link protein function to 
IAV replication. The majority of these hits, barring FGFR1 and AHR, have not been 
implicated in playing a role(s) in IAV infection. FGFR1 was down-regulated to 0.24-
, 0.25- and 0.24-fold relative to the mock-infected samples in the PR8, O175A and 
O265B samples respectively at 16 h post-infection. While FGFR1 has previously been 
proposed to be a host factor required for efficient virus entry in an RNA-interference 
screen performed by Konig and colleagues (Konig et al., 2010), a more recent study 
has suggested that FGFR1 inhibits virus replication (Liu et al., 2015b). Thus, it is not 
currently clear how a downregulation in FGFR1 abundance may affect virus 
replication. AHR was also down-regulated in all samples and has been reported to 
increase lung inflammation and reduce survival rate in mice infected with IAV 
following its activation by pollutants (Teske et al., 2005). Likewise, it is difficult to 
speculate on the significance of this finding in terms of IAV replication in A549 cells 
in vitro.  
Next, the components known to be involved in type I IFN induction and 
signalling were specifically analysed given the well characterised role of NS1 in 
antagonising IFN induction (reviewed in Chapter 1). Table 3.4 shows the proteins 
identified in the mass-spectrometry experiment that are known to play a role in either 
RIG-I-like signalling or JAK/STAT signalling as part of the type I IFN response. The 








Table 3.4. Quantitative temporal proteomics of components involved in the type I IFN response during infection of A549 cells. Shown 
are selected proteins identified in the mass-spectrometry experiment that are known to be involved in the type I IFN response (reviewed in 
Chapter 1). Hits are ranked in descending order of relative abundance in the PR8-infected sample at 16 h post-infection. Values represent 
fold-change over mock-infected sample. Fold-change values are shown for all time-points tested for all samples.   
Gene 
symbol 
Protein name PR8 O175A O265B 
8 h 16 h 8 h 16 h 24 h 8 h 16 h 24 h 
IFIH1 Interferon-induced helicase C domain-containing 
protein 1 (also known as MDA5) 
5.04 9.12 1.8 1.98 1.6 2.37 3.77 2.97 
DDX58 Probable ATP-dependent RNA helicase DDX58 
(also known as RIG-I) 
2.18 3.44 1.22 1.31 1.32 1.31 1.79 1.6 
IKBIP Inhibitor of nuclear factor kappa-B kinase-
interacting protein 
1.08 1.16 0.98 1.11 1.02 1.21 1.1 1.17 
STAT2 Signal transducer and activator of transcription 2 1.15 1.13 1.15 0.59 0.52 0.93 0.72 0.61 
STAT1 Isoform Beta of Signal transducer and activator 
of transcription 1-alpha/beta 
1.04 1.11 1.04 1.05 1.02 1.02 1.07 1.04 
TANK TRAF family member-associated NF-kappa-B 
activator 
1.11 1.07 0.97 0.85 0.91 0.97 0.84 1 
IRF3 Interferon regulatory factor 3 1.09 1.05 0.98 0.97 0.99 0.94 1.04 0.98 
MAVS Mitochondrial antiviral-signalling protein 0.95 1.01 0.95 1 0.98 1.21 0.99 1.01 
NFKB1 Isoform 2 of Nuclear factor NF-kappa-B p105 
subunit 
0.94 0.98 0.92 0.94 0.86 0.94 0.94 0.93 
NFKB2 Nuclear factor NF-kappa-B p100 subunit 1.11 0.97 1.17 0.96 0.86 1.11 0.89 1.12 
TBK1 Serine/threonine-protein kinase TBK1 1 0.9 0.93 0.83 0.78 0.95 0.82 0.77 





-infected samples. IFIH1 (or MDA5) was the protein most highly up-regulated in any 
sample, and this was in the PR8-infected sample at 16 h post-infection and was 
described above. RIG-I (DDX58) was also up-regulated in PR8-infection relative to 
O175A and O265B, which is consistent with the data described above that suggested 
that PR8 infection up-regulated interferon-inducible protein expression more so than 
the NS reassortant viruses. It was noted that PR8, O175A and O265B all reduced the 
expression of JAK1 (Janus kinase-1) to 0.40-, 0.34- and 0.38-fold respectively at 16 h 
post-infection. However, all other components of the type I IFN signalling pathway 
that were identified all fell within 2-fold of the mock-infected samples and therefore 
were not substantially altered during infection.   
Overall, the ISG profiles of O175A and O265B were similar, while WT PR8 
appeared to induce a stronger antiviral response in infected A549 cells. These data do 
not support a hypothesis that a B-allele virus induces an excessive antiviral response 
in mammalian cells that may lead to a disadvantage in terms of virus replication in a 
mammalian host in comparison to an A-allele counterpart virus. 
3.2.6 Host cell shut-off during infection with NS reassortant viruses 
Next, to investigate whether the differences in ISG profiles noted in the 
quantitative temporal proteomics study described above could be attributed to 
differences host protein synthesis rates during infection, metabolic labelling was 
employed as means of assessing host cell shut-off during infection with the panel of 
PR8-based NS reassortant viruses.   
MDCK cells were infected at high multiplicity (MOI = 10) and were pulsed 





At 8 h post-infection, MDCK cells that were infected in parallel, without the addition 
of radioisotope, were fixed, permeabilised, and immunostained for viral NP for all 
samples to assess infection rate. Fig 3.8A shows NP immunostaining for PR8-, 
O175A-, and O265B-infected cells, of which the majority were infected. Mock-
infected cells did not contain detectable NP at the imaging parameters used. Cell 
lysates were generated at 8 h post-infection and levels of labelled proteins synthesised 
in the 6-8 h window were detected by autoradiography following SDS-PAGE on equal 
volumes of cell lysate (Fig 3.8B). Mock-infected cells did not synthesise detectable 
levels of viral proteins. In all virus-infected samples, the polymerase proteins, NP, HA, 
NS1, M1 and NEP were readily detected (see annotations on Fig 3.8B). Mock-infected 
cell lysates generally contained a higher level of labelled cellular proteins than infected 
cells, indicating greater synthesis rates. This was apparent by darker regions of the gel 
in comparison to virus-infected samples at molecular weights where no viral proteins 
were detected, particularly at higher molecular weight. In virus-infected cells, there 
was a clear bias for viral protein synthesis over host-cell proteins.  To quantify cellular 
protein synthesis rates, actin was used as a marker as it is generally expressed at 
relatively high levels in uninfected cells and is therefore easily identified (see 42 kDa 
protein annotated in Fig 3.8B). The actin band was quantified by densitometry using 
ImageJ software (Fig 3.8C). All infected cells displayed a clear reduction in actin 
synthesis rates (at least two-fold on average) relative to mock-infected cells, and the 
ability to reduce actin synthesis rates was similar across both A- and B-allele 






Fig 3.8. Host cell shut-off during infection with NS reassortant viruses. MDCK 
cells were infected at an MOI of 10. (A) Immunofluorescence of intracellular viral NP 
(green) at 8 h post-infection was used to estimate successful infection rates in all 
samples. Shown are PR8, O175A and O265B infections (images for other infections 
are not shown). DAPI staining (blue) shows cell nuclei. (B) Metabolic labelling was 
performed using a 35S protein labelling mix between 6-8 h p.i.. Cell lysates were 
generated at 8 h p.i. using an SDS lysis buffer. Lysates were subjected to SDS-PAGE 
and proteins with 35S were detected using autoradiography. (C) Actin synthesis rates 
were quantified by densitometry using ImageJ software. Data represent mean and 






These data do not support the hypothesis that there is not a major deficiency 
for B-allele NS reassortant viruses in inducing host-cell shut-off in the context of virus 
infection. However, while there is evidence that NS1 is involved in preventing cellular 
gene expression by preventing processing of host pre-mRNAs (described more 
thoroughly below), it is not clear from this experiment whether the shut-off observed 
was due to the NS1 protein alone or in combination with other shut-off mechanisms 
that have been described for IAV. Other mechanisms of shut-off include host mRNA 
‘cap-snatching’ (Robertson et al., 1980, Dias et al., 2009), the degradation of host 
mRNA transcripts by PA-X (Jagger et al., 2012, Khaperskyy et al., 2016), the 
degradation of cellular RNA polymerase II (pol II) (Rodriguez et al., 2007, Vreede et 
al., 2010), and an inhibition of pol II elongation by the viral polymerase (Chan et al., 
2006). Indeed, it has been reported previously that the NS1 protein may not be required 
for host shut-off (Salvatore et al., 2002). Therefore, the influence on NS1 proteins to 
inhibit a pol II promoter in isolation were studied next, as described below.  
3.2.7 NS1 and suppression of RNA polymerase II promoter activity 
NS1 has been implicated in suppressing host gene expression by inhibiting host 
pre-mRNA maturation, splicing and nuclear export by various mechanisms including 
binding to and inhibiting host CPSF30 and PABII (Nemeroff et al., 1998, Chen et al., 
1999), U6 snRNA (Qiu et al., 1995), as well as inhibiting the mRNA nuclear export 
complex (Satterly et al., 2007), and this contributes to a dampening of the IFN response 
in infected cells (Noah et al., 2003, Kochs et al., 2007). All of the above studies were 
conducted using A-allele NS1 proteins, and to date there are no available reports 
assessing B-allele NS1 inhibition of cellular gene expression. To complement the 





in isolation to inhibit cellular gene expression, a pol II reporter assay was employed. 
A plasmid vector containing a constitutively active pol II promoter (simian virus 40 
(SV40)) upstream of the Renilla reniformis (Renilla) luciferase gene (pRL, kind gift 
from Dr. Finn Grey, the Roslin Institute, The University of Edinburgh) was co-
transfected with various NS1-GFP constructs in 293T cells, and luciferase activity 
after 48 h was used as a readout for cellular pol II-driven gene expression.  NP-GFP 
was used as a control, as NP is not known to influence host gene expression.  A PR8 
NS1-GFP mutant, which has the consensus CPSF30-binding site reinstated (S103F 
and I106M; ‘PR8 S103F/I106M’, made by Dr. Helen Wise of the Digard laboratory), 
was used as a positive control as this NS1 mutant was predicted to induce a greater 
level of shut-off than the WT PR8 NS1 (Kochs et al., 2007). A pDUAL plasmid 
expressing the A/chicken/Rostock/8/1934 (H7N1) (fowl plague virus, or FPV) PA 
gene, and also a PA-X gene known to have host-cell shut-off ability (unpublished data 
from Digard lab), was used as another positive control. Empty pDUAL plasmid was 
used as the appropriate negative control for this effector. 
293T cells were seeded in 24-well plates, and were co-transfected with 100 ng 
of pRL reporter plasmid along with 400 ng of effector plasmid. At 24 h post-
transfection, successful transfection was confirmed using epi-fluorescent microscopy 
for GFP fluorescence and all cells were transfected at similar levels (data not shown). 
After 48 h, cells were lysed and Renilla luciferase activity was quantified using 
Promega’s Renilla Luciferase Assay System. Renilla luciferase activity was plotted as 
fold-change with respect to the appropriate control (NP-GFP for NS1-GFP effector 
plasmids, and empty pDUAL for pDUAL-PA). Background luminescence was 





control – both of which gave relative luminescence values several orders of magnitude 
lower than samples expected to contain active luciferase (data not shown). 
Luciferase activity was high in the NP-GFP (mean activity 6.3 x 107 RLU +/- 
1.9 x 107 SD, n =4) and empty pDUAL plasmid (mean activity 2.5 x 108 RLU +/- 7.0 
x 107 SD, n = 4) negative controls. The dashed line on the graph shows the luciferase 
activity of the NP-GFP and empty pDUAL plasmid controls (Fig 3.9). The pDUAL-
FPV-PA effector suppressed mean luciferase activity to 0.17-fold compared to the 
empty pDUAL plasmid control sample. PR8 NS1-GFP actually increased luciferase 
activity by a mean of 2.84-fold compared to the NP-GFP control, while the PR8 
S103F/I106M mutant reduced luciferase activity to 0.76-fold of the NP-GFP sample. 
The consensus North American LPAI NS1s, O175A and O265B, both supressed mean 
luciferase activity to 0.16-fold and 0.12-fold relative to the NP-GFP control, 
respectively. Transfection of NY6750A and Sw412A NS1-GFP plasmids both also 
reduced mean luciferase activity to 0.14-fold and 0.12-fold relative to NP-GFP. The 
NS1s of Alb88B, Sw418B and J89B likewise all suppressed the pRL pol II activity, 
with mean luciferase activities of 0.13-, 0.09- and 0.21-fold respectively relative to the 
NP-GFP negative control. The NS1-GFP plasmid for NY107B, however, increased 
luciferase activity to 6.51-fold relative to the NP-GFP control. The Sw418B NS1 
protein induced a statistically significant reduction in luciferase activity in comparison 
to O175A NS1, while mean luciferase activity in the J89B sample was significantly 
higher than both the NY6750A and Sw412A samples (unpaired t-test, n = 4). A similar 
pattern of results was observed in experiments in which the pRL reporter plasmid was 






Fig 3.9. NS1 suppression of pol. II-mediated reporter gene expression. 293T cells 
were co-transfected with a plasmid constitutively expressing the Renilla luciferase 
gene under control of the SV40 promoter and NS1-GFP expression plasmids. 
Luciferase activity was measured at 48 h post-transfection. Data are plotted as fold-
change with respect to appropriate negative control. NP-GFP was employed as 
negative control effector for all NS1-GFP effectors. A pDUAL segment 3 plasmid 
expressing high activity PA-X from A/chicken/Rostock/1934 (H7N1) was included as 
a positive control effector, with empty pDUAL plasmid as the negative control for this 
effector. Data represents mean +/- SD (n = 4). Statistically significant differences from 
respective negative control effectors (NP-GFP or empty pDUAL) in unpaired t-tests 
are marked with asterisk(s). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, **** p ≤ 0.001. 
Samples labelled with the same letter are significantly different from each other in an 






and mCherry expression was quantified either by a fluorescence plate reader or 
western blotting of cell lysates (data not shown), validating the pattern of results seen 
in this system.  
These data demonstrate a strain-dependent ability of NS1 proteins tested to 
reduce pol II-mediated gene expression. WT PR8 does not have either of F103 or 
M106, which are both reported to be important for CPSF30 inhibition (Kochs et al., 
2007, Das et al., 2008). Mutating the NS1 protein to include these residues improved 
pol II promoter inhibition in comparison to WT, but did not reach the same levels as 
various other A- and B-allele NS1s tested. Interestingly, all B-allele NS1 proteins used 
in this experiment lack the F103 residue which has been suggested to be essential for 
CPSF30 binding and inhibition (Kochs et al., 2007, Das et al., 2008), and O668B 
additionally lacks M106 which is also apparently important (see Fig 2.1). All NS1 
proteins investigated do, however, contain E186 which has been reported as being 
important for CPSF30-binding (Nemeroff et al., 1998, Li et al., 2001, Noah et al., 
2003). Overall, although there is strain-dependent variability in shut-off ability, the 
data demonstrate that B-allele NS1 proteins are capable of inhibiting cellular pol II 







In this section, the ability of segment 8 reassortant viruses to circumvent and 
suppress the host innate immune response was investigated. The primary reason for 
this being that previous studies have reported that B-allele NS1 proteins are deficient 
in their ability to suppress the mammalian IFN response. The Berg group published 
several studies investigating the ability of selected A- and B-allele NS1 proteins from 
closely related strains to prevent the up-regulation of type I IFN, NF-κβ, and AP-1 
promoters using transfection-based reporter assays and IFN ELISAs during 
transfection and infection experiments. They proposed that B-allele NS1 proteins are 
deficient in supressing the activity of the aforementioned promoters and do not 
efficiently block the IFN response in mammalian cells (Zohari et al., 2010a, Munir et 
al., 2011a, Munir et al., 2011b, Munir et al., 2012). IFN-antagonism by the NS1 protein 
is essential for efficient virus replication (García-Sastre et al., 1998), and so if it was 
true that B-allele NS1 proteins are not capable of suppressing the mammalian IFN 
response, this could explain why B-allele viruses are rarely found in the mammalian 
host. However, the data presented in Chapter 2 points to full replicative ability of B-
allele IAVs in mammalian cells, and so it was hypothesised that B-allele NS 
reassortant viruses would be able to control the IFN response in mammalian cells.  
WT PR8 and consensus NS reassortant viruses O175A and O265B all coped 
similarly with the induction of the IFN response in A549 cells treated with IFN-β, 
displaying very similar IC90 values during multi-cycle infection experiments (Fig 
3.1A). When type I IFN secretion was quantified following infection of human lung 
A549 cells with a panel of PR8- and Udorn72-based NS reassortant viruses, it was 





inhibitory levels, except a PR8 NS1-mutant virus (Figs 3.2C, 3.3A and 3.3B). A panel 
of A- and B-allele NS1 proteins were also able to efficiently suppress the activation 
the human IFN-β promoter in cells stimulated with poly(I:C) (Fig 3.4A). Additionally, 
most of the NS1s tested were able to efficiently suppress the activation of the ISRE 
promoter element in a similar setup, barring PR8 and NY107B which either increased 
or failed to suppress ISRE activation, respectively (Fig 3.4B).  An increase in ISRE 
activity in human cells stimulated with type I IFN has been noted in a previous study 
following transfection of a PR8 NS1 expression plasmid or infection with WT PR8 
(Hayman et al., 2006). The mechanism behind this elevation in ISRE promoter 
activity, however, is not clear. These data, taken together, suggest that B-allele 
segment 8 viruses are able to supress type I IFN release during infection below 
inhibitory levels, and the NS1 proteins are acting to block IFN promoter activation. 
This is complemented by the findings of other studies that found B-allele avian NS1 
proteins to be equally efficient at blocking IFN-β promoter activity in human cells as 
A-allele counterparts in transfection-based reporter studies (Hayman et al., 2007, Ma 
et al., 2010). Importantly, Sw418B displayed no evidence of a deficiency in blocking 
the mammalian IFN response, in both the context of viral infection and also in 
transfection-based reporter assays. Sw418B was a representative strain from the Berg 
group’s reporter assay experiments in which it was concluded that B-allele NS1 
proteins are deficient in IFN-antagonism in the mammalian host (Munir et al., 2011a, 
Munir et al., 2011b, Munir et al., 2012). Therefore, the data presented here directly 
contradict the findings and conclusions of the studies by the Berg group, even when 
using the same NS1 protein in a similar system. Although NS1-GFP was used as an 





how the GFP-tag would provide gain-of-function particularly when an appropriate 
control (NP-GFP) failed to efficiently block IFN-β and ISRE promoter activity. To be 
critical of the studies by the Berg group, they did not show that differences observed 
in reporter assays affected virus replication.  
When human CD14+ monocyte-derived macrophages were infected with 
consensus viruses, PR8, O175A and O265B all induced a pro-inflammatory response 
(Fig 3.5B and Table 3.1), with strong up-regulation of pro-inflammatory cytokines 
such as TNF-α, CCl5, and CXCL10, which have all been reported to be up-regulated 
during PR8 infection of human alveolar macrophages (Wang et al., 2012a). 
Interestingly, WT PR8 induced a higher level of pro-inflammatory cytokine release 
than O175A and O265B. A particularly striking up-regulation of TNF-α was noted in 
comparison to O175A- and O265B-infected macrophages. The pro-inflammatory 
response recruits inflammatory cells and contributes to inflammation-induced lung 
damage. Pro-inflammatory cytokines, particularly TNF-α and type I IFNs, have been 
proposed to be responsible for the increased lung pathology noted in human infection 
with HPAI H5N1 and the 2013 H7N9 virus  (Cheung et al., 2002, Lee et al., 2009b, 
To et al., 2016). IL-1β has also been implicated in contributing to lung inflammation 
during infection with influenza A virus (Kim et al., 2015b), but this was only modestly 
up-regulated in all samples tested here (Fig 3.5B). Whether the increased cytokine 
release from PR8-infected macrophages was due the inability of its NS1 protein to 
block ISRE activation (Fig 3.4B), or another aspect of viral replication, is not clear. 
Importantly, an exaggerated immune response in macrophages infected with a B-allele 
virus was not noted. Therefore there was no evidence to suggest that B-allele viruses 





which may act to limit infection in these hosts. A more ideal experiment would have 
used alveolar macrophages rather than monocyte-derived macrophages from the 
blood, as these are the major macrophage population to encounter IAV in the lung. 
However, obtaining human alveolar macrophages is more challenging. In the next 
section, cytokine/chemokine profiling of infected mouse lung is described, which will 
reflect alveolar macrophage responses.  
It has been reported elsewhere that the expression profiles of select ISGs, such 
as Mx1 and OAS, were similar during infection of avian cells with A- and B-allele 
viruses (Adams et al., 2013). However, a relevant study had not been reported using 
mammalian cells. Here, mass-spectrometry was employed to investigate proteome-
wide changes in A549 cells that had been infected with A- and B-allele NS reassortant 
viruses at different time-points. Interestingly, WT PR8 up-regulated a host of antiviral 
factors to a greater extent than both O175A and O265B, and the ISG expression 
profiles of O175A and O265B were similar (Figs 3.7B and 3.7C). The antiviral roles 
of Mx1, OASL, IFIH1, IFIT1, IFIT2, and IFIT3 are discussed in more detail Chapter 
1. All of these proteins are IFN-inducible. These findings complement the ISRE-
promoter reporter data described above (Fig 3.4B), as well as previous studies 
reporting either a failure to supress ISRE activity or an increase in reporter assays by 
the PR8 NS1 protein or PR8 infection (Hayman et al., 2006, Hayman et al., 2007, 
Munir et al., 2011b). The quantitative temporal proteomics data did not support the 
hypothesis that a B-allele virus induces an exaggerated antiviral response in 
mammalian cells in comparison to A-allele counterparts.  
Host cell shut-off was investigated, as it was observed that B-allele NS1 





2.1), and therefore it was plausible that B-allele viruses perhaps do not inhibit host cell 
gene expression efficiently, which could be detrimental to virus replication. Shut-off 
was assessed in virus infection by metabolic-labelling of infected MDCK cells and 
also by NS1 expression in transfected cells using a pol II reporter. All viruses tested 
were able to reduce actin synthesis rates to similar levels during infection (Figs 3.8B 
and 3.8C). The majority of NS1 proteins tested also reduced expression of a pol II 
reporter in transfection studies, except PR8 and NY107B NS1 which both increased 
expression (Fig 3.9). Therefore conversely, PR8 was able to reduce host actin synthesis 
during infection despite its NS1 protein seemingly increasing pol II promoter-driven 
gene expression. However, whole-virus infections and plasmid-based reporter assays 
are rather different systems and the functions of NS1 are likely to differ between the 
two. Additionally, the virus will be inducing shut-off through additional mechanisms 
including host mRNA ‘cap-snatching’ by the polymerase to prime viral mRNA 
transcription (Robertson et al., 1980, Dias et al., 2009), PA-X endonuclease activity 
targeting host mRNAs (Jagger et al., 2012, Khaperskyy et al., 2016), inhibition of 
cellular RNA pol II elongation (Chan et al., 2006) and inducing RNA pol II 
degradation (Rodriguez et al., 2007, Vreede et al., 2010), all of which will reduce actin 
synthesis rates. Indeed, Salvatore and colleagues proposed that the NS1 protein may 
not be required for host shut-off (Salvatore et al., 2002). 
The mechanisms behind the increase in pol II driven gene expression in 
transfection-based studies with PR8 and NY107B NS1 proteins are not clear, and 
whether this is linked to the failure to inhibit ISRE activity (Fig 3.4B) and the strong 
ISG up-regulation in PR8-infected A549 cells (Figs 3.7B and 3.7C) is yet to be 





help clarify this. Interestingly, both PR8 and NY107 have an R224G change in a region 
(223-230) that is thought to be important for PABPII binding and inhibition (Fig 2.1) 
(Chen et al., 1999, Li et al., 2001). An interesting experiment would be to mutate this 
reside to R224 (and also reciprocally mutate other NS1 proteins to harbour G224) and 
compare shut-off capabilities and PABPII-binding properties across the NS1 mutants.  
It did not appear that the consensus F103 and M106 binding site for CPSF30 
was essential for efficient shut-off, given several B-allele proteins contained Y103 and 
induced shut-off efficiently. An interesting question to address is whether or not B-
allele NS1 proteins can bind CPSF30 without the consensus binding site (F103/M106). 
CPSF30 pull-downs were attempted but due to technical issues and time constraints, 
this question has currently not been answered. Perhaps F103 and M106 are not 
essential to inhibit CPSF30, or conceivably binding to PABPII is most important for 
efficient inhibition of 3’ processing of cellular pre-mRNAs. A PR8 NS1 mutant with 
the F103 and M106 binding-site instated was not particularly efficient at inducing pol 
II shut-off in a reporter assay, but there was an improvement over WT PR8 NS1 (Fig 
3.9), suggesting that CPSF30-binding is a contributor to shut-off but is not sufficient 
for a full-effect.  
In summary, the data in this section of the study suggest that there is no obvious 
penalty for a mammalian-adapted virus harbouring a B-allele NS segment in terms of 
circumventing the mammalian innate immune response. Contrary to previous reports 
(Zohari et al., 2010a, Munir et al., 2011a, Munir et al., 2011b, Munir et al., 2012), these 
data provide evidence that any apparent restriction of B-allele viruses to avian hosts is 
















In the previous sections, A- and B- allele NS reassortant viruses were 
characterised in vitro, and it was concluded that mammalian viruses harbouring a B-
allele segment 8 did not have a major replicative fitness penalty in mammalian cells, 
and were able to effectively circumvent and supress the innate immune response to 
allow efficient virus replication. In this section, the aim was to assess fitness of A- and 
B- allele NS reassortant viruses in the context of in vivo infections. It was asked 
whether i) a B-allele reassortant virus could replicate and cause disease in vivo, ii) a 
B-allele reassortant virus could suppress the innate immune response in vivo, and iii) 
whether there is a selection advantage for an A-allele NS segment into a mammalian-
adapted virus background over a B-allele equivalent in vivo.  
4.1.2 Hypothesis 
As discussed in previous sections, there have been reports published with 
conflicting conclusions regarding the contribution of A- and B- allele NS genes to 
mammalian-virus fitness. Treanor et al concluded that introduction of a B-allele NS 
segment into a human H3N2 virus attenuated the virus in the squirrel monkey host 
(Treanor et al., 1989). However, Kim and colleagues tested PR8-based reassortant 
viruses with NS segments from avian H9N2 and H5N1 strains, assessed pathogenicity 
in vivo and reported different findings (Kim et al., 2015a). The B-allele PR8-based 





comparable to WT PR8, providing evidence against the hypothesis that B-allele NS 
segments attenuate IAV in vivo.  
Given these observations, and the evidence presented in Chapters 2 and 3 that 
the in vitro fitness of an NS reassortant virus is independent of A- or B-allele lineage, 
it was hypothesised that a B-allele NS reassortant virus would be able to cause disease 
and replicate in vivo. Similarly, it was hypothesised that the B-allele reassortant virus 
would be able to supress innate immune responses as efficiently as an A-allele 
counterpart, and that there would not be a selection disadvantage for the B-allele NS 
segment in vivo.  
4.1.3 Approach 
BALB/c mice were used as a model of in vivo infection. To assess the ability 
of viruses to replicate and cause disease in vivo, mice were infected with WT PR8 or 
PR8-based reassortant viruses O175A and O265B and weighed daily while virus 
replication in the lung was assessed by plaque assay of lung homogenate. Lungs were 
fixed in formalin to allow assessment of histopathology and also virus tropism by 
immunohistofluorescence analysis of viral NP. The induction of the innate immune 
response was assessed by quantifying ISG expression by RT-qPCR from RNA 
extracted from lung tissue, as well as cytokine and chemokine profiling of mouse lung 
homogenate. Finally, in vivo competition assays were used to ask if there is a selection 






4.2.1 Weight-loss of infected BALB/c mice  
To assess the ability of NS reassortant viruses to cause disease in vivo, weight-
loss and clinical symptoms were recorded during infection of BALB/c mice. Initially, 
a small-scale pilot study was performed in which groups of 4 mice were infected with 
either 100 PFU or 500 PFU of WT or consensus PR8-based reassortant viruses 
(O175A, or O265B) or mock-infected with media. Infections were administered via 
the intranasal route in anaesthetised mice in a 40 µl droplet. The inoculum of each 
virus was subsequently titrated by plaque assay to ensure equal input (data not shown). 
The mice were weighed at the same time each day, and any clinical symptoms were 
recorded. The 100 PFU study was conducted over 8 days, while the 500 PFU study 
was halted at day 7 post-infection for ethical reasons based on weight-loss and clinical 
symptoms.  
Mock-infected mice did not lose weight at any time-point (Figs 4.1A & 4.1B). 
In both the 100 PFU and 500 PFU groups, the largest weight-loss was observed at day 
7 post-infection for all viruses. PR8-infected mice lost the most weight, and O265B 
induced more weight-loss than O175A. WT PR8 induced significantly more weight-
loss compared to mock-infected mice from day 6 onwards in the 100 PFU infection, 
and from day 3 onwards in the 500 PFU infection. By day 7 post-infection, mean 
weight-loss was 18.0% for the 100 PFU cohort, and 25.3% for the 500 PFU cohort. At 
day 8 post-infection, mice infected with 100 PFU showed recovery, with a mean 
weight-loss of 14.7%. With a 100 PFU infection, O175A-infected mice did not lose 






Fig 4.1. Weight-loss of infected BALB/c mice. (A + B) Pilot study. Four mice were 
infected with stated PFU of virus and mice were weighed at the same time each day. 
One mouse per cohort was euthanised at day 4 p.i. to harvest tissue. (C) As in (B) but 
cohort sizes at day 0 were larger (n = 15) and 5 mice were culled at each time-point of 






post-infection. In the 500 PFU cohort, O175A-infected mice lost 6.0% starting weight 
by day 7, but this was not statistically different to the mock-infected group (unpaired 
t-test). Mice infected with 100 PFU of O265B lost a mean of 8.3% starting weight by 
day 7, but this was not significantly different to the mock-infected cohort (unpaired t-
test). Mice infected with 100 PFU O265B displayed recovery at day 8 post-infection, 
with mean weight-loss reduced to 6.0%. Mice infected with 500 PFU of O265B lost 
14.7% bodyweight by day 7 post-infection, and this was significantly more than mock-
infected mice (unpaired t-test).  
The clinical symptoms of the mice correlated with the severity of weight-loss. 
Mock-infected mice appeared healthy throughout the study. All infected mice in the 
500 PFU cohort displayed clinical symptoms (ruffled coat, trembling, lethargy, 
huddling), from day 3 post-infection onwards. The severity of clinical symptoms was 
correlated with weight-loss, with PR8-infected mice displaying the most pronounced 
clinical symptoms and O175A-infected mice the least so.  The 100 PFU groups had 
less severe clinical symptoms. The PR8- and O265B-infected mice showed only mild 
clinical symptoms (ruffled coat, mild lethargy), whereas O175A-infected mice did not 
show any clinical signs of infection (data not shown).   
Using the pilot studies as a reference, it was decided to repeat the study on a 
larger scale using a 500 PFU dose, as this amount of inoculum resulted in the most 
significant weight-loss differences between the cohorts. Groups of 15 BALB/c mice 
were infected with 500 PFU of PR8, O175A or O265B, or mock-infected with media, 
in the same manner as in the pilot study described above. At days 2, 4 and 6 post-
infection, 5 mice were culled per cohort and lung tissue collected for downstream 





Mock-infected mice did not lose weight at any point during the study (Fig 
4.1C), and did not show any clinical symptoms at any stage (data not shown). All 
virus-infected mice lost weight from day 3 post-infection onwards. At day 4 post-
infection, mean weight-loss was 16.9%, 3.1% and 8.4% starting weight for PR8-, 
O175A and O265B-infected mice respectively (n = 10). By day 6 post-infection, PR8 
induced a mean weight-loss of 25.8%, O175A induced 8.2% weight-loss and O265B-
infected mice lost 19.3% initial starting weight (n = 5). All differences in weight-loss 
between groups were statistically significant from day 3 post-infection onwards, 
except in the O175A group which was not significantly different to mock-infected 
mice at day 5 post-infection (unpaired t-test). As in the pilot study, the severity of 
clinical symptoms correlated with weight-loss, with the WT PR8-infected mice 
displaying the most severe clinical symptoms (ruffled coat, shivering, lethargy, 
huddling) from day 4 post-infection onwards (data not shown).  
Thus the introduction of an avian segment 8, from either the A- and B- allele 
lineages, into the PR8 backbone reduced pathogenicity in mice relative to the WT. 
Interestingly, O265B induced greater weight-loss than O175A in all studies 
performed. These data suggest that a mammalian-adapted virus harbouring an avian 
B-allele NS segment can cause disease in a mammalian host, and to a greater extent 
than an avian virus-derived A-allele counterpart. 
4.2.2 Virus replication in the lungs of infected BALB/c mice 
Next, replicative fitness of the NS reassortant viruses was analysed by titrating 
infectious virus in the lung by plaque assay. The left lung was removed from 5 
euthanised mice at days 2 and 6 post-infection. The tissue was homogenised, clarified 





At both day 2 and 6 post-infection, mock-infected mouse lung homogenate 
contained undetectable levels of infectious virus (limit of detection 2.5 PFU/ml). At 
day 2 post-infection, the three viruses replicated to high titres, and there were no 
statistically significant differences between the groups (n = 5, unpaired t-test) (Fig 4.2). 
WT PR8 replicated to a mean titre of 1.85 x 106 PFU/ml, which was approximately 2-
fold higher than mean titres achieved by O175A (6.25 x 105 PFU/ml) and O265B (6.40 
x 105 PFU/ml). At day 6 post-infection, all groups displayed a reduction in virus titre. 
WT PR8 had the most infectious virus in the lung, with a mean titre of 2.95 x 105 
PFU/ml, and this was statistically significantly different from both O175A and O265B 
titres (n = 5, unpaired t-test). O265B had a statistically significant higher virus titre 
than O175A at day 6 post-infection, with a mean titre of 7.45 x 104 PFU/ml in 
comparison to O175A’s mean titre of 2.26 x 104 PFU/ml (n = 5, student’s t-test). 
Therefore, WT PR8 was the most fit in the BALB/c mouse host, followed by 
O265B, with O175A the least fit. These data suggest that a mammalian-adapted virus 
harbouring an avian B-allele NS segment can replicate to high virus titre in vivo, and 
can persist longer than an A-allele counterpart.  
4.2.3 Histopathology in infected mouse lung  
To compare and contrast the severity of tissue damage and inflammation 
induced by infection of NS reassortant viruses, histopathology in the lungs of infected 
mice was assessed at day 6 post-infection. The right lungs of infected BALB/c mice 
were fixed with a neutral buffered formalin solution, and sections were processed and 
stained with haematoxylin and eosin (by the Easter Bush Pathology Laboratory) to 
allow assessment of induced histopathology using light microscopy. Samples from the 






Fig 4.2. Virus titre in infected mouse lung. Groups of 5 BALB/c mice were infected 
with 500 PFU of virus, or mock-infected with media. The left lung of each euthanised 
mouse was removed and frozen at indicated time-points. Lung homogenates were 
generated in serum-free media and virus titre was calculated using plaque assay. Data 






(Dr. Philippa Beard, The Roslin Institute, The University of Edinburgh, UK). The 
following description was written by Dr. Philippa Beard: 
‘All three viruses caused lesions consistent with IAV infection, characterised 
by mild to marked, subacute, multifocal, nonsuppurative, bronchointerstitial 
pneumonia with necrosis and fibrin accumulation. Degeneration and necrosis of 
epithelial cells lining the airways, accompanied by peribronchiolar, peribronchial, and 
perivascular inflammation, was a consistent feature (Fig 4.3A). The inflammatory 
infiltrate was predominantly lymphocytic and histiocytic with variable numbers of 
neutrophils’.  
An ‘overall’ score was assigned to blinded samples (0 representing lack of 
evidence of infection, and 1-3 increasing severity levels in ascending order). All mock-
infected samples were assigned 0 during the blind scoring process, and no obvious 
difference in scoring was noted between virus-infected samples (Fig 4.3B). PR8 was 
assigned a mean score of 2.0, and O175A and O265B were both assigned a mean score 
of 2.1 (Fig 4.3B). 
Therefore the introduction of an avian NS segment, from both A- and B-allele 
lineages, into the PR8 backbone did not notably affect lung pathology in vivo, despite 
differences noted in weight-loss and clinical symptoms across the different viruses.   
4.2.4 Virus tropism in the lungs of infected mice 
To assess virus tropism within the lungs of infected BALB/c mice, lung 
sections obtained from days 2, 4 and 6 post-infection were immunostained for 
intracellular NP. Unstained sections (processed by the Easter Bush Pathology 






Fig 4.3. Histopathology in infected mouse lung. (A) At day 6 p.i., the right lung 
lobes of inoculated mice were collected, fixed, processed, and stained with 
haematoxylin and eosin. Mock-infected mice showed no significant changes, whereas 
infected mice showed degeneration and necrosis of epithelial cells lining airways with 
peribronchiolar and perivascular inflammation, and interstitial inflammation 
sometimes accompanied by necrosis and fibrin accumulation. The inflammatory 
infiltrate was predominately lymphocytes and macrophages with variable numbers of 
neutrophils. Scale bars are 50 µm. (B). Severity of pathology in the lung was assessed 
blind and an overall pathology score out of 3 was assigned. Data are mean +/- SD (n 
= 5). (Images shown in (A) were taken by Dr. Philippa Beard and the accompanying 





intracellular viral NP and DAPI staining of cell nuclei was performed. Sections were 
imaged using confocal microscopy. Background levels of fluorescence were 
determined by including ‘primary antibody only’ and ‘secondary antibody only’ 
stained samples of PR8-infected lung sections (data not shown).   
Mock-infected samples did not display viral NP staining above background 
levels at any time-point (Fig 4.4). In general, and at all time-points tested, intracellular 
viral NP from PR8, O175A and O265B was mostly localised to the epithelium of 
mouse lung airways, although there was also interstitial tissue staining observed in all 
virus-infected samples (Fig 4.4).  The number of infected epithelia per section 
appeared to correlate with the virus titre data. PR8 appeared to infect more epithelia 
per section than the avian segment 8 reassortant viruses at each time-point tested when 
sections were manually inspected by epi-fluorescent microscopy (data not shown). 
Mean PR8 titres were approximately 2-fold greater at day 2 post-infection than O265B 
and O175A, and 3-fold greater by day 6 post-infection (Fig 4.2). The number of 
epithelia per section infected with O175A and O265B were similar at each time-point 
(data not shown). Similarly, the level of interstitial staining across whole sections 
appeared to be greater in PR8-infected mice, but more comparable between O175A- 
and O265B-infected mice (data not shown).  
Overall, the cell tropism of the consensus viruses appeared similar in the lungs 
of infected BALB/c mice at all time-points tested, although the amount of viral staining 
looked to be greatest in PR8-infected mice. These data suggest that the source of 
segment 8 does not notably alter the cell type and location of infection, although the 






Fig 4.4. Virus tropism in infected mouse lung. The lungs of infected mice were 
fixed, sectioned, and immunostained for intracellular viral NP (red) and DNA (blue) 
at days 2, 4 and 6 post-infection. Images were taken by laser scanning confocal 
microscopy and differential interference contrast microscopy at 63x magnification 
using a tiling function on Ziess LSM710 software. Day 6 images were imaged and 






4.2.5 Antiviral gene expression in infected mouse-lung 
In Chapter 3, the ability of NS reassortant viruses to circumvent and block the 
mammalian innate immune response in vitro was assessed. Here, similar assessments 
were performed for in vivo infections. An array of transcripts for cellular genes 
including cytokines and antiviral restriction factors (see Table 4.1) were quantified by 
RT-qPCR of RNA extracted from the lung at day 4 post-infection, to analyse the 
induction of the innate immune response. RNA from the tip of the right-lung of 
infected mice was extracted from 3 mice per cohort at day 4 post-infection. RNA was 
extracted from 50-80 mg of tissue and 25ng of RNA was used in a reverse transcription 
reaction using random hexamer primers. cDNA was loaded onto Taqman custom-
designed qPCR array plates (designed by Dr. Brett Jagger, National Institute of Allergy 
and Infectious Diseases, Bethesda, Maryland, USA. See Table 4.1 for individual 
assays) and cycling threshold (CT) values were obtained. Each gene transcript was 
tested in triplicate per mouse, and the mean CT of this was normalised to the mean CT 
value of the GAPDH control (dCT). The mean dCT value for the three mice was 
plotted as 20 – dCT. Under PCR conditions of 100% efficiency, twice the amount of 
product results in an increase in the 20 – dCT value by 1.  
The house-keeping control gene transcripts (18S, Gapdh, Hprt1, Gusb) were 
all detected at similar quantities in the 3 mice assessed per cohort, with no statistically 
significant differences noted by unpaired t-test (n = 3) (Fig 4.5). Overall, the majority 
of ISG transcripts quantified were up-regulated in all virus-infected samples relative 
to mock-infected mice. The transcript profiles were generally quite similar across the 
viruses tested, although there was a tendency for ISG transcripts to be detected at 





Table 4.1. Individual cellular transcript assays for mouse RT-qPCR array. 
Individual RT-qPCR assays are available online (www.lifetechnologies.com).  
 









































Fig 4.5. Antiviral gene expression in infected mouse lung. RNA was extracted from 
lungs of infected mice at day 4 p.i. and levels of various cytokines, chemokines, and 
antiviral gene expression were quantified using RT-qPCR. Assays were run on RNA 
from three separate mice per cohort and each assay was performed in triplicate. Data 
are plotted as mean (20- dCT) +/- SD. All infected samples were significantly different 
from the mock-infected sample, unless labelled with ‘NS’ which indicates no 






mice. This pattern correlated with severity of weight-loss (Fig 4.1C). The majority of 
ISG transcripts quantified were statistically significantly up-regulated in virus-infected 
samples relative to mock-infected, except tumour necrosis factor (ligand) superfamily 
member 10 (Tnfsf10), an inducer of apoptosis, which was not significantly different 
to mock-infected in any of the virus-infected samples. TNF-α (Tnf), IL-1β (Il1b), 
chemokine (C-C motif) ligand 4 (Ccl4), IFN-α-2 (Ifna2) and IFN-α-4 (Ifna4), all pro-
inflammatory mediators, were not significantly up- or down-regulated in O175A-
infected samples in comparison to mock-infected mice.  IL-17b (Il17b), a pro-
inflammatory cytokine, was not significantly up- or down-regulated in PR8- or 
O265B-infected samples, but was significantly upregulated, albeit very modestly, in 
O175A-infected samples. All other gene transcripts were significantly up-regulated in 
all virus-infected samples relative to mock-infected. There were no transcripts 
significantly differentially regulated between O175A and O265B, nor between PR8 
and O265B. The only statistically significant differences in transcript levels between 
virus-infected samples were Tnfsf10, colony stimulating factor 1 (Csf1) and colony 
stimulating factor 3 (Csf3)/granulocyte stimulating factor (G-CSF), which were all 
significantly different between PR8 and O175A samples. Tnfsf10 transcripts were 
detected at higher levels in O175A-samples whilst Csf1 and Csf3 transcripts, both 
predominantly pro-inflammatory cytokines, were both higher in PR8-infected mice 
(Fig 4.5). 
While there were not many statistically significant differences in transcript 
levels between the virus-infected samples, the general pattern, barring certain 
exceptions, was for ISG transcripts to be detected at highest abundance in PR8-





These included pro-inflammatory cytokines such as TNF-α (Tnf), IL-1β (Il1b) and 
CXCL10 (cxcl10), interferons IFN-β (ifnb1) and IFN-λ (Il28b), and antiviral 
restriction factors such as IFIT1 (Ifit1) and Mda5 (Ifih1). Notably, despite the fact PR8 
induced the largest expression of antiviral transcripts during infection, PR8 actually 
replicated to the highest viral titres in the lungs of mice (Fig 4.2).  
Overall, there was not an obvious up-regulation of host antiviral gene 
transcripts during a B-allele virus infection of a mammalian host in vivo. Thus, these 
results do not support the hypothesis that B-allele viruses elicit an exaggerated antiviral 
response in mammals which may lead to restriction in these hosts.  
4.2.6 Cytokine and chemokine profiling of infected mouse lung 
To follow on from the above experiment quantifying ISG transcripts in the 
lungs of mice, a cytokine and chemokine array was to ask whether a B-allele NS 
reassortant virus would elicit and exaggerated inflammatory response in vivo, at the 
protein level, in comparison to an A-allele counterpart. In Chapter 3, cytokine and 
chemokine profiling of infected human CD14+ monocyte-derived macrophages was 
performed, and it was concluded that PR8 induced a larger pro-inflammatory response 
than either O175A or O265B, which both had comparable profiles (Fig 3.4B). Alveolar 
macrophages (AMs) are among the first immune cells to respond to viral infection and 
have been shown to be essential for efficient virus control (Tumpey et al., 2005, Kim 
et al., 2008, Tate et al., 2010). AMs are the primary producers of type I IFN and pro-
inflammatory cytokines in response to virus infection in the lung (Kumagai et al., 
2007), and so cytokine profiling of the lung will provide an idea of the extent of AM 





The lung homogenates of five mice from day 4 post-infection were pooled and 
were used in a cytokine and chemokine immunoblot array as described in the previous 
chapter (see 3.2.4 Cytokine and chemokine secretion following infection of primary 
human macrophages with segment 8 reassortant viruses). The mean intensity of 
duplicate spots was normalised to the mock-infected sample, and mean fold-induction 
values were ranked in descending order of relative abundance in the PR8 sample and 
plotted as a heat-map (Fig 4.6). Table 4.2 provides information on the roles of each 
cytokine and chemokine quantified, the mean fold-change values, and defines 
abbreviations.  
The majority of the cytokines assayed were up-regulated in mice infected with 
all three viruses, and of these, most have pro-inflammatory functions (Fig 4.6 and 
Table 4.2).  Cxcl10, Ccl3 and Ccl2, all chemotactic for inflammatory cells, were 
strongly up-regulated in all virus-infected samples. However, TIMP-1 and IL-1ra, both 
with anti-inflammatory roles, were also highly up-regulated in all cases. Certain 
cytokines were not strongly up- or down-regulated, such as chemokine Ccl17, a 
chemotactic for T-cells, IL-7, required for B- and T-lymphocyte development, and IL-
13, an anti-inflammatory chemokine, which were all within a 2-fold range relative to 
mock-infected samples. In no cases was a cytokine detected as being down-regulated 
more than 2-fold relative to the mock-infected control.  
A clear trend in the data was that PR8-infected mice produced a larger amount of 






Fig 4.6. Cytokine and chemokine profiling of infected mouse lung. The levels of 
various cytokines and chemokines in pooled lung homogenates from groups of 5 mice 
culled at day 4 p.i. were determined using an immunoblot spot array. Values are 
represent mean fold-induction relative to mock-infected (n = 2) and are plotted as a 

















Table 4.2. Cytokine and chemokine profiling of infected mouse lung. Cytokines and chemokines were quantified from pooled lung 
homogenate of five BALB/c mice. The fold-change values represent the abundance of protein relative to the mock-infected sample. A brief 
description of the main role(s) of each cytokine and chemokine is provided. 











X-C motif) ligand 10) 
IFN-γ-induced protein 
10,IP-10) 
Chemotactic for monocytes, macrophages, NK cells, T-cells, and 
dendritic cells. Secretion is stimulated by IFN-γ and also pro-
inflammatory cytokines. Important for RSV clearance in mice.  
 
170.1 74.6 63.9 (Lindell et al., 2008) 
Cxcl9 MIG (monokine induced 
by gamma interferon). 
Strongly induced during infection and inflammatory responses by pro-
inflammatory cytokines, principally IFN-γ. Chemoattractant for activated 
T-cells and NK cells.  
52.4 9.9 14.1 (Muller et al., 2010) 
Ccl12 (chemokine (C-C 
motif) ligand 12) 
MCP-5 (monocyte 
chemotactic protein 5) 




- Anti-inflammatory roles by inhibiting matrix metalloproteases, which 
contribute to the inflammatory response.  
41.8 38.7 25.0 (Lee et al., 2005) 
Ccl3  MIP-1α (macrophage 
inflammatory protein) 
Pro-inflammatory roles. Chemotactic for and activator of macrophages 
and CD8+ T-cells.  
 






















Cxcl11  I-TAC; IP-9 Chemotactic for activated T-cells. 33.8 5.6 6.3 (Widney et al., 2000) 
Ccl2  Monocyte 
chemoattractant protein 
1 (MCP-1); JE 
Chemotactic for monocytes, memory T-cells NK cells to sites of 
inflammation.  
32.1 24.2 19.3 (Deshmane et al., 
2009) 
Ccl4  MIP-1β (macrophage 
inflammatory protein 1β) 
Chemotactic for a variety of immune cells. Pro-inflammatory. 27.0 6.2 7.6 (Menten et al., 2002) 
Ccl5  RANTES (Regulated on 
Activation Normal T Cell 
Expressed and 
Secreted) 
Chemotactic for several immune cell populations at inflammatory sites. 
Activator of NK cells. Important for anti-apoptotic signalling of alveolar 
macrophages during clearance of influenza-infected apoptotic cells.  
25.9 6.9 8.3 (Tyner et al., 2005) 
Cxcl1  KC Pro-inflammatory chemokine. Neutrophil chemotactic activity. 21.8 10.4 7.5 (Rubio and Sanz-
Rodriguez, 2007) 
Cxcl13 BLC (B lymphocyte 
chemoattractant) 
Important for B cell development by recruiting naïve B-cells and follicular 
T-cells to lymphoid follicles.  


























- Anti-inflammatory cytokine. Antagonistic functions with the IL-1 receptor.  
Therefore inhibits of IL-1α and of IL-1β. Loss of IL-1ra leads to 
uncontrolled systemic inflammation and polyarthropathy. 
15.2 6.1 6.9 (Horai et al., 2000) 
Ccl1  I-309 Pro-inflammatory chemokine. Chemotactic for monocytes and T-cells. 13.9 2.1 1.9 (Miller and Krangel, 
1992) 
CSF3 (colony 




Stimulates bone marrow stem cells to differentiate into granulocytes. 
Stimulates growth, proliferation and differentiation of neutrophils. 
11.9 4.3 3.4 (Bendall and 
Bradstock, 2014) 
Cxcl2  MIP-2α (macrophage 
inflammatory protein 2α) 
and GRO-β (growth 
related oncogene-β. 
























IL-1β (interleukin-1β) IL-1F2; catabolin Pro-inflammatory interleukin produced following activation of the 
nucleotide-binding oligomerization domain (NOD)-like receptor family 
pyrin domain-containing 3 (NLRP3) inflammasome, which is activated by 
IAV M2 protein. Contributes to lung tissue damage during IAV infection.   
9.6 7.1 6.3 (Ichinohe et al., 
2010, Kim et al., 
2015b) 
IL-6  - Pro-inflammatory cytokine secreted by T-cells and macrophages. 
Important mediator of fever and acute phase response. Essential for 
effective clearance of H1N1 IAV in mice.  
9.5 2.3 2.7 (Dienz et al., 2012) 
TREM-1 (triggering 
receptor expressed on 
myeloid cells) 
 Immunoglobulin receptor. Activates activation of neutrophils, monocytes 
and macrophages. Initiates secretion of pro-inflammatory cytokines 
during infection.  
9.3 3.7 3.5 (Colonna and 
Facchetti, 2003) 
IL-1α  - Pro-inflammatory interleukin. Acts as an ‘alarmin’ to initiate the release 
of various pro-inflammatory cytokines and chemokines in acute 
inflammation.   
5.8 3.3 2.9 (Garlanda et al., 
2013) 
CSF1 (macrophage 
colony stimulating factor 
1) 
 Regulates the differentiation, chemotaxis and survival of monocytes and 
macrophages.  


























IL-2 - Important for growth, proliferation and differentiation of T-cells and 
required for T-cell immunological memory. Also promotes proliferation of 
B cells and NK cells.  
4.7 3.2 2.3 (Gaffen and Liu, 
2004) 
Cxcl12  SDF-1  (stromal cell-
derived factor 1) 
Chemotactic for leukocytes and up-regulated in inflammatory response. 
Required for CD8+ T-cell recruitment during IAV infection.  
4.4 2.2 2.2 (Lim et al., 2015) 
TNF-α (Tumour 
Necrosis Factor α) 
- Pro-inflammatory roles. Mediator of fever and acute phase response. 
Antiviral properties by activating NF-κB pathway and inducing apoptosis. 
Correlated with lung tissue damage in HPAI infections.  
3.7 1.5 1.5 (To et al., 2016, Lee 
et al., 2009b, 
Cheung et al., 2002) 
IFN-γ (interferon 
gamma) 
- Type II IFN. Major macrophage activation roles. Chemoattractant of 
leukocytes, enhances NK cell activity, regulates B-cell functions. 
3.3 1.3 2.2 (Schroder et al., 
2004) 
CSF2  GM-CSF (Granulocyte-
macrophage colony 
stimulating factor). 
Stimulates bone marrow stem cells to differentiate into granulocytes and 
monocytes. 
3.3 1.6 1.2 (Shi et al., 2006) 
IL-23 - Pro-inflammatory cytokine. Stimulates type 17 helper T-cell response.  3.1 2.3 1.7 (Teng et al., 2015) 
IL-16 (interleukin-16) - Pro-inflammatory cytokine. Chemoattractant for CD4+ T-cells, 
monocytes, eosinophils and dendritic cells. Regulates CD4+ T-cell 
development.  



























- Part of the complement system with multiple roles. Inflammatory peptide 
upregulating NF-κB and IL-1 in alveolar macrophages in lung injury.  
2.9 2.1 1.4 (Guo and Ward, 
2005) 
IL-10  Human cytokine 
synthesis inhibitory 
factor. 
Anti-inflammatory cytokine. Helps protect epithelial cell layers. 
Regulates production of pro-inflammatory cytokines such as TNF-α.  
2.8 2.2 2.0 (Ouyang et al., 2011) 
IL-5 - Essential for eosinophil maturation and recruitment to infected airway 
during IAV infection and recovery phase.   




CD54; Cluster of 
Differentiation 54. 
Adhesion molecule and activator of T-cells.   2.2 1.7 1.4 (Kuhlman et al., 
1991) 
IL-3  Produced by T cells. Works in conjunction with GM-CSF and IL-5 to 
activate a wide range of myeloid cells. Involved in mast cell and basophil 
production and activation.  
1.9 1.2 1.0 (Broughton et al., 
2012) 
Ccl11 Eosinophil chemotactic 
protein/Eotaxin 























IL-12 p70 Pro-inflammatory cytokine. Stimulates differentiation of T-cells into IFN-
γ producing class 1 helper T-cells.  
1.8 1.2 1.6 (Teng et al., 2015) 
IL-17 - Pro-inflammatory cytokine produced by type 17 helper T-cells. 
Stimulates pro-inflammatory cytokine release and therefore recruits 
macrophages and neutrophils to sites of inflammation.  
1.7 1.5 1.5 (Jin and Dong, 2013) 
IL-4 - Induces differentiation of naïve helper T-cells into type 2 helper T cells. 
Multifunctional roles in regulating macrophages and lymphocytes.  
1.6 1.2 1.4 (Luzina et al., 2012) 
IL-27 - Anti-inflammatory cytokine. Suppressor of helper T cell responses and 
limits inflammation.  
1.6 1.6 1.3 (Kastelein et al., 
2007) 
Ccl17 TARC (thymus and 
activation regulated 
chemokine) 
Pro-inflammatory chemokine. Chemotactic for type II helper T-cells.  1.4 1.2 1.0 (Vestergaard et al., 
2004) 
IL-7  Essential for both B- and T-lymphocyte development.  1.0 0.6 0.7 (Hong et al., 2012) 
IL-13 - Anti-inflammatory cytokine. Inhibits pro-inflammatory cytokine 
production in airway disease and allergic inflammation. 







cytokines quantified, except IL-13 and Il-27 which are both anti-inflammatory 
cytokines, were found to be more up-regulated in PR8-infected mice than O175A- or 
O265B-infected mice. For example, Cxcl10 was up-regulated by a mean of 170.1-fold 
in PR8-infected mice relative to mock-infected mice, compared to 74.6- and 63.9-fold 
in O175A and O265B samples respectively. The profiles of O175A and O265B were 
much more comparable, and all cytokines were quantified within a 2-fold range 
between these two samples. While the RT-qPCR data described above showed that 
PR8-infected mice had the largest up-regulation of pro-inflammatory cytokine 
transcripts, the trend that transcripts were more abundant in O265B-infected mice 
compared to O175A-infected mice was not necessarily translated to increased cytokine 
profiling in this experiment (Figs 4.5 and 4.6). For example, the RT-qPCR data 
suggested there was more Cxcl10 transcripts in O265B-infected mice, but there was 
more Cxcl10 protein detected in O175A-infected lung homogenates.  
Overall, these data show that WT PR8 infection stimulated a more pronounced 
inflammatory response in the lung than either O175A or O265B, which both had 
similar cytokine profiles. This demonstrates that the source of segment 8 influences 
the inflammatory response in vivo, but the lineage of avian NS segment is not crucial. 
4.2.7 In vivo competition assays 
In this experiment, mice were co-infected with O175A and O265B and a 
competition assay was employed to ask if an A-allele NS segment had a selection 
advantage in a mammalian-adapted virus backbone over a B-allele counterpart in vivo. 
Five BALB/c mice were infected with 250 PFU each of O175A and O265B. At day 6 
post-infection, the left lung of each mouse was harvested. The lung was homogenised 





12 plaques per homogenate were purified and assayed by RT-PCR as described in 
Chapter 2 (see 2.2.9 Competition assays)  
When competition assays were performed across 5 individual mice, four of the 
five mice displayed a favourable score for O265B over O175A (Fig 4.7). In one mouse 
lung, all 12 plaques were O265B positive only. In the mouse lung in which O175A 
was most prevalent, O175A was present in 83% of plaques. The mean score, over all 
the mice tested, was 34% O175A compared with 66% O265B. Therefore, there was 
no evidence to suggest there was even a subtle replication advantage for O175A over 
O265B in vivo. This data complements the in vitro competition data, described in 







Fig 4.7. In vivo co-infections. 5 BALB/c mice were co-infected with 250 PFU each 
of O175A and O265B. At day 6 p.i., the left lung of each mouse was harvested and the 
proportion of each virus in the lung homogenate was determined by plaque purification 







In this section, PR8-based NS reassortant viruses were characterised in the 
BALB/c mouse host to ask whether incorporation of an avian B-allele NS segment 
into a mammalian IAV strain would incur a fitness penalty in a mammalian host in 
vivo, which might explain an apparent avian-restriction of these genes in nature. In 
Chapters 2 and 3, it was concluded that B-allele reassortant viruses were replication 
competent in mammalian cells in vitro, and were able to circumvent and suppress the 
innate immune response as efficiently as A-allele counterpart viruses. In vivo 
infections, however, present a much more varied cellular environment, and are 
therefore important to validate conclusions drawn from in vitro work. WT PR8, as well 
as consensus PR8-based reassortant viruses, O175A and O265B, were used in 
infections of BALB/c mice to ask whether a B-allele virus could cause disease and 
replicate in vivo, as well as suppress innate immune responses, in comparison to an A-
allele equivalent. Co-infection studies were also performed to ask if there was a 
selection advantage for an A-allele NS segment over a B-allele NS segment into a 
mammalian-adapted virus in vivo. 
Notably, the consensus North American B-allele NS reassortant virus, O265B, 
was more pathogenic in vivo, inducing more weight-loss than the A-allele counterpart, 
O175A, whilst the WT PR8 was undoubtedly the most pathogenic (Figs 4.1A, 4.1B 
and 4.1C). These findings are important as they suggest that, in the rare case of an 
avian B-allele virus spill-over event into a mammalian host, significant pathology 
could ensue. Indeed, B-allele viruses persist and cause high pathogenic infections of 
poultry populations (Garcia et al., 1997, Suarez et al., 1999), and it is well documented 





infected poultry (Chan, 2002). Furthermore, a highly pathogenic avian-like B-allele 
virus (A/equine/Jilin/1/1989 (H3N8)) caused widespread, high-mortality outbreaks in 
equine populations, providing direct evidence of a B-allele avian-like virus causing 
serious disease in a mammalian host (Guo et al., 1992). In a separate laboratory study 
assessing PR8-based NS reassortants, Kim and colleagues found that PR8 harbouring 
a B-allele NS gene from a LPAI H5N1 virus (A/wild duck/Korea/SNU50-5/2011 
(H5N1)) induced significant pathology in BALB/c mice (Kim et al., 2015a). This was 
to similar levels as one counterpart A-allele reassortant (NS from 
A/chicken/Korea/01310/2001 (H9N2)), and significantly greater than a separate A-
allele reassortant (NS from A/chicken/Korea/KBNP-0028/2000 (H9N2)) which did 
not induce any pathology (Kim et al., 2015a). These observations, all taken together, 
suggest that viruses harbouring a B-allele NS segment are capable of causing 
significant disease in mammals. 
All viruses replicated well in the lung by day 2 post-infection, and appeared to 
display similar cell tropism (Figs 4.2 and 4.4). However, O175A was cleared the most 
rapidly, followed by O265B, with PR8 persisting at higher titres at day 6 post-infection 
(Fig 4.2). Therefore, the WT PR8 NS segment provided a fitness advantage over the 
avian NS segments tested in vivo, but interestingly O265B segment 8 provided a fitness 
advantage over O175A. PR8 has been passaged many times in the mouse host (Taylor, 
1941), therefore it is not surprising to see that the PR8 NS segment is better suited for 
mouse infection, as adaptive mutations will likely have been incurred over time. 
Indeed, adaptive mutations in the NS segment, in both the NS1 and NEP genes, have 
been noted when forcibly adapting a human virus in mice (Forbes et al., 2012). 





(Udorn72/Alb88B) was cleared more rapidly than an A-allele counterpart 
(Udorn72/NY6750A) from the nasopharynx of infected squirrel monkeys (Treanor et 
al., 1989). However tracheal virus titres were not significantly different between these 
viruses, demonstrating that the B-allele virus could still replicate well in the squirrel 
monkey host. Nonetheless the authors concluded that B-allele NS genes attenuate 
mammalian viruses in the mammalian host. The NS genes used in the Treanor et al 
study, NY6750A and Alb88B, were incorporated into PR8 in this study, but due to 
time constraints an in vivo study was not possible. It would be interesting to test these 
viruses in mice to see if similar trends would be observed as were seen for the O175A 
and O265B NS genes. Additionally, it would be useful to assess Udorn72 reassortant 
viruses, the same backbone strain used in the Treanor et al study, although the use of 
squirrel monkeys would be unrealistic. Nonetheless, the data described here provide 
clear evidence that an avian B-allele NS segment can support efficient replication of a 
mammalian IAV strain in vivo, and can contribute to significant disease.    
When lung histopathology was assessed by haematoxylin and eosin staining of 
tissue sections, it was concluded that the source of segment 8 did not significantly alter 
the degree of tissue damage incurred during infection (Figs 4.3A and 4.3B). This was 
somewhat surprising given that WT PR8 induced more weight-loss, greater ISG 
expression and a stronger pro-inflammatory cytokine response than O175A and 
O265B during infection (Figs 4.1C, 4.5 and 4.6). Despite a strong pro-inflammatory 
response being linked to greater lung tissue damage, morbidity and mortality during 
infection with a highly pathogenic IAV strain (Cheung et al., 2002, Lee et al., 2009b, 
To et al., 2016), blind scoring of tissue sections did not reveal notable differences 





WT PR8-infection elicited a global increase in abundance of both ISG 
transcripts and pro-inflammatory cytokine levels in the lung, and to greater extents 
than O175A and O265B (Figs 4.5 and 4.6). While RT-qPCR analysis showed a trend 
of a greater abundance of ISG transcripts in the lung of O265B-infected mice than 
O175A-infected mice, this did not necessarily translate to a greater level of pro-
inflammatory cytokines quantified by immunoblot in a cytokine array. Therefore, it is 
difficult to say with certainty that O265B elicited a greater inflammatory response in 
vivo than O175A, however O265B did induce greater weight-loss. The most likely 
cause of weight-loss induction is the strength of the inflammatory response, based on 
observations that susceptible mice have much stronger pro-inflammatory gene 
expression profiles than non-susceptible mice when infected with the same virus strain 
(Boon et al., 2009, Alberts et al., 2010). WT PR8 induced the greatest weight-loss and 
also unequivocally induced the largest pro-inflammatory response in the lung. 
Whether the increased inflammatory response in PR8-infection was caused by i) a 
more widespread infection in the lung, ii) greater viral load in the lung or iii) an 
inability of the virus to dampen the cytokine & ISG response, or a synergism of all 
three, is not clear. However, the observations that a 500 PFU input induced more 
weight-loss than a 100 PFU dose for all viruses tested (Figs 4.1A and 4.1B), and that 
a PR8-NS1-R38AK41A mutant virus that cannot control the IFN response induced 
less weight-loss in mice than WT (Donelan et al., 2003), suggests that the degree of 
virus replication, and probably spread, are the major determinants.  Also, these data 
demonstrate that an increased antiviral response in the lung does not correlate with 
reduced virus replication, in fact the opposite was found. Therefore, assessing ISG and 





Finally, co-infections were performed to ask if an A-allele NS segment would 
have a selection advantage over a B-allele NS segment into mammalian-adapted 
viruses in vivo, when both are present in the same host. Genetic reassortment between 
avian and mammalian viruses poses a real possibility for an avian-derived genomic 
segment(s) to enter mammalian-viruses in nature, and is often a prerequisite to 
pandemics in man (Steel and Lowen, 2014). Previous work in the Digard lab has 
highlighted differences in the RNA-packaging signal regions between A- and B-allele 
NS gene sequences, and this may lead to preferential packaging of A-allele sequences 
over B-allele sequences in mammalian viruses (Gog et al., 2007). In Chapter 2, in vitro 
competition assays were described, and it was concluded that O265B NS vRNP was 
packaged into the PR8 background as efficiently as O175A vRNP in vitro (Figs 2.14A 
and 2.14B). Here, a low multiplicity co-infection was performed in vivo, as this will 
resemble the most likely scenario for genetic reassortment in nature. Results provided 
no evidence of the O175A segment out-competing O265B, and in the majority of mice 
tested, the O265B NS segment was detected more frequently by plaque purification 
(Fig 4.7). This trend was consistent with in vitro analyses (Figs 2.14A and 2.14B), and 
so the data suggests that B-allele NS segment RNA-packaging signals are equally 
compatible for packaging into a mammalian-adapted virus background as A-allele NS 
segment packaging signals. Therefore, it appears unlikely that B-allele NS segments 
are restricted to avian viruses at the level of reassortment.  
Overall, in vivo studies of NS reassortant viruses led to the conclusion that a 
mammalian-adapted virus harbouring an avian B-allele NS segment was able to cause 
disease and replicate in vivo, and in no scenario was an A-allele equivalent deemed to 





B-allele reassortant was more fit in the BALB/c host - causing greater weight-loss and 
persisting in the lung for longer. Additionally, data suggested that an avian B-allele 
NS segment is able to reassort into a mammalian virus during co-infection. These 
findings, therefore, provide evidence that avian B-allele segment 8 genes that circulate 
in the avian population are able to complement the other 7 segments of mammalian 
viruses in a mammalian host, supporting serious pathology and disease. These genes, 
therefore, should not be discounted when risk-assessing avian influenza viruses and 
their ability infect and cause serious outbreaks, including pandemics, in mammalian 






 Chapter 5: Phylogenetic analyses of segment 





In the previous sections, B-allele NS reassortant viruses were characterised in 
the mammalian host in vitro and in vivo. There was no evidence that a mammalian 
virus harbouring an avian B-allele NS segment was less fit in vitro or in vivo than an 
avian A-allele reassortant equivalent. B-allele NS segments supported efficient virus 
replication, were packaged efficiently during co-infection studies when both A- and 
B-allele NS segments were available in vitro, and caused severe pathology in the 
BALB/c host. Therefore, it appeared unlikely that any potential avian-restriction of B-
allele NS segments is at the level of virus replication.  
It was therefore asked whether there is truly a bias against B-allele NS 
segments being introduced into mammalian hosts in nature. Using sequencing and 
surveillance information available for IAV, it is possible to estimate the apparent 
relative rates of introduction from birds to mammals for both the A- and B-allele 
lineage, and it was tested whether the relative rates are significantly reduced for avian 
B-allele genes.  
5.1.2 Hypothesis  
The hypothesis that B-allele NS segments are avian-restricted is founded on 
the observation that B-allele sequences are rarely isolated from mammalian hosts. 





were only fractional in comparison to the number available now (Treanor et al., 1989). 
The number of available A-allele NS sequences, nevertheless, still heavily outnumbers 
the number of B-allele NS sequences in both the mammalian and avian host (Sevilla-
Reyes et al., 2013). However one cannot use the total number of mammalian sequences 
per lineage as an accurate measure of ability of bird to mammal transmission. For 
example, there are thousands of NS A-allele sequences from human seasonal (H1N1, 
H2N2 or H3N2) infections, but all these sequences are derived from the pdm1918 
H1N1 outbreak (Taubenberger and Morens, 2006) which stemmed from one Aves to 
Mammalia transmission event. Thus, one introduction of an avian A-allele NS segment 
into a mammalian host has led to thousands of mammalian virus NS sequences, which 
may be inaccurately interpreted as a bias for Aves to Mammalia transmission for A-
allele NS segments over B-allele segments. Conversely, there is only one described 
sequence for the largest described B-allele outbreak in a mammalian host 
(A/equine/Jilin/1/89 (H3N8)) which was reported to have infected thousands of horses 
with a high morbidity and mortality rate (over 13 000 horses were estimated to have 
been infected (Guo et al., 1992)). Therefore, it is more appropriate to assess relative 
rates of introduction – i.e. normalising the number of estimated avian to mammalian 
introduction events by the total number of avian sequences available. This value more 
closely reflects the ability of an avian NS segment to transmit to mammals rather than 
the total number of mammalian sequences available, which can be distorted by large-
scale epidemics or endemics resulting in many mammalian sequences recorded all 
stemming from one bird to mammal transmission event. 
It was hypothesised that the relative rates of Aves to Mammalia transmission 





reported in previous chapters suggesting B-allele NS segments are equally compatible 
in a mammalian virus background both in vitro and in vivo. It was speculated that the 
paucity of mammalian B-allele sequences could stem from a smaller pool of B-allele 
viruses circulating in the avian host.  
5.1.3 Approach 
This section reports a collaboration with Dr. Samantha Lycett (The Roslin 
Institute, The University of Edinburgh, Midlothian, UK). Due to the scale of task, 
programming expertise was required to manipulate the IAV segment 8 sequences 
available on GenBank for phylogenetic analyses. Dr. Lycett performed the download 
of all NS sequences from GenBank, alignments, phylogenetic clustering, phylogenetic 
tree annotation, sequence distribution calculations, estimates of wild or domestic bird 
source, and statistical analyses to compare introduction rates and sources across A- 
and B-allele sequences.  Following Dr Lycett’s input, ‘sanity checks’ of downloaded 
sequences (discussed below), literature research, and the analysis of the virological 
implications were performed. Interpretation of the phylogenetic data was a 
collaborative effort between Dr. Lycett, Prof. Paul Digard, and myself.  
To estimate the number of independent segment 8 introduction events from 
avian hosts into mammals, all available NS sequences were downloaded from 
GenBank, phylogenetic trees were constructed, and mammalian-derived isolates were 
marked. Large clades of mammalian isolates were identified that likely acquired their 
NS from an avian source and these were scored as one introduction event per lineage 
(discussed below). For all other mammalian sequences identified in otherwise avian 
branches, manual inspection of the H and N subtype, year and location of isolation, 





with researching any available literature, to estimate the likelihood of each mammalian 
NS sequence being an independent introduction from an avian host. In some cases, 
these apparently represented a single transmission event from an avian host to a 
mammal (accepting sampling bias). In other cases, an avian NS segment appeared to 
have been successfully introduced into the mammalian population long-term, such as 
the pdm1918 H1N1 NS segment which has persisted in humans and pigs since the 
1918 ‘Spanish Flu’ pandemic (Taubenberger and Morens, 2006). In both instances, 
this was considered one independent introduction event. An ‘introduction rate’ was 
calculated by normalising the number of expected introductions by the total number 
of available avian sequences for A- and B-alleles. These were subsequently compared 
using Fisher’s Exact Test to ask if the relative rates of bird to mammal transmission 
events was different between avian A- and B-allele NS genes.    
For each independent Aves to Mammalia introduction event identified, 
evidence was assessed to determine whether the likely source of segment 8 was from 
wild or domestic birds, to ask if the source of avian host differed between A- and B- 
allele lineages. The contact rate of domestic mammals with domestic birds can be 
rather different than with wild birds. This is an area of importance as HPAI infections 
of domestic mammals, with high morbidity and mortality rates, are thought to be 
predominantly mediated by direct contact with domestic birds (Chan, 2002, 
Schrauwen and Fouchier, 2014, Herfst et al., 2014). Therefore, it was of interest to 
compare wild and domestic bird-to-mammal transmission rates between A- and B- 
allele NS segments. Using a combination of BLAST analysis of closest relatives, 





species, the avian ancestor was assigned as either wild or domestic bird and the relative 
rates compared across A- and B-alleles using Fisher’s Exact Test. 
5.2 Results  
5.2.1 Phylogenetic clustering of available NS segments 
All NS sequences available on GenBank were downloaded by Dr. Lycett on 
the 17th October 2014 via the Influenza Virus Resource (Bao et al., 2008). The 
sequences represented isolates from avian (43%), swine (10%), human (44%) and 
other (3%) hosts (Table 5.1). After removal of duplicated or erroneous sequences (see 
later), 28822 sequences remained, of which 2725 belonged to the B-allele lineage 
(Table 5.1). 8 of the 2725 (0.3%) B-allele sequences were mammalian isolates, while 
16484 of the 26097 (63.2%) A-allele isolates were mammalian.  
The following description of the protocol was provided by Dr. Lycett and adapted: 
‘Due to the large number of sequences, the sequences were aligned in groups, by 
nucleotides using ClustalW in BioEdit, manually adjusted for NS1 coding frame with 
the remaining nucleotides in the NEP coding frame, then aligned by amino acid using 
MUSCLE in MEGA6.0.  The major lineages of influenza A segment 8 (Avian A, 
Human Seasonal, Classical Swine, H1N1-pdm09, Avian B) were identified in 
neighbour joining trees - the data was split into 10 random subsamples of 
approximately 3100 sequences each to make 10 trees, and all the sequences belonging 
to the Avian lineages were extracted from the random subsamples, combined and 
alignments re-checked.  Sequences with identical isolate names, mixed subtypes, 





Table 5.1. Distribution of NS sequences. Shown is a breakdown of all segment 8 
sequences downloaded from GenBank according to the host, subtype, location and 
clade. The major clades are described in the main text and represented 
diagrammatically in Fig 5.1. In this table, the Classical Swine group also includes triple 
reassortant swine viruses. The grouping is based on sequence homology of NS 
segment and it is expected that genetic reassortment accounts for certain examples of 
unexpected subtypes or hosts present in certain groups (e.g. H7, N3, and N8 subtypes 
in the Classical Swine group, H5 in the human seasonal group, and H3 and N2 
subtypes in the pandemic 2009 group). For example, the internal gene segments of the 
pdm2009 H1N1 virus have been isolated from H1N2 and H3N2 swine viruses 
following genetic reassortment between swine viruses (Kirisawa et al., 2014). Values 







total of which 9617 were avian) and Avian B (2725 sequences in total of which 2717 
were avian) data sets’. Table 5.1 gives the distribution of sequences by all major 
lineages, hosts, geographic locations and subtypes. 
‘Sanity checks’ involved examining the sequences of all prototypic strains that 
were identified for each estimate of Aves to Mammalia transmission in the ‘Avian A’ 
and ‘Avian B’ group to ensure the sequences i) were not uploaded to GenBank in error 
or  ii) were not incorrectly classed as a unique introduction event based on the criteria 
given above. Uploading sequences to GenBank is at the authors’ discretion. Errors can 
occur such as duplicating a previously reported isolate, reporting inaccurate sequences 
that are of unexpected length or composition, or incorrectly uploading the sequence of 
a commonly used laboratory strain of IAV as a new isolate following contamination 
issues (Li et al., 2010). Indeed, BLAST analysis of segments 1-7 of all prototypic 
strains identified revealed that an Avian A isolate, A/swine/Korea/S190/2004 (H9N2) 
(GenBank accession number AY790301), was likely misclassified as several segments 
were derived from the common laboratory strain A/WSN/33/1934 (H1N1). Thus, this 
isolate was removed from the study.   
5.2.2 A-allele NS segment introductions into mammals 
The A-allele NS sequences could be divided into four ‘giant’ clades following 
phylogenetic clustering. Fig 5.1 shows these clades highlighted in colour within the 
phylogenetic tree (colours on figure are included in parentheses in main text): i) human 
seasonal (H1N1, H3N2, H2N2) (orange), ii) classical and triple reassortant swine 
(magenta), iii) pdm2009 H1N1 (cyan), and iv) an ‘avian A’ clade composed of avian 






Fig 5.1. Major lineages of influenza A virus segment 8. Phylogenetic tree shown is 
of a sub-sample of all influenza A virus segment 8 sequences, with major lineages 
highlighted in colour. Dark blue shows all B-allele NS sequences. The A-allele 
sequences contain human seasonal (orange), classical swine (magenta) and pandemic 
2009 (cyan). The rest belong to the ‘Avian A’ clade of avian and avian-like viruses 
(light blue). Within the Avian A group are specific lineages that are highlighted in 





lineages within: i) H7N7 Equine (dark brown), ii) H7N7/H3N8 Equine-Canine 
(Equine H3N8 viruses underwent reassortment with existing H7N7 viruses, resulting 
in a population of H7N7 and H3N8 viruses with the same NS (Murcia et al., 2011)) 
(light brown), iii) H5N1/H9N2 representing the 1997 Hong Kong H5N1 human 
infections and related H9N2 human and swine isolates in China 1997-2010 (pink), iv) 
the 2013 H7N9 outbreak in China (purple on pink), v) the ‘precursor’ to the H7N9 
infections which includes closely related H10N8 and H7N9 human viruses and H3N2 
and H9N2 swine viruses (purple on pink), vi) Eurasian swine (purple), vii) H3N2 
canine (green), and viii) H5N1 representing the 2003 and onwards HPAI H5N1 
infections in humans (red) (See Fig 5.1 for all major clades highlighted on a 
phylogenetic tree). Fig S5.1, included on CD, is an xls file showing a more detailed 
phylogenetic tree of the ‘Avian A’ group shown in Fig 5.1. Fig S5.1 can be viewed in 
FigTree (downloadable in Mac and PC versions from 
http://tree.bio.ed.ac.uk/software/figtree/) which allows large phylogenetic trees to be 
viewed on screen at a magnification that permits virus strain names to be read, which 
is otherwise not legible in text. Fig S5.1 was made by Dr. Samantha Lycett. 
Each of the following were considered one independent introduction of an NS segment 
from an avian virus into a mammalian host; i) human seasonal (H1N1, H2N2 and 
H3N2) epidemics, the classical and triple-reassortant swine lineages, and the pdm2009 
H1N1 viruses (the NS segment persisted from the pdm1918 H1N1 outbreak 
(Taubenberger and Morens, 2006)), ii) the 1997 H5N1/H9N2 lineage in the ‘Avian A’ 
clade, iii) the 2003 and onwards H5N1 lineage in ‘Avian A’, iv) Eurasian swine 
subtypes, v) the 2013 H7N9 cases, vi) the 2013 H7N9 ‘precursor’ viruses of H10N8, 





equine influenza lineage, viii) the H7N7/H3N8 equine and canine lineage, and ix) the 
H3N2 canine viruses (Fig 5.1 and Table 5.2). The ‘general’ avian clade (‘Avian A’) 
was manually inspected and other independent introductions were estimated based on 
subtype, year and location of isolation, and sequence homology of NS segment. An 
additional 23 introductions were determined, giving 32 in total (Table 5.2). 
Of the 32 A-allele introductions, 19 strains were estimated to have transmitted 
from mammal to mammal (Table 5.2), and 5 cases led to long-term establishment in a 
mammalian host: i) the pdm1918 H1N1/human seasonal and classic/triple reassortant 
swine lineage, ii) Eurasian swine, iii) H7N7 equine, iv) H7N7/H3N8 equine and 
canine, and v) H3N2 canine.   
5.2.3 B-allele NS segment introductions into mammals 
A phylogenetic tree of all B-allele NS sequences was constructed by Dr. Lycett 
using the neighbour joining method in MEGA6 (with the Tamura-Nei model, gamma 
distributed rates among sites and heterogeneous patterns among lineages) and the 
mammalian isolates were highlighted (Fig 5.2). The B-allele lineage split into North 
American and Eurasian clades. Initially, 9 mammalian isolates were highlighted. Upon 
manual inspection of these 9 isolates, it was apparent that one isolate was likely an 
erroneous entry into GenBank and two isolates were submitted in duplicate. The 
sequencing data of the former was reported to contain mixed virus strains in the sample 
(A/Auckland/4382/1982(mixed), accession CY112376), and so this was removed as 
the B-allele sequence may have arisen from a laboratory contamination event. 
A/muskrat/Buryatiya/1944/2000 (H4N6) (GenBank accession number GU052363) 








Table 5.2. Independent introductions of avian A-allele NS segments into mammalian hosts. Shown are representative strains from each 
of the independent Aves to Mammalia transmission events for A-allele NS segments. The ‘Transmission’ column gives an estimate of whether 
the lineage of virus transmitted within mammalian hosts based on research of available literature. Accession column provides the GenBank 
identification number of the sequence.  
 
Prototypic Strain Host Transmission Notes Accession 
(NS) 
Avian Source 
A/Brevig Mission/1/1918 (H1N1)  Human Pandemic Persists through classical swine, human H2N2, H3N2 and pdm2009 
lineages 
AF333238.1 Undetermined 
A/equine/Prague/2/1956(H7N7) Equine Transmissible Likely to be extinct.  CY087820 Undetermined 
A/equine/Miami/1/1963 (H3N8) Equine Transmissible Major circulating equine influenza A virus. Also endemic in US domestic 
dogs (canine H3N8).  
CY028840 Wild 
A/swine/China/8/1978 (H3N2) Swine Circulating in pigs Kawaoka et al suggest this belongs in Eurasian-avian lineage that is 
circulating in European pigs (Kawaoka et al., 1998). 
M80968 Domestic 
A/swine/Belgium/WVL1/1979(H1N1) Swine Transmissible Representative isolate for ‘Eurasian swine flu’  
 
CY037902 Domestic 
A/seal/Massachusetts/1/1980(H7N7) Seal Epidemic in seals Epidemic in seals with approximately 600 fatalities. (Webster et al., 1981) AB284067 Wild 
A/seal/Massachussetts/133/1982(H4N
5) 
Seal Epidemic in seals 1983 outbreak in which 60 seals were reported dead. 39 were positive for 
an H4N5 indistinguishable from the prototype virus  (Hinshaw et al., 1984) 
M80947 Wild 
A/mink/Sweden/3900/ 1984(H10N4) Mink Outbreak in Mink One of the first identified cases of avian influenza able to transmit readily in 
mammalian host (Zohari et al., 2008) 
GQ176140 Domestic 
A/whale/Maine/328B/1984(H13N2) Whale Single isolate Isolated from one sick pilot whale, no evidence of a transmission chain. 






Two closely related H3N3 viruses were detected in three seals following an 
increase in the number of stranded seals in Cape Cod in 1992 (Callan et 
al., 1995).  
GU052287 Wild 
A/swine/Hong Kong/644/1993(H1N1) Swine Possible 
transmission. 
3 independent H1N1 isolates from pigs with closely related NS segments, 

















Prototypic Strain Host Transmission Notes Accession 
(NS) 
Avian Source 
A/England/AV877/1996 (H7N7) Human Likely single 
isolate 
Isolated from 43-year-old duck farmer with mild one-sided conjunctivitis 
(Kurtz et al., 1996) 
GU053113 Domestic 
A/swine/Eire/89/1996(H1N1) Swine Single isolate No other closely related isolates of same subtype, host and year.  (Lycett 
et al., 2012) 
CY115892 Domestic 
A/Hong Kong/482/97(H5N1) Human Individuals only. Includes related H9N2 human and swine isolates in China 1997-2010. AF084285 Domestic 
A/Swine/Ontario/01911-1/99 (H4N6) Swine Likely 
transmission 
Outbreak in pigs with pneumonia in Canada (Karasin et al., 2000) AF285889 Wild 
A/swine/KU/2/2001(H11N6) Swine Possible 
transmission 
No published information available. 4 independent H11N6 pig isolates from 
same year and location suggests ability to transmit within pigs.  
CY073456 Domestic 
A/swine/Ontario/K01477/01(H3N3) Swine Likely 
transmission 
Same H3N3 virus was isolated from more than one pig in a sick group 






Two H4N6 isolates from Caspian Seals in Russia 10 years apart with very 
closely related NS segments. Nothing published for these strains. 
KJ847690 Wild 
A/Netherlands/033/03 (H7N7) Human Poorly 
transmissible 
between humans 
Mostly independent transmission events from birds to humans. H7N7 virus 
was epidemic in poultry in Netherlands in 2003 (Stegeman et al., 2004). 
H7N7 IAV was detected in 85 subjects, with 3 people from within a 
household (Fouchier et al., 2004, Koopmans et al., 2004). 
AY342423 Domestic 
A/Beijing/01/2003 (H5N1) Human Not transmissible 
in humans? 
H5N1 ‘Bird Flu’. Human to human transmission is rare or non-existent. EF587281.1 Domestic 
A/Canada/rv504/2004 (H7N3) Human Likely single 
isolates. 
Infection of two poultry workers on different farms during H7N3 poultry 
outbreak in British Columbia, Canada (Hirst et al., 2004) 
CY015010 Domestic 
A/swine/Korea/S452/2004(H9N2) Swine Likely single 
isolates 
Two independent isolates of H9N2 swine viruses with very similar NS 
genes in 2004. Nature of infections not specified in literature (Dong et al., 
2011).  
AY790309 Domestic 














Prototypic Strain Host Transmission Notes Accession 
(NS) 
Avian Source 
A/swine/Hubei/10/2008 (H10N5) Swine Transmissible in 
pigs 
Wholly avian virus, closely related to Eurasian swine IAV. (Wang et al., 
2012b) 
JX500447 Domestic 
A/swine/Jilin/37/2008 (H3N2) Swine Likely single 
isolate 
Authors sampled 279 sick pigs and this was isolated from one pig only. 
Has M and NS genes from H10 avian influenza (Cong et al., 2010) 
GU215038 Wild 
A/swine/Yangzhou/080/2009(H6N6) Swine Likely 
transmissible in 
pigs 
Detected from clinical samples, co-infection with porcine circovirus type 2 
in six pigs (Zhao et al., 2013). Closely related to 
A/swine/Guangdong/K6/2010(H6N6).  3.6% of 475 sick pigs sampled were 
seropositive against H6 IAV (Zhang et al., 2011). 
JQ815882 Domestic 
A/swine/HuBei/06/2009 (H4N1) Swine Single isolate Apparent direct avian-to-pig infection without chain of transmission. First 
H4 avian virus detected in pigs (Hu et al., 2012).  
JX878679 Wild 
A/swine/Guangdong/K4/2011(H4N8) Swine Possibly 
transmissible in 
pigs 
Isolated from a pig in a group displaying respiratory symptoms (H4N8 and 






126 seals died from this outbreak of virus (Anthony et al., 2012) JQ433883 Wild 
A/Mexico/InDRE7218/2012 (H7N3) Human Likely single 
isolates 
High-pathogenicity H7N3 virus isolated from Mexican poultry workers with 
conjunctivitis in 2012 (Lopez-Martinez et al., 2013). Likely direct infection 
from infected poultry. Similar NS segment to A/Canada/rv504/2004(H7N3) 
(CY015010) (Obenauer et al., 2006) 
CY125732 Domestic 
A/Jiangxi/IPB13/2013 (H10N8) Human Likely single 
isolates 
Human H10N8 cases likely from live poultry markets in China (Zhang et 







2013 and onwards H7N9 zoonotic episodes in China. KC896778 Domestic 
      






Fig 5.2. Mammalian B-allele segment 8 sequences. Phylogenetic tree of all avian B-
allele lineage segment 8 sequences with the non-avian sequences highlighted. Figure 






represent two GenBank uploads from one virus isolation, therefore the latter was 
removed from the analysis. Additionally, it was apparent that two mammalian 
sequences in the B-allele lineage were likely from the same Aves to Mammalia 
transmission event. A/swine/Korea/C13/2008 (H5N2) (accession number FJ461601)  
and A/swine/Korea/C12/2008 (H5N2) (accession number FJ461600) both had very 
high segment 8 sequence homology, had the same H and N subtyping, and were 
isolated in the same year, at the same location, and from the same host. Therefore, 
these two mammalian isolates were scored as one mammalian introduction event. 
Following the removal of the aforementioned sequences, a total of 6 independent 
introduction events were estimated. 2 were from the North American clade and 4 from 
the Eurasian clade (Table 5.3 and Fig 5.2).  
Of the six independent introduction events, three were estimated to have been 
transmissible within the mammalian population, of which A/equine/Jilin/1/1989 
(H3N8) caused an epidemic of high mortality infections in the equine host (Guo et al., 
1992). A/swine/Saskatchewan/18789/02 (H1N1) and A/swine/Korea/C13/2008 
(H5N2) were thought to have transmitted within a population of pigs, given positive 
sampling from numerous other swine individuals within their respective farms 
(Karasin et al., 2004, Lee et al., 2009a). A/muskrat/Buryatiya/1944/2000 (H4N6), 
A/swine/KU/16/2001(H7N2), and A/New York/107/2003 (H7N2) were all predicted 
to be individual infection events, as there were no reports of additional mammalian 
infections from any of these strains (Lvov et al., 2015, Kwon et al., 2011, Ostrowsky 
















Table 5.3. Independent introductions of avian B-allele NS segments into mammalian hosts. As described in Table 5.2 legend but for B-
allele NS sequences.  
 
Strain Host Transmission Notes Accession (NS) Avian Source 
      
A/equine/Jilin/1/1989 (H3N8) Equine Epidemic Major equine influenza epidemic (Guo et al., 1992) M65020 Domestic 
A/muskrat/Buryatiya/1944/2000 (H4N6) Muskrat Single isolate Closely related to H4N6 avian influenza circulating in Russia at 
similar time point (Lvov et al., 2015). 
GU052363.1 Wild 
A/swine/KU/16/2001(H7N2) Swine Likely single isolate Isolated from 1 pig (532 tested) from a slaughterhouse. Apparent 
reassortment between avian H7N2 and H5N3 viruses (Kwon et al., 
2011). 
CY067690 Domestic 
A/swine/Saskatchewan/18789/02 (H1N1) Swine Likely transmissible 
in pigs 
Isolated from a 1200 sow pig farm where influenza-like symptoms 
affected pigs of all ages. Fully avian virus. (Karasin et al., 2004) 
AY619957 Wild 
A/New York/107/2003 (H7N2) Human Single isolate Apparent individual infection of a 48-year-old immunocompromised 
man from the Caribbean with fever and flu-like symptoms. No 
apparent transmission to family. (Ostrowsky et al., 2012) 
EU587374.2 Domestic 
A/swine/Korea/C13/2008 (H5N2) Swine Apparent 
transmission 
Serological evidence of transmission within pigs (maybe 








5.2.4 Relative rates of Aves to Mammalia transmission events 
The total number of A-allele (32) and B-allele (6) NS mammalian introduction events 
were in favour of A-allele by approximately five to one (Tables 5.2 and 5.3). However, 
the total number of avian NS sequences is unequal between the two clades, with 9613 
avian A-allele sequences versus 2717 B-allele avian sequences (Table 5.1). Therefore, 
the rates of independent introductions into mammals relative to the total avian 
sequences available are 32/9613 = 0.0033 and 6/2717 = 0.0022 respectively (Table 
5.4). Dr. Lycett performed Fisher’s Exact Test, using the A-allele data and assuming 
a binomial distribution to calculate a range of expected B-allele introductions, and it 
was deemed that the number of mammalian introduction events per avian isolate were 
not significantly different between A- and B-allele lineages (p-value = 0.436) (Table 
5.4). Additionally, similar analyses of the data revealed that the transmissibility of A- 
and B-allele IAV within mammals was not significantly different between the two 
lineages (p-value = 0.446, Table 5.4). 
Therefore the available sequencing and surveillance data do not support the 
hypothesis that A-allele NS segments reassort into mammalian viruses at a higher rate 
than B-allele NS segments.  
5.2.5 Comparisons of the avian source of mammalian introduction 
events 
Next, it was considered whether the relative rates of A- and B-allele NS 
segment introduction into mammalian hosts differed between the sources of avian host 
(wild or domestic birds), given the contact rate between frequently sampled domestic 








Table 5.4. Expected number of avian B-allele introductions. Values were calculated using data from A-alleles, assuming a binomial 
distribution. Figures in brackets represent the range of episodes that would still be statistically non-significant (p-values ≥ 0.1). Values were 
calculated and table was constructed by Dr. Samantha Lycett.  
 
Data A-allele B-allele Fisher test 














p-value Expected number of B-
allele introductions 
All avian 9617 32 0.0033 2717 6 0.0022 0.436 9.04 (4-15) 




Undetermined 13 0.0014 Undetermined 3 0.0011 1.000 3.67 (0-8) 
Domestic only 4391 18 0.0041 648 3 0.0046 0.756 2.66 (0-6) 
 




birds. Dr. Lycett used BLAST analysis and a discrete trait model (data not shown), as 
well as manual inspection of phylogenetic trees, to analyse the closest relatives of 
exemplar mammalian isolates for each introduction event to estimate the source of NS 
as being from wild or domestic birds (Tables 5.2, 5.3 and 5.4). In 2 of the 32 A-allele 
introduction events, it was not possible to determine whether the source was wild or 
domestic bird - A/Brevig Mission/1/1918 (H1N1) and A/equine/Prague/2/1956 
(H7N7). Of the remaining 30 introductions, 18 were determined to be from domestic 
birds, and 12 from wild birds (Tables 5.2 and 5.4). Of the 6 B-allele introductions, 
there was evidence of 3 wild bird and 3 domestic bird introductions (Tables 5.3 and 
5.4). Using the A-allele data and assuming a binomial distribution, a range for 
expected B-allele introduction events was determined for both wild and domestic 
birds. Using Fisher’s exact test, there was no significant difference between A- and B-
alleles when the domestic bird to mammalian host (p-value = 0.756) or wild bird to 
mammalian host (p-value = 0.578) introduction rates were compared (Table 5.4).  
The distribution of all avian A- and B- NS sequences are depicted in Fig 5.3, 
showing the source of avian host and also the location of isolation by continent. Most 
notably, wild Anseriformes made up the largest proportion of the avian B-allele 
sequences, and there were proportionally more domestic bird (both Anseriformes and 
Galliformes) isolates in the A-allele group than the B-allele group (Fig 5.3). 
Additionally, the majority of B-allele sequences were isolated from North America, 
while the largest proportion of A-allele sequences were isolated in Asia.    
Therefore, there was no apparent difference in the rates of mammalian 
introduction events from wild or domestic birds across the A- and B- allele linages, 





Fig 5.3. Distribution of avian segment 8 sequences. The host distribution and 
location of isolation is represented for all avian A- and B-allele segment 8 sequences. 





prevalent in Asia, a region where there is significant contact between poultry and 
domestic mammals.  
5.3 Discussion 
In Chapters 2, 3 and 4, it was concluded that mammalian-adapted IAVs 
forcibly reassorted with an avian B-allele NS segment were able to replicate efficiently 
in mammalian cells in vitro and in vivo. These reassortant viruses were also competent 
in antagonising the innate immune response in mammalian cells, and the NS segment 
was able to reassort into a mammalian adapted virus efficiently when both A- and B-
allele NS segments were present during co-infection. These data contradicted 
conclusions drawn from other laboratories suggesting B-allele NS genes cannot 
efficiently support IAV replication in mammalian hosts (Treanor et al., 1989, Zohari 
et al., 2010a, Munir et al., 2011a, Munir et al., 2011b, Munir et al., 2012). The original 
hypothesis of the B-allele lineage of NS genes being restricted to avian hosts was 
partially based on a lack of sequences isolated from mammalian hosts at the time 
(Treanor et al., 1989). Since then, surveillance and sequencing efforts have increased 
dramatically, and the number of IAV genome sequences documented has risen 
exponentially. Since the first publication describing a mammalian B-allele virus in the 
equine host (Guo et al., 1992), there have been several more reports of B-allele viruses 
isolated from man, swine and muskrat (Table 5.3). Therefore, it was important to 
readdress the question of whether the introduction of an avian NS into mammals is 
biased towards the A-allele lineage over the B-allele lineage, using the comparatively 
larger bank of sequences available today. 
Manual inspection of phylogenetic trees generated from all available NS 




revealed 32 apparent independent incursions of an A-allele NS segment from birds to 
mammals, and 6 for B-alleles (Tables 5.2 and 5.3). The total number of avian NS 
sequences is heavily stacked in favour of A-alleles (9613 to 2317, Table 5.1), and 
when the relative rates of introduction per avian sequence was compared, these were 
not significantly different between A- and B-allele lineages (p value = 0.436, Table 
5.4). Therefore, it is reasonable to speculate that the paucity of B-allele mammalian 
isolates can be explained by a smaller pool of B-allele viruses circulating in birds, 
rather than a selection disadvantage in mammals. In support of this suggestion, 
Worobey and colleagues performed an analysis on the evolutionary history of the IAV 
genome and proposed that there was an event (estimated to have occurred around the 
1870s) in which the internal genes of an avian IAV (probably an H7N7 virus) ‘swept’ 
across the globe and selectively replaced all circulating avian IAV internal gene 
segments, but incompletely replaced the NS segments (Worobey et al., 2014a). This 
left a small ancestry pool in the avian host which are the ancestors of the B-allele NS 
genes (Worobey et al., 2014a). Thus, B-allele NS segments presumably provide 
sufficient fitness for avian IAVs to not be totally replaced by circulating A-allele NS 
segments. Further work examining A- and B-allele NS fitness in the avian host is 
required to understand this hypothesis further.  
It is acknowledged that the interpretation of an independent introduction event 
is not definite and is open to debate. In some cases, a single infection of a mammalian 
host with an avian virus containing a phylogenetically distinct NS segment was 
relatively straightforward to score as one introduction event. In other cases such as the 
H7N7/H3N8 equine-canine lineage, there has been an avian to mammalian 




adaptation from an equine to canine host. This was counted as one introduction event, 
as this represents bird to mammal to mammal transmission, and therefore only one 
Aves to Mammalia transmission event occurred. In a similar fashion, all pdm2009 
H1N1, human seasonal H1N1/H2N2/H3N2, and classical/triple reassortant swine 
isolates, accounting for thousands of mammalian A-allele sequences (Table 5.1), were 
classed as one introduction event as the NS segment has persisted from the pdm1918 
H1N1 introduction from birds into humans. The recurring H5N1 infections of man 
from contact with poultry in China was not so obvious to define, as this reflects 
multiple individual infections of man with an avian virus, albeit the same virus 
circulating in poultry. These were treated as two independent introductions – the 
original 1997 infections in Hong Kong and the re-emergence from 2003 onwards, as 
the multiple NS sequences are monophyletic in both cases. 
It is also accepted that these estimates are subject to influence from sampling 
bias. The observation that most avian NS sequences are A-allele may truly reflect that 
there are less B-allele viruses circulating in the avian population. Alternatively, B-
allele viruses may predominantly infect avian species that are not sampled as 
frequently as others. For example, there is surveillance evidence that IAV can infect 
bird orders that are infrequently sampled such as Apodiformes, Passeriformes, and 
Columbiformes (Keawcharoen et al., 2011, Williams et al., 2012). Adams et al 
proposed that an H9N2 avian reassortant virus harbouring a B-allele segment 8 was 
less competent at replicating in chicken and turkey cells, but more fit in duck cells 
relative to an A-allele segment 8 reassortant counterpart (Adams et al., 2013). 
Additionally, Post and colleagues observed a reduction in pathogenicity and systemic 




H7N7 virus compared to the A-allele parent (Post et al., 2013). However, there is 
surveillance evidence suggesting avian B-allele viruses can infect poultry (Fig 5.3), 
persist and spread in poultry populations (Garcia et al., 1997, Suarez et al., 1999), and 
can cause highly pathogenic infections in domestic birds (Garcia et al., 1997). While 
the proportion of avian B-allele viruses isolated from domestic galliform birds was not 
as high as for A-allele viruses (Fig 5.3), there was still a sizeable number from this 
host. These observations, taken together, suggest it is unlikely that B-allele viruses are 
solely restricted to avian species that are not sampled frequently. The sampling of 
mammalian species is clearly biased towards domestic species such as swine and man. 
Although perhaps unlikely, it is not inconceivable that B-allele viruses are circulating 
in mammalian species that are not sampled for IAV.  
Additionally, it was determined that the relative rates of introduction from wild 
and domestic birds into mammals were not significantly different between A- and B-
alleles (Table 5.4), therefore it is unlikely that avian B-allele viruses are at a 
disadvantage for poultry-to-mammal transmissibility. Interestingly, B-allele 
sequences appeared to be found proportionally less frequently in Asia than A-allele 
sequences (Fig 5.3), a continent where live poultry markets are popular and present an 
increased opportunity for transmission of avian IAV into man (Chan, 2002). 
Therefore, while there does not appear to be a disadvantage for B-allele viruses in 
poultry to transmit to a mammalian host, there will undoubtedly be more domestic 
birds infected with A-allele viruses in Asia at any one time, in a region where contact 
between domestic mammals and poultry can be comparatively high due to farming 




A successful cross-species transmission event does not always lead to long-
term establishment within the new host. Further assessment of the Aves to Mammalia 
transmission events revealed occasions on which there was no documented evidence 
of further transmission within mammals, and examples where the NS genes seemingly 
persisted in a mammalian population(s) for a period of time. Of the 32 A-allele 
introductions, 19 of these were estimated to have transmitted within a mammalian 
population, compared to 3 of 6 B-allele introductions, and there was not a significant 
difference between these ratios (p-value = 0.446, Table 5.4). However, it is accepted 
that the sample size is small in this instance, and further work needs to be done to ask 
whether transmissibility between mammals is influenced by the lineage of NS 
segment. It is apparent that certain A-allele NS lineages have become established in 
the mammalian host (pdm1918 H1N1, Eurasian swine, H7N7/H3N8 equine and 
canine, H3N2 canine), whereas B-allele viruses have not persisted in mammals beyond 
epidemic levels to date, therefore it would be interesting to test the hypothesis that B-
allele viruses are less well suited to mammal to mammal transmission than A-allele 
equivalents. Establishment of a mouse model for transmission was attempted, based 
on a report by Edenborough and colleagues, in which successful transmission of 
Udorn72 was observed between BALB/c mice (Edenborough et al., 2012). However, 
when this experimental set-up was attempted as part of this study, transmission was 
not detected between infected mice and naïve mice using plaque assay of lung 
homogenate and RT-PCR for segment 8 vRNA in the lung (data not shown).  
Overall, thorough bioinformatic and phylogenetic analyses of all available NS 
sequences revealed that avian B-allele NS segments are introduced into the 




that the observed paucity of B-allele NS sequences isolated from mammalian hosts is 
due to a smaller number of B-allele viruses circulating in avian hosts. Therefore, B-
allele viruses should not be discounted during pandemic and zoonotic risk assessment 
of avian influenza viruses, as data collected here and in other reports suggest that B-











 Chapter 6: Concluding remarks 
 
6.1 Conclusions  
The aim of this study was to improve our understanding of IAV host 
adaptation. In particular, the contribution of the NS segment to mammalian host range 
and pathogenicity was studied. By elucidating the mechanisms restricting the B-allele 
lineage of NS segments to avian hosts, a hypothesis based primarily on the paucity of 
B-allele isolates in mammals, it was hypothesised that new insights into IAV host 
range could be developed. The data presented in this thesis provide evidence that avian 
B-allele NS segments are actually able to facilitate successful IAV infection of 
mammalian hosts and cause significant disease, and are estimated to enter the 
mammalian population at similar rates to avian A-allele NS segments. The findings 
challenge a dogma held in the field for over 20 years, and have important implications 
in the assessment of avian IAVs when considering zoonotic potential and pandemic 
risk. While the NS segment of IAV is important for host adaptation, this seems to be 
independent of A- or B-allele lineage. 
6.2 Future work and directions 
An important question to address is whether or not the lineage of NS segment 
impacts the transmissibility of IAV within mammalian hosts. Work presented in 
Chapter 5 showed that there is no strong evidence for bias in A- or B-allele avian NS 
segments transmitting from birds to mammals in nature. While available sequencing 
and surveillance information did not point to an obvious difference in transmissibility 
of A- and B-allele viruses within mammalian hosts (Table 5.4), the sample size was 




do not reliably transmit IAV (Schulman and Kilbourne, 1963), even when infected 
with mouse-adapted strains of IAV or those that are highly transmissible in humans 
and readily cause disease in mice (Lowen et al., 2006). Despite this, Edenborough and 
colleagues demonstrated contact transmission of Udorn72 between BALB/c mice with 
relatively high efficiency (Edenborough et al., 2012). Therefore, a similar 
experimental setup was tested here in an attempt to establish a transmission model 
with an animal model readily available at the Roslin Institute. Two index mice were 
infected with 104.5 PFU of Udorn72 via the intranasal route, and after 6 h were 
introduced to a cage containing three naïve contact mice. The mice were weighed daily 
but no weight-loss was seen, as expected with this dose of Udorn72 (data not shown). 
At day 4 post-infection, virus in the lung was titrated by plaque assay, and while the 
lungs of index mice had viral titres of 104 PFU/ml, there was no detectable virus in the 
lungs of contact mice by plaque assay or by RT-PCR of segment 8 vRNA (data not 
shown). Thus, no transmission was detected in this attempt. The most ideal 
transmission model of IAV is ferret infection, as the manifestation of infection is 
similar to that seen in humans and transmission between ferrets occurs with high 
efficiency (Reuman et al., 1989, Herlocher et al., 2001). However, ferrets are relatively 
very expensive and it is challenging to acquire cohort sizes large enough for 
meaningful experiments without the prior commitment of specific funding. Therefore, 
it was not realistic to perform an experiment using ferrets in this study. An alternative 
experiment could be to try the guinea pig model of transmission. Guinea pigs are 
highly susceptible to human IAV strains without prior adaptation and permit the 




are much cheaper and more readily available than ferrets, thus represent a realistic 
option for future studies. 
Both NS1 and NEP amino acid sequences differ substantially between A- and 
B- allele lineages (Figs 2.1 and 2.2). Sequence alignments and a review of the literature 
revealed that the proposed CPSF30-binding site of NS1 is missing in B-allele NS1 
proteins (Fig 2.1).  However, transfection-based reporter assays described in Chapter 
3 suggested that these NS1 proteins are still able to inhibit cellular gene expression 
efficiently despite the lack of the consensus CPSF30-binding site (Fig 3.7). Thus, an 
obvious question to ask is whether or not B-allele NS1 proteins can bind to CPSF30 
in mammalian cells. It was planned to assess this by GFP-TRAP pulldown following 
co-transfection of NS1-GFP and CPSF30-FLAG expressing plasmids, but technical 
difficulties prevented the completion of this study within time constraints. Similar 
studies were also planned for other host factors reported to interact with NS1. In 
addition to the CPSF30-FLAG construct, expression plasmids for tagged human 
TRIM25, PKR, PI3K p85β, Riplet, and RIG-I were also kindly provided by Prof. Ben 
Hale (University of Zurich, Switzerland), but have yet to be tested. It was also planned 
to perform GFP-TRAP pulldown following NS1-GFP transfection on whole cell 
lysates to compare all cellular NS1 interactors between the two lineages. NEP-GFP 
constructs should also be made and tested in a similar fashion. Nevertheless, even if 
the interactors of A- and B-allele NS1 or NEP proteins differed, this would not detract 
from the overall conclusions of this study. By one means or another, B-allele NS1 and 
NEP proteins are able to perform essential functions efficiently in mammalian cells.  
According to available sequence and surveillance data, there are less B-allele 




explain the paucity of B-allele sequences in mammalian hosts, as there would be less 
opportunity for avian-to-mammalian transmission events in comparison to the more 
prevalent A-allele. It would be useful to generate avian IAV-based NS reassortant 
viruses and to ask if A-allele NS segments confer a fitness advantage in avian hosts. 
Adams and colleagues assessed an A- and a B-allele NS segment from isolated from 
waterfowl on the background of an H9N2 guinea fowl virus in duck, chicken and 
turkey cells (Adams et al., 2013). The authors suggested that the A-allele reassortant 
virus had a fitness advantage over the B-allele in chicken and turkey cells, but the B-
allele was more suited to duck cells. In addition, Worobey and colleagues proposed 
that the B-allele NS genes represent a small pool of ancestry genes that survived a 
global ‘sweep’ of avian IAV internal genes that incompletely replaced all circulating 
NS segments (Worobey et al., 2014b). This suggests that the B-allele NS segments 
confer sufficient fitness for avian IAVs, otherwise one would expect them to have been 
fully succeeded by A-allele segments (as was predicted to have occurred for all other 
internal gene segments by Worobey and colleagues). However, further work is 
necessary to dissect this question.  
Another question to address is whether there are particular genetic traits of 
segments 1-7 of IAV that are required for A- or B-allele NS segments to reassort into 
a mammalian-adapted viruses in nature. This would require another large-scale 
phylogenetic analysis and it may be necessary to look at sequence motifs within the 
other 7 segments, which would represent a challenging task. It could be hypothesised 
that avian A- and B-allele NS segments require specific complementation with one or 
more other segments of the IAV genome to successfully infect mammalian hosts. 




Mammalia transmission across A- and B-allele lineages, perhaps the question should 
ask which genetic traits in the other 7 segments are required for any avian NS segment, 










 Chapter 7: Materials and methods 
 
7.1 Materials  
7.1.1 Suppliers of general reagents 
General purpose reagents were supplied by Fisher Scientific, Scientific 
Laboratory Supplies Ltd, and Sigma. The Roslin Institute Central Services Unit (CSU) 
made and provided phosphate buffered saline (PBS). Other specific reagents are listed 
below alongside their respective suppliers. 
Acrylamide:bisacrylamide (37.5:1) solution    Bio-Rad. 
Agarose for electrophoresis      Invitrogen. 
Amplify Fluorographic Reagent     GE Healthcare. 
CAS-Block blocking agent      Invitrogen. 
DNA molecular weight markers     Promega. 
DNA plasmid miniprep kit      Promega. 
DNA plasmid midiprep kit      Qiagen. 
Guanidine HCl       Thermo Fisher. 
HEPES        Sigma. 
Lipofectamine 2000       Invitrogen. 
Luciferase systems       Promega. 
Neutral Buffered Formalin      Leica. 




PCR purification kit       Qiagen. 
Polyinosinic:polycytidylic acid (poly(IC)).    InVivoGen. 
Protein molecular weight markers     Promega. 
Protein A-agarose beads      Roche.  
Quantitative RT-PCR system      Bioline. 
Resolving buffer for acrylamide gels     Protogel. 
Stacking buffer for acrylaminde gels     Protogel. 
Tetramethylethylenediamine (TEMED)    Protogel. 
Trizol reagent        Invitrogen. 
TrueBlue Peroxidase Substrate  Kirkegaard & Perry Laboratories, Inc. 
X-ray film        Thermo Fisher . 
Xylene         Genta Medical. 
7.1.2 Enzymes 
The following enzymes were supplied by the stated suppliers, and were used 
according to manufacturer’s instructions unless otherwise stated: 
DNA restriction endonucleases    New England Biolabs.  
AMV Reverse Transcriptase     Promega. 
Taq DNA polymerase      Invitrogen. 




DNase        Life Technologies. 
T4 DNA ligase      New England Biolabs. 
L-1-Tosylamide-2-phenylethyl chloromethyl ketone-  
-(TPCK)-treated bovine pancreatic trypsin   Sigma. 
Trypsin acetylated from bovine pancreas (NAT)  Sigma. 
7.1.3 Antibodies and dyes  
Table 7.1. Primary antibodies and antisera raised against IAV proteins 
Antibody Application Source/Reference 
Rabbit polyclonal anti-PR8 NS1 (V29) WB (1:500), IF (1:500), IP 
(1:100) 
(Carrasco et al., 2004) 
Rabbit polyclonal anti-O265B NS1 (A2) WB (1:500), IP (1:100) Custom made 
(Genosphere) 
Rabbit polyclonal anti-PR8 NS1 (NS1-
RBD) 
WB (1:500), IF (1:250) Custom made 
(Genosphere) 
Rabbit polyclonal anti-PR8 NEP (V13) WB (1:500), IP (1:100) (Elton et al., 2001) 
Rabbit polyclonal anti-PR8 M1 (2917) WB (1:500) (Amorim et al., 2007) 
Rabbit polyclonal anti-PB1 (V19) WB (1:500) (Digard et al., 1989) 
Rabbit polyclonal anti-MBP-PB2 
(2N580) 
WB (1:500) (Carrasco et al., 2004) 
Rabbit polyclonal anti-MBP-NP (2915) WB (1:500), Plaque 
immunostaining (1:1000) 
(Noton et al., 2007) 
Mouse monoclonal anti-PR8 NP (AA5H) IF (1:1000) Abcam (abAA5H) 
Rabbit polyclonal anti-PR8 IF (1:1000) (Amorim et al., 2007) 





Polyclonal rabbit antiserum raised against O265B NS1 (A2) and PR8 NS1-
RBD (NS1-RBD) were custom made by Genosphere.  A2 and NS1-RBD were raised 
by inoculating rabbits with a keyhole limpet hemocyanin (KHL)-peptide conjugate of 
sequence CGPPLPPKQKRYMARRV and CDRLRRDQKSLRGRGST respectively. 
Pre-immune serum/antiserum was provided in lyophilised form and reconstituted in 
sterile water as instructed by manufacturer.  
To validate antisera A2 and NS1-RBD, infected cell lysates were analysed by 
western blot and probed with either antiserum or the corresponding pre-immune serum 
(Fig 7.1). The A2 antiserum detected avian A- and B-allele polypeptides (see lanes 3-
13 in Fig 7.1A), but not WT PR8 NS1 (see lane 2). The A2 pre-immune serum did not 
detect NS1 in any sample above background levels. Successful infection was 
confirmed by detection of viral NP in all samples except the mock-infected. The NS1-
RBD antiserum detected WT PR8 as well as consensus A- and B-allele avian NS1 
(O175A and O265B) polypeptides (see lanes 2-4 of Fig 7.1B). As above, the pre-
immune antiserum did not detect NS1 in any sample, and NP was only detected in 
viral-infected cell lysates and was not detected in mock-infected cells.  
Table 7.2. Primary antibodies raised against cellular proteins. 
Antibody Application Source 
Rat monoclonal anti-alpha-tubulin WB (1:1000) Serotec (MCA77G), clone 
YL1/2 
Rabbit polyclonal anti-Mx1 
(N2C2) 







Fig 7.1. Validation of custom made anti-NS1 antisera. Western blot analysis of 
infected cell lysate ((A) MDCK cells and (B) A549 cells, MOI = 3, 8 h) was performed 
using antiserum and pre-immune serum in parallel at 1:500 dilution overnight at 4°C. 
Anti-MBP-NP was used to confirm successful infection. Anti-tubulin was used as a 




Table 7.3. Primary antibody raised against GFP. 
Antibody Application Source 
Mouse monoclonal anti-GFP (JL8) WB (1:5000) Clontech 632380 
 
Table 7.4. Secondary antibodies. 
Antibody Application Source 
Donkey anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 conjugate 
IF (1:1000) Thermo Fisher 
(A-21202). 
Donkey anti-Rabbit IgG (H+L) Secondary 
Antibody, Alexa Fluor® 488 conjugate 
IF (1:1000) Thermo Fisher 
(A-21206). 
IRDye® 680LT Goat anti-Rat IgG (H + L) WB (1:10000) Li-Cor 925-68076 
IRDye® 800CW Donkey anti-Mouse IgG (H + L) WB (1:10000) Li-Cor 925-32212 
IRDye® 800CW Donkey anti-Rabbit IgG (H + L), 
0.5 mg 
WB (1:10000) Li-Cor 926-32213 
IRDye® 680LT Donkey anti-Mouse IgG (H + L) WB (1:10000) Li-Cor 925-68022 
IRDye® 800CW Streptavidin WB (1:2000) Li-Cor 925-32230 





Table 7.5. Fluorescent dyes. 
Dye Application Source 
ProLong Gold Antifade Mountant with 
DAPI 
IF (neat) Invitrogen 






7.1.4 Eukaryotic cell & bacterial culture medium  
7.1.4.1 Eukaryotic cell culture  
Media and additives used for culturing eukaryotic cells were purchased from 
the following suppliers: 
Dulbecco’s Modified Eagle Medium (D-MEM)  Sigma. 
Fetal Bovine Serum (FBS)     Life Technologies. 
L-Glutamine        Life Technologies. 
Penicillin/Streptomycin      Life Technologies. 
Geneticin       Life Technologies. 
Blasticidin       InvivoGen. 
Zeocin        InvivoGen. 
0.25% Trypsin-EDTA     Life Technologies. 
Calcium/Magnesium-free Phosphate Buffered Saline Invitrogen. 
Opti-MEM       Life Technologies. 
RPMI-1640       Sigma. 
Minimum Essential Medium     Gibco. 
Methionine- and Cysteine-free D-MEM   Gibco. 




7.1.4.2 Bacterial Culture 
Luria Broth (LB) and LB agar were made and provided by the Roslin Institute 
CSU.  
Luria Broth 10 g/L tryptone, 5 g/L yeast extract, 5 g/L 
sodium chloride (pH 7.0). 
LB agar  15 g/L agar, 10 g/L tryptone, 5 g/L yeast extract, 
10 g/L sodium chloride (pH 7.0). 
7.1.5 Eukaryotic cells 
Madin-Darby Canine Kidney Cells (MDCK)    Sigma. 
Human Embryonic Kidney 293T Cells (293T)    Sigma. 
Human Adenocarcinomic Alveolar Basal Epithelial Cells (A549)  Sigma. 
MDCK-Sialyltransferase 1 Cells (MDCK-SIAT)  Prof. John 
McCauley (The Francis Crick Institute, Mill Hill, London, UK). 
Human Colorectal Adenocarcinomic Cells (CaCo-2)   Sigma.  
HEK293-Blue IFN-α/β Cells (HEK-Blue)             InvivoGen.  
7.1.6 Protein buffers and solutions 
7.1.6.1 Lysis buffers 
Laemmli’s sample buffer 20% (v/v) glycerol, 2% (w/v) SDS, 100 mM DTT, 24 
mM Tris, 0.016 % (v/v) bromophenol blue, 0.016% 




Tris-lysis buffer 50 mM Tris HCl (pH 8.0), 10% (v/v) glycerol, 0.5% 
(v/v) Nonidet P40, 200 mM sodium chloride, 1 mM 
DTT, 1 mM PMSF, 1 x protease inhibitor tablet (Fisher 
Scientific). 
Guanidine HCl lysis buffer 6M Guanidine HCl, 50 mM HEPES. 
7.1.6.2 Acrylamide gel electrophoresis 
SDS-PAGE running buffer.   25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS. 
4 x resolving buffer (Protogel) 1.5 M Tris-HCl, 0.4 % (w/v) SDS, pH 8.8. 
4 x stacking buffer (Protogel)  0.5 M Tris-HCl, 0.4 % (w/v) SDS, pH 6.8. 
10% resolving polyacrylamide gel 3.33 ml 30% acrylamide:bisacrylamide (37.5:1), 
2.5 ml 4 x resolving buffer, 4.06 ml water, 100 
µl 10% (w/v) APS, 10 µl TEMED. 
4% stacking polyacrylamide gel 1.3 ml 30 % acrylamide:bisacrylamide (37.5:1), 
2.5 ml 4 x stacking buffer, 6.1 ml water, 50 µl 
10% (w/v) APS, 10 µl TEMED. 
Polyacrylamide gel fix solution 50% (v/v) methanol, 10% (v/v) acetic acid.  
7.1.6.3 Western blotting 
Protein transfer buffer. 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, 
20% (v/v) methanol. 





Wash buffer   PBS/0.1% (v/v) Tween20. 
7.1.6.4 Pulldown buffers 
Medium stringency IP buffer 100 mM KCl, 50 mM Tris-Cl pH 7.6, 5 mM 
MgCl2, 1mM DTT, 1% (v/v) Triton X-100, 
0.1% (w/v) SDS, 1% (w/v) sodium 
deoxycholate.  
Low stringency IP buffer 100 mM KCl, 50 mM Tris-Cl pH 7.6, 5 mM 
MgCl2, 0.1% (v/v) Nonidet P40. 
7.1.7 Solutions and buffers for molecular cloning  
7.1.7.1 Agarose gel electrophoresis  
TAE running buffer was made and supplied by the Roslin Institute CSU. 
TAE running buffer 40 mM Tris, 20 mM acetic acid, 1 mM 
EDTA.  
6x DNA loading buffer 10 mM Tris-HCl (pH 7.6) 0.15% (w/v) 
Orange G dye, 0.03% (w/v) xylene 
cyanol FF, 60% (v/v) glycerol,  60 mM 
EDTA.  
7.1.8 Other solutions and buffers 
7.1.8.1 IHF buffers 





Antigen retrieval buffer 10 mM sodium citrate (pH 6.0)/0.05% 
(v/v) Tween20. 
Permeabilisation buffer  TBS/0.25% (v/v) Tween20. 
Wash buffer    TBS/0.025% (v/v) Tween20.  
7.1.9 Plasmids  
Table 7.6. Plasmids. 
Name Description Source 
pDUAL Reverse genetics plasmid. Bidirectional pol I and pol II 
promoters either side of insert lead to mRNA and 
vRNA-like RNA synthesis. 
Gift from Prof. 
Ron Fouchiera  
pHH21 Reverse genetics plasmid. Pol I promoter leads to 
vRNA-like RNA synthesis. 
Gift from Prof. 
Robert Lambb  
pcDNA3.1 CMV pol II promoter upstream of insert leads to 
constitutively high protein expression 
Gift from Prof. 
Robert Lambb  
pEGFP-N1 Constitutively expresses eGFP under control of CMV 
promoter. MCS upstream allows opportunity to clone 
C-terminally tagged proteins. 
Clontech. 
pRL Constitutively expresses Renilla luciferase under 
control of SV40 promoter. 
Gift from Dr. 
Finn Greyc  
pPol I Luc Reporter for RNP reconstitution assays. Contains 
firefly luciferase reporter gene in the reverse 
orientation and flanked by the UTRs of PR8 segment 
8, under the control of a pol I promoter. 
Gift from Prof. 
Laurence Tileyd  
pIFN-β::Luc Firefly luciferase under control of human IFN-β 
promoter. 
 
Gift from Prof. 




Name Description Source 
pISRE::Luc Firefly luciferase under control of ISRE element. Gift from Prof. 
Rick Randalle  
a Erasmus University Medical Center, Rotterdam, Netherlands. 
b Department of Molecular Biosciences, Northwestern University, Illinois, USA. 
c The Roslin Institute, The University of Edinburgh, Edinburgh, UK. 
d Department of Veterinary Medicine, The University of Cambridge, Cambridge, UK. 
e Biomolecular Sciences Building, University of St. Andrews, St. Andrews, UK. 
 
7.1.10  Viruses and reverse genetics systems 
7.1.10.1 Reverse genetics systems 
i) A/Puerto Rico/8/1934 (H1N1) 
The eight-plasmid PR8 reverse genetics system was a kind gift from Prof. Ron 
Fouchier (Erasmus University Medical Center, Rotterdam, Netherlands) (de Wit et al., 
2004).  
Table 7.7. Reverse genetics system for A/Puerto Rico/8/1934 (H1N1). 
Plasmid backbone Segment Accession number Reference 












ii) A/Udorn/1972 (H3N2)  
The twelve-plasmid Udorn72 reverse genetics system was a kind gift from 
Prof. Robert Lamb (Department of Molecular Biosciences, Northwestern University, 
Illinois, USA).  
Table 7.8. Reverse genetics plasmids for A/Udorn/1972 (H3N2). 
Plasmid backbone Segment Accession number Reference 













iii) A/California/7/2009 (H1N1) 
The Cal7 reverse genetics plasmids (pHW2000) were a kind gift from Prof. 
John McCauley (The Francis Crick Institute, Mill Hill, London, UK). Accession 





7.1.10.2 A- and B- allele NS segment reverse genetics plasmids 
NS reverse genetics plasmids are detailed in Table 7.9. pHH21 plasmids 
containing cDNA for LPAI NS segments were a kind gift of Prof. Jeffery 
Taubenberger (National Institute of Allergy and Infectious Diseases, Bethesda, 
Maryland, USA). cDNA corresponding to the NS segments of Alb88B, NY6750A, 
Sw412A, Sw418B, and NY107B was synthesised by Biomatik and cloned into the 
pDUAL vector (see below in 7.2.5.8 Cloning NS segments into pDUAL). 
A/equine/Jilin/1/1989 (H3N8) (J89B) NS reverse genetics plasmid was a gift of Dr. 
Pablo Murcia (The Centre for Virus Research, The University of Glasgow, Glasgow, 
UK). 
Table 7.9. Reverse genetics plasmids for A- and B- allele NS genes. 
Short 
Name 







A pHH21 CY018881.1  
O173A A/mallard/Ohio/173/1990 
(H11N9) 




A pHH21 CY021873.1  
M1124A A/mallard/Maryland/1124/2
005 (H11N9) 
A pHH21 CY021473.1  
O265B* A/Mallard/Ohio/265/1987 
(H1N9) 
B pHH21 CY017279.1  
O430B A/green-winged 
teal/Ohio/430/1987 (H1N1) 













B pHH21 CY016399.1  
O339B A/pintail/Ohio/339/1987 
(H3N8) 
B pHH21 CY019201.1  
O668B A/mallard/Ohio/668/2002 
(H4N6) 
B pHH21 CY020793.1  
O671B A/mallard/Ohio/671/2002 
(H4N6) 




B pHH21 CY020937.1  
O246B A/bufflehead/Ohio/246/198
6 (H11N2) 
B pHH21 CY017079.1  
















B pDUAL EU587374.2  
J89B A/Equine/Jilin/89/1/1989 
(H3N8) 
B pDUAL M65020.1 (Guo et al., 
1992) 
* O175A and O265B represent consensus A- and B-allele segments respectively. 
7.1.11  Oligonucleotides  




Table 7.10. Sequencing primers.  
Primer name Sequence (5’ to 3’) Description 
pDUAL FP ATGTCGTAACAACTCCGCCC 
 
For sequencing from the 5’ end of 
insert in pDUAL plasmid 
pDUAL RP TTTTTGGGGACAGGTGTCCG For sequencing from the 3’ end of 
insert in pDUAL plasmid 
Uni 12 AGCAAAAGCAGG Complementary to the 3’ end of all 
IAV vRNA segments. 




Complementary to the 3’ end of 
PR8 NS cRNA 
A1643 FP GCAACCGGTACCATGGACTCC
AACACGATAACC 




Complementary to 3’ end of A-allele 
LPAI NS. 
Alb88 NS FP GCTATACGTCTCTGGGGAGCA
AAAGCAGGGTGAC 
 
For sequencing segment 8 cDNA of 
Alb88B, NY6750A, Sw412A, 
Sw418B, NY107B and J89B. 










Table 7.11. Primers for NS1-GFP cloning.  





For cloning PR8 NS1 ORF with 









For cloning O265B NS1 ORF with 









For cloning O175A NS1 ORF with 









For cloning O668B NS1 ORF with 









For cloning Alb88B NS1 ORF with 










For cloning NY6750A NS1 ORF 














For cloning Sw412A NS1 ORF 
with KpnI and AgeI restriction 









For cloning Sw418B NS1 ORF 












For cloning NY107B NS1 ORF 
with KpnI and AgeI restriction 









For cloning J89B NS1 ORF with 






Table 7.12. Primers for cloning avian NS cDNA into pDUAL. 


















For cloning NY6750 segment 8 









For cloning Sw412 segment 8 









For cloning Sw418 segment 8 









For cloning NY107 segment 8 






Table 7.13. Primers for reverse transcription. 
Primer 
name 
Sequence (5’ to 3’) Description 
Uni 12 AGCAAAAGCAGG Complementary to the 5’ end of vRNA of all 
IAV segments. 
PD637 AGCAAAAGCAGGGTGAC Complementary to the 5’ end of PR8 
segment 8 vRNA and also efficient for LPAI 






Table 7.14. Primers for RT-PCR based competition assay. 





Designed to specifically amplify the 










Designed to specifically amplify the 










Sequence (5’ to 3’) Description 
qO175A-FP CTCCAAAGCAGAAACGGAAA Designed to specifically amplify cDNA 
from O175A vRNA in RT-qPCR. qO175A-RP TCTTGCTCCACTTCAAGCAG 
qO265B-FP AATCCTCATCGGTGGACTTG Designed to specifically amplify cDNA 
from O265B vRNA in RT-qPCR. qO265B-RP TCTGCTCGAAGCTGTTCTCA 
 
7.1.12  Drugs  
Excludes antibiotics used in eukaryotic cell culture as detailed above in 7.1.4.1 
Eukaryotic cell culture. 
Ampicillin sodium salt used at 100 µg/µl     Sigma. 




Human recombinant IFN-β       Abcam. 
Human recombinant IFN-α 2a      Abcam. 
7.1.13  Radiochemicals 
[35S]-L-methionine and [35S]-L-cysteine protein labelling mix Perkin-Elmer. 
[14C] Protein Molecular Weight Marker    Perkin-Elmer. 
7.2 Methods 
7.2.1 Ethics statement 
The following ethics statement was provided by Prof. Bernadette Dutia (The 
Roslin Institute, The University of Edinburgh, Edinburgh, UK): All animal 
experiments were carried out under the authority of a UK Home Office Project Licence 
(held by Prof. Bernadette Dutia at the Roslin Institute, The University of Edinburgh, 
Edinburgh, UK (60/4479)) within the terms and conditions of the strict regulations of 
the UK Home Office ‘Animals (scientific procedures) Act 1986’ and the Code of 
Practice for the housing and care of animals bred, supplied or used for scientific 
purposes. Ethical approval for experiments using human macrophages was obtained 
from the Lothian Research Ethics Committee (11/AL/0168). All subjects provided 
written informed consent at each donation. 
7.2.2 Cell culture 
7.2.2.1 Eukaryotic cell culture medium 
i) Complete D-MEM: D-MEM supplemented with 10% (v/v) FBS, 2mM 
glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. 




7.2.2.2 Cell culture and manipulation 
MDCK cells, 293T cells, A549 cells, and CaCo-2 cells were all grown in 
complete D-MEM at 37°C in 5% CO2. MDCK-SIAT cells were cultured in complete 
D-MEM with 1mg/ml Geneticin. HEK-Blue cells were cultured in complete D-MEM 
supplemented with 30 μg/ml blasticidin and 100 μg/ml Zeocin. Cells were typically 
passaged twice weekly: cells were washed twice (once for 293T and HEK-blue) with 
PBS and dissociated using a 0.25% trypsin-EDTA solution (or Mg and Ca ion-free 
PBS for HEK-Blue). Cells were resuspended in complete D-MEM and typically split 
1 in 10.  
Primary CD14+ human monocytes were isolated from whole blood by Dr. 
Alasdair Jubb, Dr. Malcolm Fisher (both of the Prof. David Hume laboratory, the 
Roslin Institute, the University of Edinburgh, Edinburgh, UK) and Dr. Sara Clohisey 
(of the Dr. Ken Baillie laboratory, The Roslin Institute, The University of Edinburgh, 
Edinburgh, UK) as described below in 7.2.2.4 Isolation of human CD14+ monocytes. 
Monocytes were plated in 24-well plates in RPMI supplemented with 10% (v/v) FBS, 
2 mM glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 104 U/ml (100 
ng/ml) recombinant human (rh)CSF-1 (a gift from Chiron, Emeryville, California, 
USA) for 7 days for differentiation into macrophages. Infections were performed on 
day 8. 
7.2.2.3 Cell counting 
Cells were counted using a Neubauer cell counting chamber. Typically, 9 µl of 
cell suspension was added to each side of the chamber under a glass cover slip. Using 




cell concentration was estimated (cell concentration (cells/ml) = number of counted 
cells x 104). 
7.2.2.4 Isolation of human CD14+ monocytes 
All subjects provided written consent before donating blood, and samples were 
kept anonymous during research and labelled with a unique ID number that could be 
traced back to the subject. 
Human CD14+ monocytes were kindly isolated and provided by members of 
the Prof. David Hume and Dr. Ken Baillie laboratories as described above, which were 
isolated as described in (Irvine et al., 2009). Fresh blood was centrifuged (1200 x g, 5 
min) without a brake to prevent disruption of cells. The plasma was removed by 
pipette, and the buffy coat was aspirated. Typically, 20 ml of buffy coat was obtained 
per sample. The 20 ml buffy coat was diluted to a total volume of 50 ml with RPMI 
media, gently laid over two 15 ml preparations of Ficoll (GE Healthcare), and 
centrifuged at room temperature with no brake (200 x g, 45 min). The uppermost layer 
(RPMI) was removed. The mononuclear cell layer was aspirated and washed with 
RPMI media (added to a total volume of 50 ml) by centrifugation (300 x g, 10 min). 
The cell pellet was resuspended in 10 ml of PBS, counted, and centrifuged (400 x g, 
10 min, 10°C). The supernatant was removed and the cells were resuspended in 40 µl 
MACS buffer (PBS/2 mM EDTA and 0.5% (v/v) FBS) per 107 total cells. 10 µl of 
CD14 microbeads (Miltenyi Biotec) per 107 total cells were added and incubated at 
4°C on an orbital shaker. 50 ml of chilled MACS buffer was added and this was 
centrifuged (400 x g, 5 min, 4°C). Supernatant was removed and cells were 
resuspended in 500 µl MACS buffer per 108 total cells. Magnetic separation columns 




cell suspension was run through the magnetic separation column. The column was 
washed three times with 3 ml MACS buffer. Cells were eluted by running through 5 
ml MACS buffer and applying plunger force. Cells were counted, centrifuged (400 x 
g, 5 min, 4°C), washed with 10 ml PBS and centrifuged (400 x g, 5 min, 4°C). 
Supernatant was removed and cells were resuspended and plated in culture medium as 
described above in 7.2.2.2 Cell culture and manipulation. 
7.2.3 Virus work 
7.2.3.1 Virus culture medium and solutions 
i) Virus growth medium: D-MEM supplemented with 2 mM glutamine, 100 
U/ml penicillin, 100 μg/ml streptomycin, 0.14% (w/v) BSA, and 1 µg/ml 
TPCK-treated trypsin. 
ii) Reverse genetics medium: Virus growth medium with 5 µg/ml TPCK-
treated trypsin.  
iii) Acid wash buffer: 10 mM HCl, 150 mM NaCl (pH 3.0). 
7.2.3.2 Generation of P0 stocks 
Reverse genetics plasmid sets were transfected into 293T cells in 6-well plates 
using Lipofectamine2000 reagent (Invitrogen). Reverse genetics plasmids (250 ng 
each for PR8 and Cal7 systems, 500 ng each for Udorn72) were diluted in 100 µl Opti-
MEM. 4 µl Lipofectamine2000 was mixed with 100 µl Opti-MEM medium (or 6 µl in 
100 µl for Udorn72) for 10 min then incubated with diluted DNA for 30 min. 293T 
cells were harvested (a T75 flask resuspended in 25 ml complete D-MEM) and 1 ml 
was added to each well of a 6-well plate. The transfection mix was added dropwise 




ml reverse genetics medium. Following a 48 h incubation, supernatants were collected 
and stored at -80°C as P0 stocks. 
7.2.3.3 Generation of P1 stocks 
MDCK cells were seeded in T25 flasks. When fully confluent, cells were 
washed twice with 10 ml serum-free D-MEM. 100 µl of P0 stock was diluted in 1 ml 
reverse genetics medium. The serum-free D-MEM wash was removed from the cells, 
and 1 ml of diluted P0 stock was added. Cells were incubated for 1 h at 37°C and 5 ml 
of reverse genetics medium added. Cells were incubated at 37°C for 48 h. Supernatants 
were clarified by centrifugation (3000 rpm, 5 min) and stored at -80°C in 0.5 ml or 1 
ml aliquots. Virus titration was always performed after one freeze-thaw cycle to 
account for loss of infectivity.  
7.2.3.4 Egg grown virus stocks   
Embryonated chicken eggs (Henry Stewart & Co.) were incubated at 37°C, 40-
50% humidity, for 10 days and were candled to check viability of embryo prior to 
infection. Virus was diluted to 104 PFU/ml in serum-free D-MEM. A small hole was 
punctured in the egg shell just below the line of the air sac. The shell was sterilised 
with 70% (v/v) ethanol and, using a 1 ml syringe and 25 G needle, 100 µl of diluted 
virus stock was gently inoculated into the allantoic cavity. The puncture was then 
sealed with Scotch Magic Tape and eggs were incubated at 37° C, 40-50% humidity, 
for 48-72 h.  
Eggs were culled by chilling overnight at 4° C. The top of the shell was 




Allantoic fluid was collected using a P1000 Gilson, clarified (4000 rpm, 10 min), and 
stored in 0.5-1 ml aliquots at -80°C.  
7.2.3.5 Virus infections 
Cells were typically plated the day prior to infection to achieve approximately 
90% confluency (unless otherwise stated) on the day of infection. Cells were washed 
with serum-free D-MEM to remove FBS. Virus stocks were diluted in serum-free D-
MEM and were applied to cells in a low volume (e.g. 200 µl for 24-well plate format) 
for 1 h at 37ºC. For multicycle infections, cells were overlaid with virus growth 
medium. For single-cycle infections, inoculum was aspirated, acid wash buffer was 
applied for 1 min to inactivate non-internalised particles, and cells were washed three 
with PBS prior to overlay with serum-free D-MEM. For infections to be analysed using 
immunofluorescence or proteomics, cells were overlaid with complete D-MEM.  
Supernatants were clarified (3000 rpm, 5 min) and stored at -80°C prior to downstream 
analyses.   
7.2.3.6 Plaque assays – PR8 and Udorn72 
MDCK cells were seeded in 6-well plates the day prior to plaque assay to 
achieve 100% confluency the next day. Typically, this was achieved by seeding 4 x 
106 cells per well in a 2 ml volume of complete D-MEM. Cells were washed with 2 
ml serum-free D-MEM. Virus samples were serially diluted ten-fold in serum-free D-
MEM. 400 µl of virus dilution was applied to each well and incubated for 1 h at 37°C. 
After incubation, 2 ml of overlay was added to each well. For Avicel overlay, virus 
growth media was supplemented with 1.2% (w/v) Avicel. For 0.6% agarose plaque 
assays, 2% (w/v) agar was boiled and incubated at 55° C, and 7.5 ml was mixed with 




Bicarbonate, 10 mM HEPES, 0.007% (w/v) Dextran, 3 mM L-Glutamine, 140 U/ml 
penicillin, 140 µg/ml streptomycin, and 1.4 µg/ml NAT) incubated at 37°C. Virus 
inoculum was aspirated and 2 ml of agarose overlay was added per well. After agarose 
had set, plates were incubated upside down at 37°C.  
Unless otherwise stated, plaque assays were incubated at 37°C for 48 h. For 
fixing and staining, 2 ml of 10% neutral buffered formalin was added per well and 
incubated for 20 min – 24 h. The formalin and remaining overlay were removed and 
cells stained with 0.1% (w/v) toluidine blue for 20 min – 6 h. Toluidine blue stain was 
removed and cells were washed with water prior to plaque counting and titre 
calculations. For plaque purification, live cellular debris/agarose was taken up using a 
P1000 Gilson by scraping isolated plaques and aspirating agarose. This material was 
then ejected onto a monolayer of fresh MDCK cells in 24-well plates under 0.5 ml 
virus growth medium. Cells were incubated at 37°C for 24 h to allow virus 
amplification.  
7.2.3.7 Plaque assays – Cal7  
Plaque assays for Cal7 backbone viruses were performed essentially as 
described above in 7.2.3.6 Plaque assays – PR8 and Udorn72, but using MDCK-SIAT 
cells and a modified overlay: serum-free D-MEM with 1 µg/ml TCPK-treated trypsin 
and 0.8% (w/v) Avicel. Cells were immunostained for intracellular NP: 
Cells were fixed by adding 2 ml of 10% NBF per well and incubating for 30 
min. Overlay was removed and cells were washed with 2 ml PBS per well. Cells were 
permeabilised with 1 ml PBS/0.2% (v/v) Triton X-100 per well for 10 min. Cells were 




anti-MBP-NP diluted 1:1000 in PBS/2% (w/v) BSA fraction V for 1 h at room 
temperature on a rocker. Cells were washed twice with PBS and then incubated with 
0.5 ml per well with a goat anti-rabbit IgG-HRP conjugated secondary antibody diluted 
to 1:1000 in PBS/2% (w/v) BSA fraction V for 1 h at room temperature on a rocker. 
Cells were washed three times with PBS and 0.5 ml per well of TrueBlue peroxidase 
substrate was added. Cells were incubated at room-temperature until plaques were 
visible with blue staining. Cells were then washed with water, allowed to dry, and 
plaques counted.  
7.2.3.8 Virus RNA extraction from supernatant of infected cells 
Virus RNA was extracted using Trizol reagent (Invitrogen). Typically, 750 µl 
of Trizol reagent was added to 250 µl of infected cell supernatant and mixed 
thoroughly. Lysates were typically stored overnight at -80°C. 200 µl of chloroform 
was added, mixed extensively, and incubated at room temperature for 5 min. Samples 
were centrifuged at full speed in a standard microcentrifuge machine at 4°C for 20-30 
min. The aqueous layer, containing RNA, was transferred to a clean microcentrifuge 
tube. RNA was precipitated by adding 500 µl isopropanol, mixing, and incubating at 
-20° C for 30 min.  Samples were centrifuged at 13000 rpm for 20 min at 4°C. The 
isopropanol was removed and RNA was washed with 500 µl 70% (v/v) ethanol. 
Samples were centrifuged at 13000 rpm for 5 min at 4°C, and the ethanol wash 
removed. At this point, RNA was either resuspended in 44 µl water and stored at -
80°C or, if sequencing of P1 stocks was desired, treated with DNase to remove 
potential residual plasmid carryover from P0 generation. DNase treatment was 
performed using TURBO DNase (Life Technologies) in a 50 µl reaction (as instructed 




RNA, 200 µl of water was added, and RNA was purified by performing another round 
of phenol:chloroform extraction: 250 µl of phenol:chloroform:isoamyl alcohol 
(25:24:1, Sigma), was added and mixed well, and samples were centrifuged (15000 
rpm, 4°C, 5 min). 250 µl chloroform was added, mixed well, and samples were 
centrifuged again (15000 rpm, 4°C, 5 min). The aqueous layer was transferred to a 
clean microcentrifuge tube. 625 µl of ethanol and 25 µl of 3 M sodium acetate (pH 
5.2) was added, mixed, and incubated at -20°C for 10 min. Samples were centrifuged 
(15000 rpm, 20 min, 4° C), the ethanol & sodium acetate removed, and a wash was 
performed by adding 500 µl 70% (v/v) ethanol and centrifuging the sample (15000 
rpm, 5 min, 4°C). The ethanol wash was removed, the RNA was resuspended in 15 µl 
water, and samples stored at -80°C prior to downstream analysis. 
7.2.3.9 Viral RNA extraction from infected cells 
Typically, cells were washed with PBS and 200 µl Trizol reagent was added to 
a 24-well. RNA extraction was performed as described above in 7.2.3.8 Virus RNA 
extraction from supernatant of infected cells using appropriately adjusted volumes of 
chloroform and isopropanol.   
7.2.3.10 Virus sequencing 
Viral RNA was extracted from P1 stocks (infected cell supernatants or egg 
allantoic fluid) using Trizol reagent as described above. 4 µl of resuspended RNA was 
used in a reverse transcriptase reaction using AMV RTase (Promega). 4 µl of 10 µM 
RT primer was annealed to the RNA in a 10 µl volume by heating at 75°C for 5 min, 
and then immediately placing on ice for 2-5 min. A 25 µl reaction was set up with 1 x 




reaction was incubated at 42° C for 1 h. The AMV RTase was deactivated by heating 
at 75° C for 10 min. cDNA was stored at -20° C or used immediately. 
3 µl of cDNA product was amplified using PCR prior to sequencing. Taq DNA 
polymerase was employed in a 25 µl reaction containing 1.5 mM magnesium chloride, 
1 x Taq PCR buffer (Invitrogen), 200 nM forward primer, 200 nM reverse primer, 250 
µM (each) dNTPs, and 2.5 units Taq DNA polymerase. Thermocycling conditions 
were adjusted depending on target amplicon. Typically, a primer annealing 
temperature of Tm – 5° C (for primer with lowest Tm) was employed, and a range of 
annealing temperatures were tested for new primer:template combinations. The 
following describes thermocycling conditions for amplification of WT PR8 NS 
segment cDNA with PD637 and PD638 primers: Initial denaturation of template DNA 
was performed by heating at 94° C for 2 min. Then, 30 cycles of a 1 min 94°C 
denaturation step, a 1 min 50°C primer annealing step, and a 3 min 72°C amplicon 
elongation step were performed. After 30 cycles of the above, a 10 min 72°C amplicon 
elongation step was performed and reaction cooled to 4°C. Product was stored at -
20°C or purified immediately. PD637 and PD638 (Table 7.10) were efficient at 
amplifying B-allele NS segment cDNA, but not A-allele NS cDNA. A-allele segment 
8 cDNA was successfully amplified using PD637 and A1644 RP (Table 7.10). 
Alb88B, NY6750A, Sw418B, and NY107B were amplified using terminal primers 
described in Table 7.12. 
Before sequencing, PCR product was purified by column purification using 
QIAGEN’s QIAquick PCR Purification kit (cat# 28104) as described in 




PCR product was added to 5 µl of 5µM appropriate forward primer (see Table 7.10). 
Sanger sequencing of cDNA was performed by GATC.  
7.2.3.11 Competition Assays 
i) Validation of primers in RT-PCR 
To test the specificity of primers designed to be specific for the NS1 ORF of 
O175A (O175A NS1 FP and O175A NS1 RP) and O265B (O265B NS1 FP and O265B 
NS1 RP) cDNA (Table 7.14), PCR was set-up with Taq DNA polymerase (as 
described above in 7.2.3.10 Virus sequencing) using pHH21 plasmids for O175A and 
O265B with the O175A and O265B primer pairs. Initial PCR conditions tested were 
i) 94°C: 5min, ii) 94°C: 30 sec, iii) 50°C: 30 sec, iv) 72°C: 2 min, v) 72°C 10 min (40 
cycles of ii, iii and iv) : Strong amplification was only detected in homologous primer-
template pairings (Fig 7.2). To test the specificity of primers following plaque 
purification, the same primer-template pairings and PCR conditions were tested 
following plaque purification, RNA extraction, and RT of segment 8 vRNA (using 
PD637 primer) for both O175A and O265B. Primer specificity was only optimally 
achieved following modifications of the PCR cycling conditions to increase the primer 
annealing temperature and reduce the number of cycles due to undesirable background 
(Fig 7.2). Optimal cycling conditions were: i) 94°C: 2 min, ii) 94°C: 1 min, iii) 62°C: 
1 min, iv) 72°C: 3 min, v) 72°C: 10 min (30 cycles of steps ii, iii and iv). Therefore, 
primer specificity was confirmed and competition assays could be performed. 
ii) Competition assays. 
MDCK cells were infected with equal PFU of two viruses in a multicycle setup 





Fig 7.2. Validation of primers for competition assay. (A) Primers were tested in 
PCR on O175A and O265B NS1 ORFs in pHH21 plasmids. (B) Primers were tested 
in RT-PCR following plaque purification of O175A and O265B viruses, RNA 
extraction, and reverse transcription of NS vRNA using PD637 primer. Temperatures 
denote primer annealing temperatures tested in RT-PCR. ‘A’ and ‘B’ represent O175A 





was subjected to plaque assay under a 0.6% agarose overlay for 48 h. Individual plaque 
picks were amplified in MDCK cells by transferring cellular debris and agarose to 
fresh MDCK cells under 0.5 ml of virus growth medium in 24-well plates. After 24 h, 
viral RNA in the supernatant was extracted using Trizol Reagent (Life Technologies) 
as described above and the cells were lysed in Laemmli’s sample buffer. To identify 
the source of segment 8, cDNA was synthesised as described above using PD637 
primer and RT-PCR was performed using Taq DNA polymerase (Invitrogen) with 
primers specific for the NS1 ORF of O175A and O265B as described above.  
Alternatively, the NS1 content of cell lysates was analysed by SDS-PAGE and western 
blotting, using the differential reactivity of rabbit polyclonal antisera V29 (detects PR8 
and O175A NS1) and A2 (detects O175A and O265B NS1) to score plaque picks. 
Typically, 25 plaques were scored for each assay. Where passaging of output was 
involved, the progeny virus mix was infected in MDCK cells at MOI 0.001 for 48 h.  
7.2.3.12 RT-qPCR of O175A and O265B NS segment vRNA 
RT-qPCR to quantify O175A and O265B vRNA levels in co-infected cells was 
performed using the SensiFAST SYBR Hi-ROX system (cat# BIO92005, Bioline). 
Primers specific for the cDNA derived from O175A and O265B NS segment vRNA 
(Table 7.15) were designed using Primer3 online software 
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/) to achieve parameters recommended by 
manufacturer (amplicon length 80 - 200 bp, Tm ~ 60°C). Primers were validated by 
testing primer pairs in triplicate on a 10-fold dilution series of pHH21 plasmids (100 
ng to 0.0001 ng) for both O175A and O265B NS sequences to assess specificity. RT-
qPCR was set up as recommended by manufacturer and run on a Qiagen Rotor-Gene 




step cycling set-up (initial polymerase activation step of 3 min at 95°C, followed by 
40 cycles of a 20 sec 95°C step to denature dsDNA, 20 sec at 60°C for primer 
annealing, and 20 sec at 72°C after which SYBR Green fluorescence was read. This 
was followed by a 50°C to 99°C melt analysis as programmed by software) based on 
recommendations by Bioline for the SensiFAST SYBR Hi-ROX system. 
Amplification was only detected within 30 cycles with homologous primer-template 
matches, therefore O175A and O265B primers were specific to their respective targets 
(data not shown). Additionally, amplicon quantification increased linearly with 10-
fold increases in pHH21 template amount, suggesting accurate quantification of 
template with these primers (data not shown). Melt analysis results showed no obvious 
amplification of a second amplicon for both primer pairs on respective templates (data 
not shown). 
To assess the relative values of O175A and O265B vRNA in co-infected cells, 
total RNA was extracted from co-infected (or infected with one strain only) MDCK 
cells (as described in 7.2.3.9 Viral RNA extraction from infected cells) and quality of 
preparations were assessed by a NanoDrop ND-1000 spectrophotometer and 
contaminants removed using sodium acetate precipitation and ethanol wash as 
described below in 7.2.5.4 Spectrophotometer analysis of nucleic acid preparations. 
cDNA synthesised from vRNA using the Uni12 primer using equal amounts of total 
RNA (1 µg) was performed using AMV RTase (Promega) as described above in 
7.2.3.10 Virus sequencing. RT-qPCR was set up as above including a set of pHH21 
standards at three quantities in triplicate (100 ng, 10 ng, 1 ng) and the cDNA samples 
were run at 10-1 and 10-2 dilutions with both O175A- and O265B-specific primers in 




detected within 30 cycles in homologous primer-template samples, demonstrating 
adequate primer specificity (data not shown). Similarly, no RT and no template 
controls did not show amplicon amplification within 30 cycles of PCR (data not 
shown). Threshold levels and Ct values were calculated by the Rotor-Gene Q Series 
software (v2.1.0). The quantities of pHH21 standards were entered into the Rotor-
Gene Q Series software (v2.1.0) and subsequent quantification of O175A and O265B 
vRNA levels per sample were calculated by the software based on these standards.   
7.2.3.13 RNP reconstitution assays 
2 x 105 293T cells were seeded in 1 ml complete D-MEM per well of a 24-well 
plate to achieve 70-80% confluency the following day for transfection. 50 ng of 
pDUAL plasmids for each of the IAV polymerase components (PB2, PB1, PA, NP) 
and the NS segment were added to 20 ng of firefly reporter construct (pPol I Luc). The 
plasmid DNA mix was diluted in 50 µl Opti-MEM. 1 µl lipofectamine2000 was mixed 
with 50 µl of Opti-MEM per transfection, and incubated at room temperature for 5-10 
min at room temperature. 51 µl of lipofectamine2000/Opti-MEM mix was added to 
each sample, mixed, and incubated for 30 min. The media for the 293T cells was 
removed and replaced with 0.5 ml Opti-MEM per well. 100 µl of transfection mixture 
was added dropwise to each well. Cells were incubated at 37° C for 48 h.  
The media was gently removed and cells were lysed with 100 µl 1 x Reporter 
Lysis Buffer (Promega). Cells were scraped and mixed with a P200 Gilson tip and cell 
lysates were centrifuged (12000 x g, 2 min, 4°C). 60 µl of cell lysate was added to a 
white-bottomed 96-well plate and kept on ice. A Promega GloMax Multi Detection 




to measure the luciferase activity (injection speed 200 µl/sec, 0.5 sec gap, 5 sec 
integration time) following manufacturer’s instructions.  
7.2.3.14 NS1 pol II shut-off assays 
2 x 105 293T cells were seeded in 1 ml complete D-MEM in 24-well plates 
(with 13 mm glass coverslips for samples to be analysed by IF) to achieve 70-80% 
confluency the following day for transfection. 100 ng of pRL was mixed with 400 ng 
of effector plasmid (pEGFPN1 or pDUAL with relevant insert), and diluted with 50 µl 
Opti-MEM. 1 µl lipofectamine2000 reagent was mixed with 50 µl Opti-MEM and 
incubated for 5-10 min. 51 µl of the Lipofectamine2000/Opti-MEM mixture was 
mixed with the diluted plasmid DNA and incubated for 30 min. The media on the 293T 
cells was changed to 400 µl transfection medium (complete D-MEM minus 
antibiotics) per well, and 100 µl of transfection mixture was added dropwise. Cells 
were incubated for 48 h. Successful transfection, and efficiency, was gauged by 
fluorescent microscopy for NS1-GFP fluorescence. Cells were transfected in triplicate.  
Renilla luciferase expression was quantified using Promega’s Renilla 
Luciferase Assay kit (cat# E2810), using a Promega GloMax Multi Detection Unit as 
instructed by manufacturer. Briefly, the cells were washed gently with 1 ml PBS. The 
cells were subsequently lysed in 100 µl 1 x lysis buffer and rocked for 15 min. Cells 
were scraped, mixed, and collected on ice using a P200 Gilson. 20 µl of cell lysate was 
added to a white-bottomed 96-well plate. 100 µl of 1 x Renilla luciferase substrate was 




7.2.4 Protein analyses  
7.2.4.1 Protein Electrophoresis 
Proteins were separated by molecular weight by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) using a discontinuous 
polyacrylamide gel. All SDS-PAGE apparatus was supplied by Bio-Rad (Mini-
PROTEAN tetra system). Polyacrylamide gels were cast using buffers and solutions 
supplied by Protogel according to manufacturer’s instructions, altering the 
concentration of acrylamide:bisacrylamide (37.5:1) solution to achieve desired 
percentage for resolving gel – large proteins requiring a lower percentage resolving 
gel to be efficiently resolved and vice versa. Stacking gels were cast at 4%. See 7.1.6.2 
Acrylamide gel electrophoresis for example recipes for 10% resolving gels and 4% 
stacking gels. 0.75 mm spacer plates were used with appropriate short plates.  
 To generate cell lysates, typically 4 x 105 cells in a 24-well plate were lysed 
with 200 µl of Laemmli’s solution. Samples were boiled at 95°C for 5 min, vortexed 
for 5 sec, centrifuged briefly, boiled for a second time and centrifuged at 13 000 rpm 
for 5 min. 4-20µl of sample was loaded per lane of each gel. Gels were run vertically 
at a constant voltage of 120V for desired length of time, using a pre-stained protein 
molecular weight marker (Promega) as a guide for protein migration.  
7.2.4.2 Western Blotting 
Proteins separated by SDS-PAGE were blotted onto nitrocellulose membrane 
(Bio-Rad) using a wet electroblotting setup (Bio-Rad). The nitrocellulose membrane 
was placed onto the polyacrylamide gel (on the positive cathode side) supported by 3 
pieces of 3MM Whatman paper either side, and placed between two sponges inside a 




transfers were run at 100 V for 1 h. Nitrocellulose membranes were blocked in 
PBS/0.1% (v/v) Tween20 with 5% (w/v) skimmed milk (Marvel) for 30 min on a 
platform rocker. Blocked membranes were washed three times with PBS/0.1% (v/v) 
Tween20 before probing with primary antibody, diluted in PBS/0.1% (v/v) Tween20. 
Primary antibody incubation was typically performed overnight at 4°C or for 1 h at 
room temperature with rocking. Membranes were washed three times as above, and 
secondary antibody, diluted in PBS/0.1% (v/v) Tween20, was added for 45 min at 
room temperature on a platform rocker. Membranes were washed three times with 
PBS/0.1% (v/v) Tween20 before imaging on the LiCor Odyssey imaging platform.  
7.2.4.3 35S-methionine/cysteine- labelled protein immunoprecipitation  
For immunoprecipitation studies, MDCK cells were seeded in 24-well plates 
and infected at an MOI of 10 as described in 7.2.3.5 Virus infections with 35S metabolic 
labelling as described in 7.2.8.1 35S-methionine/cysteine metabolic labelling of infected 
cells. Cells were lysed in 500 µl medium stringency IP buffer. Cells were scraped, 
collected, and clarified (13000 rpm, 5 min, 4°C). 100 µl of clarified cell lysate was 
diluted in 100 µl medium stringency IP buffer and incubated on ice for 30 min. 2 µl of 
rabbit polyclonal antiserum (or pre-immune rabbit serum) was added and samples 
were mixed and incubated on ice for 1 h. Protein-A agarose beads (Roche) were 
washed 3 times in medium stringency IP buffer and resuspended to 50% (v/v) in 
medium stringency IP buffer. 50 µl of resuspended protein-A agarose beads was added 
to each lysate and incubated for 30 min on a rotator at room temperature. The beads 
were pelleted by pulsing in a microcentrifuge for 10 sec. The beads were washed twice 
with 750 µl medium stringency IP buffer by mixing, pulsing, and removing the 




remove sodium deoxycholate which interferes with SDS-PAGE. Supernatant was 
removed and protein eluted from the beads by addition of 40 µl Laemmli’s sample 
buffer and boiling at 95°C for 5 min. Protein-A agarose beads were pelleted by pulsing 
the samples before loading onto a polyacrylamide gel for protein separation by SDS-
PAGE as described in 7.1.6.2 Acrylamide gel electrophoresis. Autoradiography of 
dried polyacrylamide gels was performed as described below in 7.2.8.2 
Autoradiography of dried polyacrylamide gels.  
7.2.4.4 Densitometry 
Protein quantification following western blotting was determined by 
densitometry using the LiCor Odyssey software package. Protein quantification 
following SDS-PAGE and autoradiography was performed using the gel analyser tool 
on scans of exposed film in ImageJ. 
7.2.4.5 Quantitative temporal proteomics of infected A549 cells 
5 x 106 A549 cells were seeded in 100 mm x 20 mm dishes with two glass 
coverslips included in 10 ml complete D-MEM. The following day, cells were infected 
at MOI 5 using 2 ml of inoculum following standard infection protocols. After 1 h 
incubation at 37º C, inoculum was aspirated and cells overlaid with 10 ml complete 
D-MEM. Cells were infected for 8 h, 16 h and 24 h. After the desired length of time, 
the two coverslips per dish were retrieved and processed for IF and western blot 
analysis to validate infection. Cells were washed twice with 10 ml cold PBS before 
lysis in 420 µl 6 M guanidine lysis buffer. Cells were scraped, collected, and stored on 
ice. Cell lysates were sonicated in a water bath sonicator with ice added (full power, 
30 sec on 30 sec off, 10 cycles). Lysates were clarified by centrifugation (21 000 x g, 




conducted by Dr. Michael Weekes (Cambridge Institute for Medical Research, 
University of Cambridge, Cambridge, UK), Dr. Joao Paulo and Dr. Steven Gygi 
(Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA) 
as described in a previous report (Weekes et al., 2014). Dr. Weekes interpreted the 
spectrometry data and provided fold-change values for all peptides quantified relative 
to highest abundance detected across the 10 samples.  
7.2.5 Molecular cloning  
7.2.5.1 Making agar plates for selection of transformed DH5α bacteria 
LB agar was heated in a microwave until all agar had dissolved. When cool, 
appropriate selection antibiotic was added to molten agar and the solution mixed. 
Molten LB agar was poured into 100 mm x 20 mm dishes, working under the flame of 
a Bunsen burner to reduce contamination. Agar was allowed to set at room 
temperature.  
7.2.5.2 Transformation of competent DH5α cells with plasmid DNA 
250 ng of plasmid DNA (or equivalent volume of water) was added to 10 µl of 
competent DH5α cells kept on ice, gently mixed, and incubated for 5-15 min (20 µl of 
cells were used for subcloning work). Cells were transformed by a 45 sec heat shock 
at 42° C, and cells were immediately placed on ice for 2 min. 900 µl of LB broth was 
added and cells allowed to recover in a shaker (200rpm) for 1 h at 37°C. Cells were 
pelleted using centrifugation (13000 rpm, 1 min), and all but 100 µl of supernatant was 
removed. Cells were resuspended in remaining supernatant, and 10 µl of resuspension 
was spread on an agar plate containing appropriate antibiotic using a sterile spreader 
working under a Bunsen burner flame to reduce contamination. For subcloning work, 




Agar plates were incubated for 12-18 h at 37° C. Antibiotic selection was 
confirmed by absence of colonies on the water-only control sample. Single colonies 
were grown in LB broth (2 ml for mini-prep, 100 ml for midi-prep) at 37° C in a shaker 
(200 rpm) with appropriate selection antibiotic added for 16 h. Bacterial cells were 
pelleted by centrifugation (4300 rpm, 20 min, 4°C) and supernatant removed. Cells 
were used immediately or stored at -20°C.  
7.2.5.3 Plasmid DNA purification.  
Plasmid DNA mini-preps were performed using Promega’s Wizard SV mini-
prep kit (cat# A1460) according to manufacturer’s instructions. Plasmid DNA midi-
preps were performed using QIAGEN’s Plasmid DNA Midi Prep (cat# 12143) kit 
according to manufacturer’s instructions. The concentration and quality of purified 
plasmid DNA was assessed using a NanoDrop ND-1000 spectrophotometer.  
7.2.5.4 Spectrophotometer analysis of nucleic acid preparations 
Typically, 1.5 µl of resuspended nucleic acid preparation was loaded onto a 
NanoDrop ND-1000 spectrophotometer for analysis. Nucleic acid absorbs maximally 
at 260 nm wavelength while other contaminants such as protein and phenol absorb 
maximally at 280 nm and EDTA, carbohydrates and phenol absorb maximally at 230 
nm. Absorbance ratios at wavelengths 260/280 and 260/230 were calculated and used 
as an indicator of quality and presence of any contaminants. A 260/280 ratio of ~ 1.8 
for DNA and ~2.0 for RNA, and a 260/230 ratio of 2.0 – 2.2 indicate pure preparations. 
If ratios were considerably lower, sodium acetate (pH 5.2) was added to achieve a final 
concentration of 0.3 M and mixed. 3 volumes of 100 % ethanol was added and kept 
on ice for 40 min. Samples were centrifuged at 15000 rpm for 20 min (4 °C) and 




7.2.5.5 Restriction enzyme digests 
DNA endonuclease enzymes were obtained from New England Biolabs, and 
digests were performed as instructed by manufacturer. Typically, 1 µg of DNA was 
digested in a 50 µl reaction. The buffer used, amount of enzyme added, and incubation 
conditions were determined using NEB’s NEB Cloner tool 
(http://nebcloner.neb.com/#!/redigest). 
7.2.5.6 DNA gel electrophoresis 
Agarose was boiled in 1 x TAE running buffer at desired concentration 
(typically 0.8 – 1.0% (w/v), higher percentage for smaller DNA products and vice 
versa) and 1 x SYBR Safe DNA gel stain (Thermo Fisher) was added to cooled molten 
agarose and mixed. DNA samples were mixed with 1x DNA loading dye (final 
concentration) and loaded into set agarose gel alongside Promega 1 kb DNA ladder 
marker. Gels were typically run at 100 V for desired length of time, using Orange G 
and xylene blue FF dyes as markers for DNA migration. 
7.2.5.7 NS1-GFP cloning using eGFPN1 vector 
The ORF of various NS1 proteins were cloned out of appropriate pDUAL or 
pHH21 plasmids using primers designed to incorporate a 5’ KpnI site and a 3’ AgeI 
site (Table 7.11). 10 ng of plasmid DNA template was amplified in a 50 µl PCR using 
Pfu Ultra II Fusion HS DNA Polymerase (Agilent) using a reaction setup as 
recommended by the manufacturer. Thermocycling conditions were as follows: i) a 2 
min denaturation step at 95°C, ii) a 20 sec denaturation step at 95°C, iii) a 20 sec 
primer annealing step at 60°C, iv) a 15 sec elongation step at 72°C, with steps ii) – iv) 




PCR product was analysed by DNA gel electrophoresis and purified using 
Qiagen’s QIAquick PCR purification kit as instructed by manufacturer, but eluting 
with 30 µl water. The whole purified PCR product and 5 µg of pEGFPN1 vector was 
digested with KpnI and AgeI-HF DNA endonucleases (New England Biolabs) using 
conditions recommended by the NEB Cloner tool 
(http://nebcloner.neb.com/#!/redigest), and purified as above. 50 ng of cut pEGFPN1 
was used in a DNA ligation reaction at a molar ratio of 5:1 (insert:vector) using T4 
DNA ligase (New England Biolabs), as recommended by manufacturer. 2 µl of ligase 
reaction product was transformed into competent DH5α cells as described in 7.2.5.2 
Transformation of competent DH5α cells with plasmid DNA. Individual colonies were 
grown overnight (37ºC, 200 rpm shaking) in 2 ml LB with kanamycin (50 µg/µl). 
Plasmid DNA was extracted from individual clonal bacterial suspensions by mini-prep 
plasmid purification and samples were screened for successful plasmid transformation 
by digesting mini-preps with KpnI and AgeI-HF, which cuts either side of the insert 
site, and using DNA gel electrophoresis to identify plasmid preparations with 690bp 
insert. Positive cultures were added 1:1000 to 100 ml LB with kanamycin (50 µg/µl) 
and grown overnight. Midi-prep plasmid purification was performed, validated with 
restriction digest and DNA gel electrophoresis as above, and plasmid DNA was 
sequence verified by GATC to confirm desired insert was present. To test that NS1-
GFP was expressed in transfected cells, 500 ng of select NS1-GFP expressing plasmids 
was transfected into 293T cells in 24-wells (as described above in 7.2.3.14 NS1 pol II 
shut-off assays). GFP fluorescence was confirmed by epi-fluorescence of live cells, 




buffer. NS1-GFP expression was confirmed by western blot analysis using the mouse 
monoclonal anti-GFP (JL8) antibody (Fig 7.3).  
7.2.5.8 Cloning NS segments into pDUAL 
Corresponding cDNA for the NS genes of Alb88B, NY6750A, Sw412A, 
Sw418B, and NY107B were synthesised and cloned into a backbone vector (pBSK(+)-
Amp)  by Biomatik. As the full 890bp gene sequence was not available in any case, 
the termini of the NS segment was taken from the closest relative using a web-based 
nucleotide BLAST tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch) – see Table 
7.16. NS genes were checked for BsmBI sites using the web-based endonuclease site 
finder WebCutter 2.0 (http://rna.lundberg.gu.se/cutter2/). For the NS genes with 
BsmBI sites (Alb88 and Sw418), the nucleotide sequence was altered as to remove the 
site, but not affect NS1 or NEP protein sequence – for mutations see Table 7.16.    
Primers were designed to allow amplification of the NS genes with ends 
compatible for ligation into pDUAL vector following BsmBI digestion (Table 7.12). 
10 ng of plasmid DNA template was amplified in a 50 µl PCR using Pfu Ultra II Fusion 
HS DNA Polymerase (Agilent) using a reaction setup recommended by the 
manufacturer. Thermocycling conditions were as follows: i) a 2 min denaturation step 
at 95°C, ii) a 20 sec denaturation step at 95°C, iii) a 20 sec primer annealing step at 
60°C, iv) a 15 sec elongation step at 72°C, with steps ii) – iv) performed for 30 cycles, 
and v) a final 3 min elongation step at 72°C.  
PCR product was analysed by DNA gel electrophoresis and purified using 





Fig 7.3. Western blot validation of NS1-GFP expression from pEGFPN1 plasmid. 
293T cells were seeded in 24-wells and were transfected for 48 h with 500 ng of 
plasmid DNA. Cell lysates were generated in Laemmli’s sample buffer and western 
blot analysis using a mouse monoclonal anti-GFP antibody (JL8) was performed. Top 





with 30 µl water. The whole purified PCR product and 5 µg of pDUAL vector was 
digested with BsmBI DNA endonuclease (New England Biolabs) as recommended by 
the NEB Cloner tool (http://nebcloner.neb.com/#!/redigest), and PRC-purified using 
Qiagen’s PCR purification kit as above. 50 ng of cut pDUAL was used in a DNA 
ligation reaction at a molar ratio of 5:1 (insert:vector) using T4 DNA ligase (New 
England Biolabs), as recommended by manufacturer. 2 µl of ligase reaction product 
was transformed into competent DH5α cells as described in 7.2.5.2 Transformation of 
competent DH5α cells with plasmid DNA. Individual colonies were then screened for 
successful plasmid transformation by digesting mini-preps with SacI (NEB), which 
cuts either side of the insert site of pDUAL, and using DNA gel electrophoresis to 
check for presence of insert. Midi-preps were performed on cultures showing positive 
results, and plasmid DNA was sequence verified by GATC.  
Table 7.16 Avian IAV NS gene cloning into pDUAL. 





B M25373.1 BsmbI site removed by g242a mutation. 
Has termini of A/blue-winged 
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7.2.6 Immunofluorescent staining 
Cells were seeded on 13 mm glass coverslips (SLS) in 24-well plates and 
infected using standard protocols. After infection, cells were washed with 1 x 1 ml 
PBS and fixed using 250 µl PBS/4% (v/v) formaldehyde for 20 min. Fixed cells were 
washed 3 x 1 ml PBS and permeabilised using 250 µl PBS/0.2% (v/v) Triton X-100 
for 5 min. Permeabilised cells were washed 3 x 1 ml PBS/1% (v/v) FBS and stained 
with appropriate primary antibody diluted in PBS/1% (v/v) FBS (1 h at room 
temperature or overnight at 4°C on  a platform rocker). Cells were washed as above 
and incubated with appropriate secondary antibody diluted in PBS/1% (v/v) FBS at 
room temperature for 45 min with rocking, protected from exposure to light by foil. 
Cells were washed as above and coverslips were mounted on glass microscopy slides 
(Thermo Scientific) using 2 µl ProLong Gold Antifade reagent. Slides were cured for 
at least 24 h before imaging using a confocal microscope (Zeiss LSM 710).  
7.2.7 Interferon and cytokine assays 
7.2.7.1 IFN-β dose-inhibition experiments 
A549 cells were seeded in 24-well plates at 2 x 105 cells per well in 1 ml 
complete D-MEM. The following day, cells were treated with varying concentrations 
of exogenous human interferon-β (Abcam) diluted in 1 ml complete D-MEM. 24 h 
after treatment, a 48 h multicycle infection (MOI 0.01) was performed using standard 
infection protocols. At 48 h p.i., cell lysates were generated for western blot analysis 
of viral NP and cellular interferon-induced GTP-binding protein Mx1 to confirm IFN-
β had activated the JAK/STAT signalling pathway. Cell supernatant was clarified 




Titres were normalised to no-IFN control and IC90 values were calculated using 
GraphPad Prism 6 software. 
7.2.7.2 HEK-Blue type I interferon assays 
A549 cells were seeded in 24-well plates at 2 x 105 cells per well in 1 ml 
complete D-MEM, on 13 mm coverslips. The following day, cells were infected at 
varying multiplicities for 24 h, using a serum- and trypsin-free virus growth medium. 
Supernatant was collected and immediately placed on ice. Supernatants were clarified 
(3000 rpm for 5 min) and stored at -80°C prior to assaying. The cells were fixed and 
stained for virus NP, as described in 7.2.6 Immunofluorescent staining, to determine 
the successful infection rate.  
Samples were UV-treated to inactivate infectious virus particles by transferring 
300 µl of sample to a 24-well plate, kept on ice with lid removed, and treating at 
120000 μJ/cm2 for 10 min in a CL-1000 Ultraviolet Crosslinker (UVP). To determine 
levels of type I IFN in the supernatant of infected cells, 180 µl of HEK-Blue cell 
suspension (at 2.8 x 105 cells/ml) was added to 20 µl of UV-treated sample in 96-well 
plates and incubated for 24 h at 37°C. 20 µl of HEK-Blue cell supernatant was 
transferred to 180 µl of Quanti-Blue substrate (InVivoGen) in a separate 96-well plate 
and incubated for 1 h at 37°C. Absorbance at 630 nm was recorded using a micro plate 
reader (BioTek) using Gen5 software and used as a read-out for active type I IFN levels 
in the initial samples. A standard curve was generated in parallel by incubating known 




7.2.7.3 Plasmid-based IFN and ISRE reporter studies 
1.5 x 105 293T cells were seeded per well of a 24-well plate in 1 ml of complete 
D-MEM the day prior to transfection. The following day, cells were co-transfected 
with 50 ng of reporter plasmid (IFN-β::Luc or ISRE::Luc) and 400 ng of pEGFPN1 
with appropriate NS1 ORF upstream of eGFP gene (PR8 NP-GFP was used as a 
negative control) using Lipofectamine 2000 (Invitrogen) as described in 7.2.3.14 NS1 
pol II shut-off assays. 24 h after transfection, cells were stimulated (or mock 
stimulated) with 5 µg/well of poly(IC) (InvivoGen) by transfection using 
Lipofectamine 2000 – as above except the transfection mix involved a 2:50 
Lipofectamine 2000: Opti-MEM mixture. Mock-stimulated cells were transfected with 
a transfection mix in which poly(IC) had been replaced with Opti-MEM medium. 24 
h post-stimulation, luciferase activity in cell lysates were measured using Promega’s 
Luciferase Assay System (cat# E1500) by following manufacturer’s instructions using 
the Promega GloMax Multi Detection unit.  
7.2.7.4 Primary human macrophage cytokine array 
Primary human CD14+ monocyte-derived macrophages were isolated and 
plated as described in 7.2.2.4 Isolation of human CD14+ monocytes. On the day of 
infection, macrophages were washed with 1 ml serum-free RPMI. Virus stocks were 
diluted in serum-free RPMI medium so that a 200 µl inoculum would achieve an 
estimated MOI of 1. 200 µl of diluted virus was incubated on macrophages for 1 h at 
37°C. The virus inoculum was removed, and macrophages were overlaid with 1 ml 
serum-free RPMI. After 24 h, the supernatant was clarified (3000 rpm, 5 min) and 
stored at -80°C. Macrophages were fixed and stained with AA5H anti-NP antibody as 




The supernatant was used in R & D System’s human cytokine panel A 
proteome profiling kit (cat# ARY005), and quantified using the near infrared detection 
system using the Li-Cor Odyssey system. Briefly, supernatant was incubated with a 
cocktail of biotinylated detection antibodies for various human cytokines and 
chemokines. The antibody-cytokine mixture was then run over a nitrocellulose 
membrane with capture antibodies spotted, in duplicate, which capture the detection 
antibody/cytokine complex.  A streptavidin-tagged secondary conjugate was run over 
the membrane, and the amount of dye present at each spot quantified using the Li-Cor 
Odyssey system. The amount of dye in a spot was proportional to the quantity of 
corresponding cytokine in the supernatant of infected macrophages. Mean fold-change 
over mock-infected sample was calculated and plotted as a heat map created in 
Microsoft Excel. 
7.2.8 Radioactive isotope experiments 
7.2.8.1 35S-methionine/cysteine metabolic labelling of infected cells 
MDCK cells were seeded in 24-well plates and infected at an MOI of 10 using 
standard protocols. Cells were seeded in duplicate to allow generation of cell lysates 
and also assessment of successful infection rate by IF.  
At 6 h post-infection, cells were washed twice with warm PBS and overlaid 
with 1 ml Methionine- and Cysteine-free D-MEM supplemented with 5% (v/v) 
dialysed PBS and 2 mM L-Glutamine to starve the cells of methionine and cysteine. 
At 8 h post-infection, cells were washed twice with warm PBS and overlaid with 0.5 
ml of methionine- and cysteine-free D-MEM (with 2 mM L-Glutamine and 5% (v/v) 
dialysed FBS) supplemented with 35S-methione/cysteine protein labelling mix (Perkin 




activated charcoal (Fisher). After a 1 h pulse, cells were washed once with ice-cold 
PBS. PBS wash was removed and cells were lysed/fixed for downstream processing.  
7.2.8.2 Autoradiography of dried polyacrylamide gels 
SDS-PAGE was run as described in 7.2.4.1 Protein Electrophoresis. Gels were 
fixed by rocking in gel fix solution (50% methanol (v/v), 10% acetic acid (v/v)) for 5 
min. The fix solution was replaced and gels were incubated twice further for 5 min. 
Gels were incubated in Amplify Fluorographic Reagent (GE Healthcare) for 15 min 
with rocking. Gels were laid onto 3MM Whatman filter paper and covered with film. 
The gels were dried in a gel dryer (Bio-Rad) by heating to 80°C for 2 h under vacuum 
pressure. Dried gels were placed in sealed cassette with X-ray film (Thermo Fisher) 
overnight at -80°C, or for longer periods of time according to desired signal strength. 
X-ray film was developed using a Konica SRX-101A X-ograph film processer using 
manufacturer’s instructions. 
7.2.9 Mouse experiments 
7.2.9.1 Viral infections 
BALB/c mice were purchased from Harlan UK Ltd (Oxon, UK) and housed in 
the Roslin Institute Biomedical Research Facility (BRF). All work was carried out 
under a UK Home Office licence according to the Animals (Scientific Procedures) Act 
1986. Infection of BALB/c mice was conducted by Prof. Bernadette Dutia, Dr. Helen 
Wise, and Dr. Marlynne Nicol (The Roslin Institute, The University of Edinburgh, 
Edinburgh, UK). Five- to 6-week-old female mice were anaesthetized using 
isofluorane (Merial Animal Health Ltd) and infected intranasally with 100 or 500 PFU 
of virus in 40 μl serum-free D-MEM. Mice were weighed daily and assessed for visual 




days 2, 4, and 6 p.i., mice were euthanized by CO2 asphyxiation, performed by Prof. 
Dutia and Dr. Nicol.  Tissue collection was performed with the help of Prof. Dutia, Dr. 
Nicol, Dr. Yvonne Ligertwood, and Dr. Gareth Hardisty (The Roslin Institute, The 
University of Edinburgh, Edinburgh, UK). The tip of the left lung was harvested into 
200 µl preservative (RNA later, Life Technologies) prior to RNA extraction, while the 
remainder of the left lung was removed onto dry ice. Both were stored at -80°C prior 
to downstream processing. For titration of infectious virus in the left lung, and cytokine 
profiling, the left lung was diced with a sterile scalpel and added to 1.5 ml serum-free 
D-MEM with 0.1 mM Pefa-Bloc (Sigma). The lung tissue was homogenised using the 
Tissue Lyser II (Qiagen) system. Briefly, a 5 mm diameter metallic ball bearing (cat # 
69989) was added and the sample shaken at 28000 Hz for 4 min. Homogenised tissue 
was clarified by centrifugation (3000 rpm, 5 min). Titres of infectious virus in the left 
lung were determined by plaque assay on MDCK cells as described above in 7.2.3.6 
Plaque assays – PR8 and Udorn72.  
7.2.9.2 Histopathology 
The lobes of the right lung were inflated with and fixed in 10% neutral buffered 
formalin. Fixed lung tissue was processed and embedded in paraffin*. 5 µm thick 
sections were cut and stained with haematoxylin and eosin* before being assessed 
(blinded) by a pathologist and lesions scored (Dr. Philippa Beard, the Roslin Institute, 
The University of Edinburgh, Edinburgh, UK). The scoring system was designed by 
Dr. Beard and provided as follows: 0, no lesions; 1, mild, focal inflammation and rare 
degeneration and necrosis; 2, moderate, multifocal inflammation with frequent 
necrotic cells; 3, marked, multifocal inflammation with common necrosis and 




*Performed by the University of Edinburgh Easter Bush Histopathology 
Laboratory.  
7.2.9.3 Immunohistofluorescence 
For immunohistofluorescence imaging, lung tissue was deparaffinised by 
incubating sections for 3 min in xylene, and repeating with fresh xylene. Sections were 
then incubated in decreasing concentrations of ethanol (3 min each step: 100% (v/v) 
ethanol, 100% (v/v) ethanol, 100% (v/v) ethanol, 95% (v/v) ethanol, 70% (v/v) 
ethanol, 50% (v/v) ethanol) before being rinsed with water for 5 min.   
An antigen retrieval step was performed by heating sections in sodium citrate 
buffer at 96°C for 30 min. After cooling, slides were rinsed with water for 5 min. Slides 
were washed three times for 5 min on a rocker with TBS/0.025% (v/v) Triton X-100 
(TBST). Cells were permeabilised by incubating sections in TBS/0.25% (v/v) Triton 
X-100 on a rocker for 10 min. Cells were washed three times in TBST for 5 min. 
Samples were blocked by incubating in TBST/10% (v/v) FBS for 30 min on a rocker. 
Sections were washed three times with TBST, and 200 µl CAS-blocking agent was 
added and sections were incubated on a rocker for 1.5 h. Slides were washed with 
TBST three times as above. Immunological staining was performed essentially as 
described for staining fixed cells in vitro in 7.2.6 Immunofluorescent staining, except 
antibodies were diluted in CAS-block blocking agent rather than PBS/1% (v/v) FBS. 
Sections were stained for intracellular viral NP using rabbit polyclonal antiserum anti-
MBP-NP (2915). The lung tissue was subsequently stained with an anti-rabbit IgG 
antibody conjugated with a fluorescent dye (Alexa Fluor 594, Life Technologies) at 
1:1000 in CAS-block blocking agent for 45 min at room temperature prior to 




7.2.9.4 Mouse quantitative reverse-transcription PCR (RT-qPCR) array.  
Custom Taqman® Array Plates (Applied Biosystems) were designed by Dr. 
Brett Jagger (National Institute of Allergy and Infectious Diseases, Bethesda, 
Maryland, USA) to analyse 3 RNA samples in triplicate per plate, with 32 unique 
assays per sample (see Table 4.1 in Chapter 4 for individual RT-qPCR assays for 
cellular transcripts). RNA extraction and RT-qPCR was performed with the aid of Dr. 
Nikki Smith (The Roslin Institute, The University of Edinburgh, Edinburgh, UK). 
Total RNA was extracted from the tip of the left lung (50 – 80 mg of tissue) of 3 mice 
per cohort at day 4 p.i. using Qiagen’s QIAshredder RNA extraction kit (cat# 79654) 
as instructed by manufacturer. Reverse transcription of 25 ng total RNA was 
performed using random hexamer primers and the high-capacity RNA-to-DNA 
reverse transcription kit (Applied Biosystems) according to manufacturer’s 
instructions. cDNA was mixed with Taqman Universal Mastermix (Life 
Technologies) and 20 µl loaded into each well of the array plate. Plates were sealed 
with film and centrifuged briefly. RT-qPCR was run in a 7500 Q-PCR thermocycler 
(Applied Biosystems) as recommended by the manufacturer. Cycling conditions were 
as follows: i) 2 min hold step at 50ºC, ii) a 10 min hold step at 95ºC, and 40 cycles of 
iii) 15 sec at 95 ºC and iv) 1 min annealing and extension at 60 ºC. Cycle threshold 
(CT) values were obtained using 7500 Software v2.0.6 (Applied Biosystems) and data 
was exported to Microsoft Excel for further analysis. Mean CT values were calculated 
from triplicate data and were normalised to mean Gapdh CT values (dCT). dCT values 
were plotted as 20 – dCT for each mouse, thus the higher the value the more transcript 




7.2.9.5 Mouse cytokine array 
Cytokines and chemokines in the left lung homogenate were quantified using 
a mouse cytokine array (Mouse Cytokine Antibody Array Panel A, R & D Systems). 
Lung homogenate of the five mice per cohort at day 4 post-infection were pooled and 
assayed as described in manufacturer’s instructions using the near infrared detection 
protocol, essentially as described earlier for the human cytokine array in 7.2.7.4 
Primary human macrophage cytokine array. Imaging and quantification was 
performed using the LiCor Odyssey Imaging platform. Mean fold-change over mock-
infected sample was calculated and plotted as a heat map created in Microsoft Excel. 
7.2.10  Statistical analyses 
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